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Abstract 
 
Glycosyltransferases (GTs) are essential for the biosynthesis and diversification of 
many therapeutically important natural products. Of these, UDP-sugar: sterol 
glucosyltransferases (UGTs) (2.4.1.173) catalyse the synthesis of therapeutically 
important steryl glycosides (SGs). Guided by the sequence similarity with a 
previously characterised N-terminally truncated UGT from Saccharomyces 
cerevisiae (UGT51), this study reports the cloning of the gene fragment encoding 
the C-terminal catalytic domains from related yeasts and the expression and 
characterisation of their encoded products produced. N-terminally histidine tagged 
proteins were purified for in vitro assays against a panel of sterol and steroidal 
acceptors. Liquid chromatography-mass spectrometry (LC-MS) and kinetic 
analysis led to the successful characterisation of two novel UGTs from Pichia 
angusta  and Kluyveromyces lactis. In addition, testosterone was shown to be 
utilized by all UGTs, including the previously characterised S. cerevisiae UGT51. 
Random mutagenesis of UGTs and homology modelling of the S. cerevisiae UGT 
revealed structural similarities with family 1 bacterial glycopeptide GTs. Given 
the structural and mechanistic similarities among GT family 1 UGTs, this 
approach may provide a template for genetic manipulation of novel UGTs from 
other members of the GT superfamily with a better understanding of catalytic 
domains and for broadening their scope in drug development. It may also aid the 
development of a generic process in the synthesis of SGs. 
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1.1 Natural product glycodiversification 
It has been estimated that 40-70% of all new chemical entities currently entering 
drug development programs possess insufficient aqueous solubility owing to their 
polycyclic and hydrophobic nature. This in turn leads to their poor oral 
bioavailability and therapeutic efficacy resulting from poor dissolution rate 
primarily in the gastrointestinal (GI) tract (Hauss 2007). In this regard, lipid-based 
formulations are well documented and proven to enhance drug absorption by 
direct delivery into systemic circulation by avoiding hepatic first-pass metabolism 
and by increasing membrane permeability. However, several factors influence the 
success of lipid-based formulations such as viscosity and consistency of dosage 
that can affect drug release in vivo. Furthermore, reproducing the complex GI 
environment in vitro represents a major challenge for drug dissolution studies 
along with additional concerns such as ageing which may affect the overall drug 
bioavailability (Wasan 2001). 
Many new drugs under development are therefore poorly water soluble and have 
non-ideal pharmacokinetic properties. One strategy is the use of pro-drugs, where 
the drug substance is linked to a water soluble moiety such as a carbohydrate 
which increases solubility and potential drug availability (Luzhetskyy et al. 2007; 
Seibel et al. 2006). The drug is subsequently released by normal metabolic 
processes, ideally at the desired site of action. In a similar manner, drugs are 
commonly metabolised by conversion in vivo by specific host-encoded 
endogenous enzymes into soluble carbohydrate derivatives which can  then be 
excreted  (Luzhetskyy et al. 2005). For example, the  systemic the detoxification 
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and removal of steroid hormones takes place by glucuronic acid conjugation 
(Meech  Mackenzie 2010; Stevenson 1999). 
The synthesis of appropriate carbohydrate derivatives can therefore be employed 
either as drug delivery tools or as a means to understand drug pharmacokinetics 
such as adsorption, distribution, metabolism and excretion (ADME) (Erb et al., 
2009; Hauss et al., 2007).  
Approximately 50% of prescription products sold in Europe and the US are either 
natural products or derivatives thereof (Newman et al. 2003). Secondary 
metabolites from plants and microorganisms represent diverse as well as 
promising candidates for the development of new medicines in addition to their 
agronomic relevance (Ahn et al. 2009; Gachon et al. 2005). For example 
flavonoids, compounds with anti-inflammatory, antioxidant and antitumour roles 
form a major part of medicinal research. Of these metabolites, the vital role of 
natural products harboring sugar moieties, predominantly glycoproteins and 
glycolipids is well documented in eubacteria, eukaryotes, archaebacteria and 
viruses (Zhang et al. 2007). The occurrence of a myriad of complex carbohydrates 
such as polysaccharides, glycoproteins and glycolipids govern a diverse range of 
defined cellular functions such as energy storage and cell wall structural integrity 
in the form of starch and cellulose respectively in plants and other processes such 
as cellular interactions, cell adhesion and immune defense (Klement et al., 2007; 
Park et al. 2009b). 
Therefore, since drug-linked sugar moieties participate in interactions between 
drugs and their biological targets consequently increasing their pharmacokinetic 
properties (ADME) and promote drug solubility and stability, glycosylated  
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natural products are being exploited by the pharmaceutical industry as potential 
leads in drug discovery and development (Kohara et al. 2007). Newman et al. 
(2003) have extensively reviewed the prospects of glycosylated products as 
sources for new drugs. For example several glycosides produced by 
microorganisms such as anthracyclines, amino-glycosides, macrolides and plants 
such as lignans and anthraquinones have been used as biologically active natural 
products in the treatment of various diseases. Some examples of these uses have 
been summarized in Table 1.1. Biotech companies such as Neose (Horsham, PA) 
for example have therefore invested billions of dollars with a view to improve 
glycosylation of medically useful glycoproteins. 
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Table 1.1 Glycosylated plant and microorganism derived natural products and their 
pharmaceutical uses (Luzhetskyy et al. 2008) 
Glycosylated natural 
product 
  Mode of action       Pharmaceutical use 
Glycosylated natural products from microorganisms 
anthracyclines 
(daunomycin, 
doxorubicin, 
aclacinomycin A, 
nogalamycin) 
DNA intercalation daunomycin- acute 
lymphoblastic/myeloblastic 
leukaemias; 
doxorubicin- breast cancer, 
juvenile tumours, soft tissue 
and aggressive sarcomas;  
aclacinomycin A, 
nogalamycin- tumours with a 
acquired resistance to 
daunomycin 
Macrolides 
(erythromycin, 
oleandomycin, 
spiramycin, 
josamycin, 
midecamycin) 
binding to 50s 
rRNA 
respiratory tract and soft tissue 
infections caused by 
streptococci, pneumococci, 
staphylococci and enterococci  
coumarins 
(novobiocin) 
gyrase inhibition infections caused by 
Staphylococcus epidermidis 
glycopeptides 
antibiotics 
(vancomycin 
(Amycolatopsis 
orientalis), 
teicoplanin) 
binding to N-acyl-
D-Ala-D-Ala 
termini of non-
crosslinked lipid-
PP-disaccharide-
pentapeptides 
fatal infections by gram 
positive bacteria 
Glycosylated natural products from plants 
anthraquinones absorption, 
inhibition of 
Na+/K+-ATPase 
laxative agents 
flavonoids 
(hesperidin, rutin, 
vitexin, hyperosid, 
apigenin-glycosides, 
luteolin-glycosides) 
radical-oxygen 
scavengers 
hesperidin, rutin- tone 
improvement in vein walls;  
vitexin, hyperosid- treatment 
of congestive heart failure; 
apigenin-glycosides, luteolin-
glycosides- improvement in 
blood circulation 
etoposide DNA-
topoisomerase II 
inhibition 
anticancer therapy 
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Structure-based approach to drug design is at the forefront of the pharmaceutical 
industry and therefore structural modification of natural metabolites is an 
emerging research area. In addition, from a chemical standpoint, sugar 
conjugation results in both increased stability (through the protection of reactive 
nucleophilic groups) and water solubility (Luzhetskyy et al. 2008).  
Understanding the specific roles that glycans play in the disease process could 
offer new targets for specific therapeutic intervention of these events (Dove 
2001). For example highly modified glycans on tumour cell surfaces that mediate 
carbohydrate-protein and carbohydrate-carbohydrate interactions are involved in 
critical events in the progression, dissemination and invasion of cancer cells 
(Barchi 2000; Gorelik et al. 2001) as depicted in Fig. 1.1. Antitumour drug design 
strategies therefore encompass targeting the production or interaction of tumour-
associated glycans by carbohydrate based drugs or vaccines that mimic the sugars 
involved in these interactions. For example cytotoxicity tests with pluramycins, 
antibiotics consisting of an aryl-C-glycoside core, have demonstrated potency 
against several murine and human cell lines (Bililign et al. 2005). 
Understanding the biochemical implications of these altered cell surface glycans 
has experienced a renaissance in the past decade. For example cell-wall proteomic 
profiling and direct mass spectrometric (MS) analysis of fungal wall glycoproteins 
could help identify suitable vaccine candidates (Yin et al. 2008). 
In Nature, diversification of carbohydrate structure and function occurs in two 
ways: (i) novel sugar structures are generated through enzymatic modification of 
the functional groups of a common sugar precursor- this process is most elaborate 
in prokaryotic cell wall and secondary metabolite biosynthesis (Klement et al. 
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2007); (ii) a variety of glycoforms with differing regio- or steriochemistries are 
created by the attachment of sugar substrates to ‘acceptor’ molecules that include 
natural product aglycones, proteins, lipids and other sugars by the action of 
specific glycosyltransferases (GTs) (Thibodeaux et al. 2007) For example 
glycoprotein based targets for drug design consist of oligosaccharide chains 
covalently linked to an amino acid backbone (N-linked or O-linked), the structural 
composition of which is defined by the expression of GTs and glycosidase genes 
in different cells and the availability of their sugar nucleotide cofactors (‘donors’) 
of a specific saccharide (Barchi 2000). This makes the prospects of studying GTs 
as potential drug targets very exciting. 
In addition, despite their versatility and potential in drug development, there are 
concerns over using natural carbohydrates as drugs. This is because monovalent 
interactions between proteins and carbohydrates are relatively low compared to 
known drugs and their acceptors (Barchi 2000). Moreover, most oligosaccharides 
are highly water soluble and therefore prone to degradation by digestive 
glycosidases or clearance by hepatic receptors, highlighting concerns over overall 
drug bioavailability. Furthermore, chemical synthesis of oligosaccharides involves 
regio, stereochemistry of bond formation to be controlled for synthesis of well 
defined products (Erb et al. 2009). This presents as a laborious and challenging 
process that requires additional protection and deprotection steps to obtain the 
required stereochemistry of the final product, and proving industrially unfeasible 
owing to decreased product yield, waste generation and formation of reaction by-
products (Palcic 1999; Robertson and Steer 2004). For example for the synthesis 
of the pharmaceutical compound quercetin (Fig. 1.2) containing five –OH groups, 
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each of which can form glycosidic bonds, four of these must be protected to 
synthesize a specific desired monoglycoside (Lim and Bowles 2004).  
This Chapter will highlight the potential of GTs for the synthesis of glycosylated 
compounds. It will shed light on GTs as a means to understanding complex 
carbohydrate synthesis. In addition, the prospects for engineering GTs with a view 
to better understand catalytic domains will be discussed. 
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Fig. 1.1 Intravasation and metastasis of tumour cells by selective carbohydrate-
mediated interactions (adapted from Barchi, 2000). Sugar chains (pink hexagons) bind 
with carbohydrate binding proteins (lectins) at surfaces of other cells- endothelial or 
tumour (brown ovals). These interactions are promoted by specific peptide sequences 
(blue arrowheads) recognised by cell adhesion molecules (integrins). Tumours interact 
with endothelial cell surface leading to intravasation. Binding with extracellular matrix 
(ECM) proteins (laminin) through polylactosamines (double hexagons) promotes release 
of proteases causing matrix degradation and tumour metastasis. 
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     Fig. 1.2 Structure of quercetin 3’-O-glucoside (Wang et al., 2009).  
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1.2 Glycosyltransferases  
Due to the nature of some cellular functions wherein carbohydrate moieties act as 
cellular language that depends on specific carbohydrate structures, the 
biosynthesis of complex sugars involves the action of a diverse range of selective 
GTs generating an infinite number of glycoconjugates and polysaccharides 
(Aharoni et al. 2006). GTs catalyze the sequential transfer of the monosaccharide 
units of their activated donor (usually nucleotide donor) to specific acceptor 
molecules such as lipids, saccharides and  proteins resulting in the formation of a 
glycosidic bond (Hashimoto et al. 2009). 
Activated sugar dependent transferases account for the vast majority of naturally 
occurring  glycosyl transfer reactions and even though the range of acceptors is 
highly diverse, the donors are typically restricted to monosaccharides (glucose, 
galactose, mannose, xylose, fucose, arabinose etc) linked to a nucleoside mono- or 
di- phosphate leaving group (NMP or NDP) such as uridine diphosphate (UDP), 
GDP and CMP (Thorsoe et al. 2005). Of these, UDP-glycosyltransferases (UGTs) 
account for more than  60% of all GTs characterised so far (Hu  Walker 2002). 
 
1.2.1 GTs across genomes  
Even though in eukaryotes, only ten different NDP sugars are utilised in the 
majority of biosynthetic glycosylation reactions, prokaryotic NDP-sugars are 
much more diverse (Thorson et al. 2001). Bacterial GTs therefore serve as 
excellent targets for drug development since most of these sugars are absent in 
humans. Since these sugars are important constituents of the bacterial cell wall, 
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their biosynthesis involves mechanistically novel enzymatic steps that have been 
actively targeted for inhibitor development. For example CHLαGcT, a cholesterol 
glucosyltransferase from a peptic and gastric ulcer causing bacterium 
Helicobacter pylori represents an excellent drug target due its vital role in the 
synthesis of cell wall lipids (Lebrun et al. 2006; Lee et al. 2006).  
On the other hand, considering the vast number of glycosides in plants compared 
to other eukaryotes, it was believed that plant derived GTs would be more 
promiscuous. Even though plants GTs are known for their highly regio- and stereo 
selective nature, they can recognise common features on a range of substrates 
including hormones, secondary metabolites or xenobiotics. For example, 
glycosylation at the 3-OH position of certain plant pigments such as anthocyanins 
is crucial for the stability of the aromatic ring (Fukuchi-Mizutani et al. 2003; 
Gachon et al. 2005). This may imply that a wide range of substrates are accepted 
by plant GTs. For example Offen et al., (2006) described the promiscuity of 
VvGT1, a grape flavonoid UGT with respect to both the acceptor and donor 
substrates. It is important to note however that even though in vitro studies 
suggest plasticity in GT reactions, low substrate specificity could lead to 
undesired side reactions within the natural environment unless activity is 
regulated under transcriptional control (Osmani et al. 2009). 
In addition to prokaryotes and other eukaryotes, glycosylation is a well 
established phenomenon in fungi where complex polysaccharides and glycolipids 
such as glucans and chitin form vital cell wall components (Gorelik et al. 2001; 
Hashimoto et al. 2009). Although glycolipids are known to contribute to the 
biophysical properties such as ion impermeability of membranes in these 
organisms, their specific roles have only recently being characterised. For 
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example membrane lipid- protein interactions are now known to govern the 
folding, localisation and function of membrane proteins. More recently Warnecke 
and Heinz (2010) have suggested an alternative but complementary approach to 
the current methods being employed for deciphering the function of specific 
glycolipids. Instead of creating deletion mutants of GTs involved in lipid 
metabolism that result in phenotypes with incomplete or lack of membrane 
systems in many cases, this approach would involve an exchange of a lipid GT in 
the organism by a heterologous GT with different specificity; for example 
substitution of a galactosyltransferase (GalT) with a glucosyltransferase. This 
would help in creating mutants without the complete loss of general functions but 
would highlight the specific role of the lacking membrane lipid.  
N-linked and O-linked glycoprotein synthesis is however, is a well established 
process in yeasts such as S. cerevisiae, P. pastoris and Candida albicans, 
orchestrated by the action of specific GTs (Kim et al. 2006; Klutts et al. 2006; 
Mille et al. 2008). Golgi and ER GTs are involved in enhancing the stability and 
solubility of secretory proteins which also functions in the maintenance of fungal 
morphology in filamentous yeasts such as the Aspergillus species and are 
involved in virulence for example, in the fungal pathogen Cryptococcus 
neoformans that possesses a glycan rich cell wall surrounded by an intricate 
polysaccharide capsule (Goto 2007; Klutts et al. 2006). For example, an A. 
nidulans mutant lacking a protein O-mannosyltransferase (PMT), PmtC showed 
abnormal hyphae development and absence of conidia suggesting the vital role of 
PMTs in fungal development (Goto 2007). 
The majority of GTs involved in eukaryotic cell wall polysaccharide and 
glycoprotein synthesis are Golgi-resident type II- membrane localised proteins 
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consisting of a short N-terminal cytoplasmic domain followed by a 
transmembrane domain, a stem region and the lumen facing C-terminal globular 
catalytic domain (Keegstra and Raikhel 2001; Qasba et al. 2008; Rabbani et al. 
2006). 
Quite recently, proteomic approaches coupled with MS have enabled the rapid 
and sensitive identification, as well as quantification of fungal wall glycoproteins 
and the involved GTs, which may pave the way to the development of novel 
diagnostic tools as well as vaccines (Lin et al. 2008; Yin et al. 2007). 
 
1.2.2 Classification of GTs 
The rapidly increasing number of genome projects has provided a wealth of 
sequence and biochemical information. GTs represent one of the most diverse 
groups of enzymes in biological systems and their classification thus provides a 
useful insight into their divergent evolution. Over the years, a few different 
systems of GT classification have been proposed.  
It was initially believed that the most logical way to classify GTs would be 
according to their reaction mechanisms. Based on this, all GTs would be grouped 
as either ‘inverting’ or ‘retaining’ (Kapitonov and Yu 1999) (Reaction 
mechanisms described in section 1.2.2.1).  
GTs may also be classified based on differences in the carbohydrate glycosyl 
donors involved in the reaction (Compain and Martin 2001). Thus, they may 
either belong to the Leloir pathway, named after the 1970 Nobel Chemistry prize 
winner Luis Leloir following the discovery of uridine diphosphate D-glucose 
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(UDPG) and glycoside biosynthesis, or the Non-Leloir pathway. The former 
comprises of approximately 65% of all GTs, where donors may be activated by 
the addition of a mono- or diphosphate (CMP, GDP, UDP etc) forming a 
nucleotide sugar; the non-Leloir pathway GTs which utilise glycosyl phosphates 
or sucrose and other starch-derived oligosaccharides  as donors (Weijers et al. 
2008). 
However, the universally recognised system for GT classification, based on amino 
acid sequence similarity (Campbell et al. 1997) is the Carbohydrate Active 
Enzymes database (CAZy) (http://www.cazy.org/) (Cantarel et al. 2009). This 
system comprises enzymes with roles in carbohydrate metabolism, biosynthesis 
and modification and is composed of 4 enzyme classes- glycoside hydrolases 
(GHs), glycosyl transferases (GTs), polysaccharide lyases (PLs) and carbohydrate 
esterases (CEs). Each class is further divided into families that incorporate both 
structural and mechanistic (stereochemistry of the glucoside linkage) features with 
members of one family assuming similar 3-D structural folds (GT-A, GT-B or 
GT-C) and catalytic mechanism (Liu and Mushegian, 2003; Luzhetskyy et al. 
2005). However, sequence comparison cannot reliably predict catalytic 
mechanism (Osmani et al. 2009) and therefore, Coutinho et al. (2003) proposed 
sub-grouping of GTs into four clans as either inverting GT-A fold (clan I) or GT-
B fold (Clan II) or retaining GT-A fold (clan III) or GT-B fold (clan IV).  
So far, GTs have been classified into 92 CAZy families (designated as GTx) with 
over 50,000 open reading frames (ORFs) encoding putative GTs isolated from 
various plant, mammalian, fungal and prokaryotic sources.  
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This classification is underpinned by the assumption that signature structural 
motifs can be deciphered on the basis of primary protein sequence information 
(Henrissat and Davies 1997). Enzymes within a specific family may therefore 
have very different substrate specificities but be closely enough related to be 
considered divergent of one historical ancestor (i.e. homologous). It can also 
highlight convergent evolution whereby enzymes with very similar function and 
substrate specificity which would normally be grouped together by the IUBMB 
(International Union of Biochemistry and Molecular Biology) system of 
classification are shown to belong to several distinctly different families. For 
example, the large polyspecific families, such as GT2, consist of more than 3500 
sequences that vary in donor and/or acceptor specificity and therefore demonstrate 
distinct functions (Breton et al. 2006). GT cclassification based on catalytic 
mechanism and structural fold will be further described in the following sub-
sections. 
 
1.2.2.1 Classification based on catalytic mechanism 
GT catalysed reactions proceed by the sequential binding of the metal ion (if 
required for activity as a cofactor) and sugar nucleotide to the enzyme, followed 
by the acceptor (Qasba et al. 2005; Seibel et al. 2006) as shown in Fig. 1.2 A. The 
saccharide product is then ejected upon glycosyl transfer by ‘inversion’ or 
‘retention’. Analogous with glycosidases, GTs catalyse glycosidic bond formation 
with two possible stereochemical outcomes- inversion of the anomeric 
configuration (example UDP-glucose to β-glucoside) or retention of the anomeric 
configuration (example UDP-glucose to α-glucoside). There is limited knowledge 
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at the sequence level indicating differences between the two reaction mechanisms 
even though differences in UDP-binding amino acids have been suggested (Rosen 
et al. 2004). 
Inverting GTs catalyse via a single displacement mechanism with nucleophilic 
attack by the acceptors at the C-1 (anomeric carbon) of the sugar donor (Fig. 1.3 
B). This mechanism requires an active-site side chain to serve as a base to activate 
the sugar acceptor for nucleophilic attack by deprotonation because sugar 
hydroxyls themselves are poor nucleophiles (Charnock et al. 2001; Lairson et al. 
2008). In addition, most GT Clan I enzymes characterised so far use a divalent 
cation (Mn+2 or Mg+2) coordinated by the diphosphate moiety of the NDP-sugar. 
This ion binds with the conserved active site amino acid side chains to facilitate 
the departure of the NDP leaving group by stabilising the developing negative 
charge.  
The inverting mechanism for GTs was first highlighted by the 3-D X-ray structure 
of both native and UDP-complexed SpsA, a GT-2 family member from Bacillus 
subtilis (Charnock and Davies 1999). Three side chain aspartate (D) residues are 
predominantly involved in binding the UDP-sugar. It showed that at the N-
terminal, a nucleotide binding domain, D39 coordinated with the uracil base of the 
sugar donor whereas D98 and D99 (from a conserved DxD motif; described in 
section 1.2.2.2.) was coordinated with ribose and UDP-bound Mn+2 respectively. 
In addition, the side chain carboxylate of D191 served as a base catalyst in the 
inverting mechanism. 
Two reaction mechanism strategies have been proposed for retaining GTs. The 
earlier proposed strategy states the involvement of a double displacement 
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mechanism with the formation of a covalent intermediate. The SN2 double-
displacement mechanism involves a direct nucleophilic attack on the C1 of the 
UDP-sugar to form a β-linked glycosyl-enzyme intermediate. The leaving group 
phosphate itself plays the role of a base catalyst activating the incoming acceptor 
hydroxyl for nucleophilic attack (Lairson et al. 2008; Seibel et al. 2006). 
Another more likely adopted strategy suggests that the enzyme uses a SN1 
transition state in which the approach of the attacking acceptor and the leaving 
donor are on the same side of the sugar ring (Zhang et al. 2007). It involves the 
production of a nucleophile by the dissociation of the leaving group NDP and 
attack on the transition state by the acceptor from the same side of the sugar ring 
as the scissile glycosidic linkage to the leaving NDP.  
Although the both inverting and retaining catalytic mechanisms have been 
proposed, only the mechanism of inverting GTs has been well characterized so far 
(Qasba et al. 2005). This is due to the absence of any studies reporting the 
identification of the involvement of a catalytic nucleophile and/or a glycosyl-
intermediate as has been suggested in the reaction mechanism.  
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Fig. 1.3 A. Ordered reaction mechanism of GTs (Qasba et al. 2005). The binding of 
metal ion (m*) followed by the sugar-nucleotide donor (N-S) leads to a conformational 
change in the enzyme (E) creating the acceptor (A) binding site. Upon glycosyl (S) 
transfer to A, the product (S-A) is ejected followed by a reversal of E conformation to its 
native ‘closed’ state during which the metal-nucleotide complex (m-N) is ejected. 
              
 
Fig. 1.3 B. Reaction mechanism of GTs (Thibodeaux et al. 2007). Inverting GTs-1.: 
general base (B)-catalysed SN2 attack at C1 of the NDP-sugar donor by the acceptor 
forms an oxocarbenium-type transition state leading to the inversion of stereochemistry at 
the anomeric carbon; 2.: The double displacement mechanism for retaining GTs involves 
the SN2 attack of an active site nucleophile (Nu) at C1 of the NDP-sugar to form a 
covalent sugar–enzyme intermediate, followed by an SN2 attack of the acceptor at C1 to 
form the glycosidic linkage with retention of anomeric configuration. 
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1.2.2.2 Classification based on structural fold topology 
As compared with GHs where structural representatives from a large number of 
the 122 families are available, there is a relatively limited structural database for 
GTs (Hu and Walker 2002). Interestingly, in the former case, the highly diverse 
overall structural folds with conserved catalytic domains suggest evolutionary 
convergence during development of catalytic mechanisms. However, all NDP-
sugar utilising GT structures so far fall into one of the two distinct structural fold 
families- the GT-A or GT-B. These observations indicate that a vast number of 
GTs may have evolved from a small number of progenitor sequences (Coutinho et 
al. 2003). Recently however, a third GT-C fold family (Liu and Mushegian, 2003) 
utilising lipid donors has also been described and is discussed in section 1.2.5. 
The two main GT folds (A and B) are well documented, with the overall topology 
of GT-A fold members consisting of two separate but closely associated β/α/β 
domains creating an active site in the centre. Fig. 1.4 A. depicts the structure of 
Mycobacterium avium GT (MAP2569c) that adopts this fold (Fulton et al. 2008). 
The N-terminal or NDP-sugar binding domain possesses a common DXD or EXD 
motif (Asp-X-Asp or Glu-X-Asp) flanked by non-polar residues. The DXD motif 
interacts with the phosphate group of the donor through the coordination the 
divalent metal ion cofactor. The acceptor binds at the C-terminal. Most Leloir 
pathway Golgi and endoplasmic reticulum residing GTs, as well as most 
prokaryotic GTs belong to this fold family (Hu and Walker 2002).  
All GT-A fold members such as the α-mannosyltransferases (α-ManTs) and GalTs 
characterized so far require the presence of a metal ion cofactor that coordinates 
with the DXD side chain motif or its variants (example EDD, TDD) and was 
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therefore believed to be a characteristic feature of GT-A enzymes. However, one 
GT-A structure has been reported recently that does not possess this signature 
motif and Arg and Lys side chain residues were involved in stabilisation of 
electrostatic charges (Pak et al. 2006). Differences are also observed in the 
function of the DXD conserved motif residues in inverting and retaining GT-A 
enzymes. In the former case, both Asp residues interact with the metal ion 
whereas only the second Asp residue interacts with the metal ion in inverting 
members (Breton et al. 2006). 
The second structural GT-B fold, was first studied in the T4 β-glucosyltransferase 
and members of this family consist of two separate Rossman-like β/α/β domains 
with a connecting linker region and a deep cleft between the domains which 
functions as the catalytic centre. Fig. 1.4 B. shows the GT-B fold of the crystal 
structure of a plant flavonoid GT (UGT71G1) (Shao et al. 2005). As opposed to 
the GT-A family, the C-terminal domain is the nucleotide binding domain in this 
case. The N-terminal domains are less conserved and are evolved to accommodate 
different acceptors (Kapitonov and Yu 1999). Members of this fold family 
comprise most of the prokaryotic GTs, such as those involved in glycosylation of 
natural secondary metabolites and cell wall synthesis (Thibodeaux et al. 2007) 
and are therefore more diverse compared to GT-A members. 
As opposed to GT-A family enzymes, GT-B members catalyse in a metal ion 
independent manner (Breton et al. 2006). An example of this can be demonstrated 
by a study by Mulichak et al. (2003) where the crystal structure of Clan II GtfA 
from Amycolatopsis orientalis responsible for vancomycin biosynthesis showed 
that helix dipole and interactions with side chain hydroxyl and imidazole groups 
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were vital in stabilising the negative charge on the leaving group and therefore did 
not require the presence of divalent cations.    
Iterative searches and multivariate data analysis employing several computational 
models and sequence information of characterized and putative GTs have revealed 
the prediction of a third GT-C fold (Liu and Mushegian 2003; Rosen et al. 2004; 
Wimmerová et al. 2003) now classified for 10 GT families including GT39, GT22 
and GT51, GT66 and GT85 to name a few based upon two crystal structures. The 
predicted structure of the GT-C fold had indicated a large hydrophobic integral 
membrane protein which consisted of 8-13 transmembrane helices with a catalytic 
signature motif in the extracellular loop (Igura et al. 2008; Lairson et al. 2008). 
Fig. 1.5 A. shows the structure of the C-terminal domain of a GT66 
oligosaccharyltransferase (OST) from Campylobacter jejuni (PglB) that adopts 
the GT-C fold (Maita et al. 2010). OSTs are involved in N-glycosylation by 
catalysing oligosaccharide transfer from lipid donors to polypeptide chains and 
are responsible for the virulence of pathogens such as C. jejuni (Maita et al. 
2010). 
So far all CAZy family members predicted to adopt this fold utilize lipid-
phosphate activated donor sugar substrates (Lairson et al. 2008) as opposed to 
nucleotide-sugar donors or pyridoxal phosphate utilizing GT-A and GT-B fold 
enzymes. GT-C family members therefore belong to the Non-Leloir pathway of 
GTs. Thus, GT-C families mainly comprise of ManTs that use dolichol 
pyrophosphate-mannose as the sugar donor for the O-linked mannosylation of 
membrane lipids. In addition, GT85 arabinofuranosyltransferases (Aft) are 
involved in the synthesis of M. tuberculosis cell wall components as shown by 
Alderwick et al. (2006). 
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Fig. 1.4 Ribbon diagrams of GT structures depicting GT-A and GT-B folds. A: GT-
A fold of the MAP2569c structure complexed with ligands (ball and stick representation) 
as indicated (Fulton et al. 2008). The N-terminal domain (pink), Rossman domain (cyan) 
and the catalytic DXD motif (red), acceptor binding site (green), flexible loop (yellow), 
helical region (purple) and the remainder of the C-terminal domain (salmon) are shown; 
B: GT-B fold of the UGT71G1 complexed with the UDP-sugar donor (ball and stick 
representation) as indicated (Osmani et al. 2009). The PSPG motif (cyan and pink) and 
inter-domain linker (red) are also shown. 
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Fig. 1.5 GT-C fold of PglB highlighting the conserved residues of GT-C members. A. 
Structure of the C-terminal domain of PglB (Maita et al. 2010) showing a 10-stranded β-
sheet structure (green) within the α-helical core domain (blue). The conserved WWDYG 
motif (magenta) is shown followed by a helix (pink). The long, kinked helix constituting 
the active site of OST is also shown (light brown). A bound metal cation is shown 
(yellow sphere) B: Schematic of the full length OST structure and possible reaction 
mechanism (adapted from Igura et al., 2008). The N-terminal TMs and C-terminal 
globular domains are shown with the conserved motifs (shown in red, discussed in text) 
and bound cation (green) that are involved in N-linked glycosylation of the polypeptide 
chain using lipid-linked oligosaccharides (chain of pink hexagons and orange spheres). 
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1.2.3 GT Family 1 UGTs 
The GT1 family currently consists of over 3,600 sequences with representatives 
from all phylae. Members of this family adopt the GT-B fold and mechanistically 
are inverting in nature, classifying them within Clan II according to the 
classification proposed by Coutinho et al. (2003). There is widespread interest in 
GT1 members as they are mainly recognised for the glycosylation of small 
molecules including important organic compounds such as terpenes, steroids, 
macrolides as well as are involved in detoxification pathways (Lairson et al. 2008; 
Lim and Bowles 2004). For example, the pollutant 3, 4-dicholoroaniline was 
detoxified by glucosylation using an Arabidopsis GT (N-GT) (Loutre et al. 2003). 
Of the total 93 3-D structures of GTs solved so far, the GT1 family comprises 19, 
which is the maximum number of solved structures for any one GT family so far. 
This makes homology modelling an attractive tool for structure elucidation of 
novel GTs classified within this family. 
GT1 includes UGTs as members where they represent the majority of all 
sequences within this family. Of these, plant derived sequences are most 
prominent. For example, approximately 120 Arabidopsis sequences are included 
within the UGT superfamily (Hansen et al. 2010). Sequences sharing at least 40% 
amino acid sequence identity are further classified within the same UGT 
subfamily (Osmani et al. 2009). All characterised as well as putative plant UGTs 
identified so far lack the presence of a signal peptide sequence or membrane 
spanning domains suggesting that these enzymes mainly function within the 
cytosol but may be associated as peripheral components of the endo-membrane 
system (Lim and Bowles 2004). 
                                                                                      Chapter 1 Introduction 
 
26 
 
In addition, all GT1 UGT sequences, regardless of their origin share a conserved 
consensus sequence in the C-terminal domain denoted as the UGT signature 
sequence (USS) as originally proposed by Mackenzie et al. (1997). Among plant 
UGTs, this signature sequence is more conserved and is represented by a 44 
amino acid PSPG (putative secondary product glycosyltransferase) box (Vogt and 
Jones 2000). This region has been characterised as the NDP-sugar binding domain 
(Lim and Bowles 2004; Mackenzie et al. 1997) and will be further described in 
the section 1.2.4. 
GT family 1 also includes a large number of glucuronosyltransferases (EC 
2.4.1.17) involved in cellular homeostasis and phase II detoxification pathways 
(Offen et al. 2006). This class of GTs catalyse glucuronic acid transfer to 
potentially toxic lipophilic compounds such as bilirubin and steroid hormones 
thereby promoting their systemic clearance as highlighted earlier (Lim and 
Bowles 2004; Meech and Mackenzie 2010).  
GT1 family UGTs contain a class of UDP-sugar: sterol glucosyltransferases 
(USGTs); also known as UDP-glucose: sterol 3-O-β-D-glucosyltransferases (EC 
2.4.1.173). The first UGT of this class was purified from oat following which 
USGTs from both prokaryotes as well as eukaryotes were characterised (Idnurm 
et al. 2003; Kim et al. 2010; Madina et al. 2007). However, reports of sterols from 
bacteria are rare and only a few members of the Mycoplasma  and Helicobacter  
species have shown to produce steryl glycosides from free sterols that they take 
up from their host organisms (Warnecke and Heinz 2010). Within the last decade, 
the identification and cloning of several sterol glycosyltransferase genes have 
aided the use of genetic approaches to investigate the current limited 
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understanding of the specific biological functions of steryl glycosides (SGs) in 
eukaryotes (Grille et al. 2010). 
 
1.2.4 Conserved amino acid residues are involved in substrate recognition  
Until recently, the molecular basis for GT donor and acceptor selectivity was 
unclear. However, in the past decade with a surge in the number of crystal 
structures that have become available from over 26 CAZy families within the GT 
3D structure database (http://glyco3d.cermav.cnrs.fr/cgi-bin/rxgt/rxgt.cgi), it is 
now possible to better understand GT catalytic domains.  
GTs are highly regio- and stereoselective with regards to substrate recognition in 
vivo (Weijers et al. 2008). However, as illustrated earlier in the case of plant GTs, 
modifications on the acceptor substrates can be tolerated in vitro. However, 
analysis of substrate specificity based on the contribution of individual functional 
groups for recognition and binding poses a great challenge due to the limited 
availability of unnatural oligosaccharides and high cost of NDP-sugar donors.  
In the following sections (1.2.4.1 and 1.2.4.2), conserved amino acids and/or 
peptide motifs that play a major role in GT function will be discussed, with a 
special emphasis on GT-B fold UGTs as they are supported with better structural 
information. 
1.2.4.1 Conserved residues in NDP-sugar recognition 
A general pattern for substrate recognition can be observed among characterized 
GT-A and GT-B fold members. An inter-domain linker connects the N and C-
terminal domains and the secondary structure elements are connected by less 
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conserved, flexible loop regions associated with substrate binding (Fig. 1.4). For 
example, in the GT-A family, these flexible loops are associated with NDP-donor 
induced conformational change from open to closed where the loop acts as a lid 
covering the bound donor substrate creating an acceptor binding site (Qasba et al. 
2005). This is also suggested to prevent hydrolysis of the sugar donor (Breton et 
al. 2006; Unligil and Rini 2000). The length and composition of the linker region 
may differ among different GTs and serves to define domain positioning and 
consequent substrate accommodation. For example,  the inter-domain linker 
shows both length and sequence variability in the crystal structures of four GT1 
family plant UGTs- MtUGT71GT, VvGT1, MtUGT85H2 and AtUGT72B1 
(Osmani et al. 2009). This region differs significantly in comparison with crystal 
structures of bacterial GT1 members- GtfA, GtfB, GtfD from A. orientalis where 
it is much shorter and is directly involved in NDP-sugar binding (Mulichak et al. 
2003; Mulichak et al. 2001; Mulichak et al. 2004). No single motif is conserved 
across GT families classified within the CAZy database (Hashimoto et al. 2009). 
However, the presence of a few conserved residues in the NDP-binding pocket 
across GT members from different species determine nucleotide sugar specificity 
and/or transfer to aglycones (Qasba et al. 2005). A classical example of this can 
be demonstrated by the presence of highly conserved His, Asp/Glu, Gln residues 
in the C-terminal PSPG motif (also known as the USS for UGTs as described 
earlier) of the GT1 family members. Fig. 1.4 B. indicates the position of the PSPG 
motif wherein apart from the other residues involved in binding the UDPG, the 
Asp, Gln and Trp residues of UGT71G1 form hydrogen bonds with the ribose 
group of the saccharide moiety of the donor (Osmani et al. 2009). A study by 
Potocka and Zimowski (2008) revealed that the Glu or Asp residue(s) in the 
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Solanum melongena  (eggplant) UGT were crucial for UDPG binding whereas the 
His and Cys residues were important for both nucleotide and sterol binding.  
The additional residues within the USS that do not directly interact with the sugar 
donor are believed to be involved in facilitating intramolecular interactions to 
stabilise the developing negative charge, as previously described (section 1.2.2.1).  
As earlier described, GT-A fold members coordinate the essential metal cation via 
the DXD motif. Although GT-B fold members lack this motif, they do exhibit a 
pattern of Gly and Ser/Thr residues located within the donor-binding domain 
(Klutts et al. 2006). These residues have been shown to interact with the 
phosphate group of the NDP-donor. For example the crystal structure of a GT-B 
family N-acetylglucosaminyltransferase (MurG) from E. coli involved in 
peptidoglycan biosynthesis contains three glycine rich loop motifs: one in the C-
terminal that is suggested to bind the phosphate of the NDP-sugar and the other 
two within the N-terminal domain proposed to interact with the phosphate groups 
of the lipid-linked acceptor (Ha et al. 2000). 
Although in the case of GT-B family UGTs, the majority of sugar substrate 
interactions occur in the structurally conserved C-terminal domain, some key N-
terminal amino acids may also play a significant role in donor recognition and 
binding.  
1.2.4.2 Conserved residues in acceptor recognition 
In both the GT-A and GT-B members, the acceptor binding domain is generally 
less conserved suggesting that these may have evolved in order to accommodate a 
diverse range of aglycones (Hansen et al. 2009). However, some key residues 
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with charged side chains located within the acceptor binding pocket act as the 
general base triggering deprotonation of the acceptor as described in the reaction 
mechanism of GTs. In a majority of GT-B inverting enzymes, this base is His 
whereas the carboxylate group of the base catalyst Asp/Glu have been shown to 
be involved in deprotonation of the acceptor in some GT-A family members as 
illustrated earlier. The specific roles of these residues can be illustrated by the 
following examples. Mutation of the H19 and D117 resulted in complete loss of 
AtUGT72B1 activity of the respective Ala variants, suggesting the vital role of 
these residues in the nucleophilic attack on the acceptor (Brazier-Hicks et al. 
2007). It is also proposed that in a majority of inverting GTs, the histidine forms 
an Oacceptor-H-D triad where the Asp residue balances the charge on the His 
after proton abstraction. This was demonstrated by Shao et al., (2005) where 
substitution of the H22 and D121 with Ala in another plant UGT, UGT71G1 
resulted in inactive variants suggesting that interaction of Asp with His was 
critical for catalytic activation by possibly forming an electron transfer chain.  
 
1.2.5 Bioinformatic approaches for structure and function prediction of GTs 
The number of families is continually increasing with the discovery and 
biochemical characterization of new GT genes. However, functional prediction of 
a putative GT based on sequence homology can be unreliable, as closely related 
sequences may express different catalytic activities. One such example can be 
presented by the UGTs of Streptomyces fradie, UrdGT1b and UrdGT1c that are 
responsible for the synthesis of the antibiotic urdamycin. These GTs differ in 
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acceptor specificity despite sharing 91% amino acid identity, (Hoffmeister et al. 
2001) thereby exemplifying the complex nature of substrate specificity.   
For large polyspecific families such as the GT2, it is especially difficult to predict 
the specificity. Sequence similarities are generally observed for the entire catalytic 
domain in the case of monospecific GT families, as opposed to polyspecific 
families where they are mostly restricted to only a portion of the catalytic domain 
(Breton et al. 2006). These sequences therefore cannot be classified functionally 
using bioinformatics (Hansen et al. 2010). Thus, novel putative GTs with no 
characterized homologues can only be identified on the basis of catalytic signature 
motifs employing bioinformatics strategies. This was further highlighted in the 
case of the GT-C family classification as demonstrated by the following 
examples. 
As outlined earlier, bacterial GTs represent excellent potential drug targets and 
with the genome sequence of human pathogens such as Mycobacterium 
tuberculosis H37Rv available, cell wall synthesizing GTs for this pathogen for 
example are both an attractive and unexplored area. For example, the M. 
tuberculosis cell wall synthesizing enzymes EmbA, EmbB, and EmbC are 
currently one of the only few known drug targets for TB treatment and apart from 
Mycobacterium and related genera, they show no sequence similarity to 
homologues from other species (Berg et al. 2005). 
Furthermore, GT-C members characterised so far use lipid donors and are pivotal 
in archaeabacterial and eubacterial cell wall synthesis, clearly suggesting the 
exclusivity of the involvement of these GTs in the process. However, GT-C 
classification will need to be further established on the basis of structural data as 
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so far, no characterized lipid phospho-sugar donor utilizing peptidoglycan 
synthesizing GTs (PGTs) have been assigned the GT-C fold. For example, crystal 
structures of the soluble domains two prokaryotic PGTs grouped under GT51 
have recently been determined and have interestingly shown to adopt a novel Ȝ-
lysozyme-type fold even though lysozymes degrade peptidoglycan chains 
(Lovering et al. 2007; Yuan et al. 2007).  
On the other hand, the first 3-D crystal structure of the GT-C assigned archaeal 
OST STT3 from Pyrococcus furiosius was determined recently (Igura et al. 
2008). Similar to the C. jejuni OST (Fig. 1.5 A), the P. furiosius OST adopts a 
novel α-helical fold surrounded by three β-sheet domains and is void of any 
characteristic Rossman-folds (Igura et al. 2008). Interestingly however, even 
though the C-terminal domain used for structural analysis consisted of the loop 
harbouring the predicted active site, the truncated protein resulted in a loss of 
activity suggesting the vital role of the N-terminal transmembrane region in OST 
activity. On comparison with the only other GT-C family solved structure an OST 
from the prokaryote C. jejuni, it was observed that the two OSTs shared 
significant structural similarity despite low sequence similarity (Maita et al. 2010) 
and are now grouped under GT66. 
It is interesting to note that both the GT-C structures available so far have been 
determined using only the truncated soluble C-terminal domains of OSTs. These 
domains consist of conserved catalytic motifs in the first extracellular loop after 
the N-terminal domain (Berg et al. 2005) as shown in Fig. 1.5 B. The Asp in the 
conserved WWDYG motif acts as a catalytic base whereas the DK and DXD 
motifs are involved in binding lipid-linked donors through a transiently bound 
cation (Igura et al. 2008). Based upon this, a novel Aft from M. tuberculosis 
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(AftA) was identified and classified as a GT-C fold member (GT85) following 
structural sequence alignment with these conserved motifs (Alderwick et al. 
2006).  
The above studies therefore highlight the fact that computational methods based 
on motif-extraction, Hidden Markov models (HMM) prediction and structural 
comparison of sequenced genomes (Rosen et al. 2004; Wimmerová et al. 2003) 
may represent a more reliable approach in identifying novel GTs and predicting 
their structural folds as primary sequence properties may be more conserved 
despite low sequence similarity. However, determining acceptor specificity solely 
from the amino acid sequence may still present a challenge unless orthologs 
within a family are compared. 
 
1.3 Diversifying functions of UGTs 
The rational design of novel non-natural glycosylated compounds with desired 
properties requires a detailed knowledge of the function and mechanism of GTs. 
As illustrated in the previous sections, GT substrate specificity cannot be 
predicted from sequence comparison alone (Osmani et al. 2009). Even though the 
number of GT families classified in the CAZy database has almost doubled within 
the last decade, structural elucidation studies have struggled to keep pace with the 
increasing amount of sequence information of gene clusters involved in 
glycosylated natural product synthesis. Structure or sequence guided rational GT 
engineering attempts have largely been limited to single site-directed mutagenesis 
to decipher the roles of specific residues and/or elicit desired changes to enzyme 
properties (Hancock et al. 2006; Kim et al. 2010).  
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Since GTs display a two domain architecture with conserved 3-D structural folds, 
yet varied substrate (donor and/or acceptor) preferences, they represent ideal 
candidates for gene manipulation and engineering by methods such as directed 
evolution (DE) and combinatorial biosynthesis. These approaches would not only 
increase our present understanding of catalytic domains but would also help 
generate GTs with novel specificities (Hancock et al. 2006). Rational engineering 
and DE approaches are not entirely exclusive of one another because even though 
the latter approach does not necessarily require knowledge of the enzyme 
structure, knowledge-based design of GT variant libraries may improve overall 
engineering strategies (Dalby 2007). 
The following sections will aim to review some of the approaches that have been 
employed to obtain novel enzymes with improved biochemical, physical and 
catalytic properties as well as desired substrate specificities. 
 
1.3.1 GT metabolic pathway engineering of as a means to natural product 
glycodiversification 
Due to the limited availability of NDP-sugars as well as the difficulty in accessing 
chemical derivatives using chemical synthesis routes, whole cell catalysis for the 
generation of glycosylated natural products is an evolving area. For example, in a 
recent study, a plant flavonoid GT was expressed in S. cerevisiae for the 
glycosylation of naringenin using endogenous UDPG (Werner and Morgan 2009). 
The metabolic pathway of interest of a natural product producing strain can be 
manipulated to generate novel natural products through gene disruption and 
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heterologous expression of a gene encoding a GT catalysing the synthesis of the 
required glycosylated product. For example dnrV, the gene encoding 4-
ketoreductase of the daunorubicin pathway of Streptomyces peucitius was 
disrupted and replaced by its homologue eryBIV that altered this biosynthetic 
pathway into producing epirubicin, an antitumour drug with improved therapeutic 
properties (Luzhetskyy and Bechthold 2008; Thibodeaux et al. 2007). 
Combinatorial biosynthesis is the systematic modification and interchange of 
genes involved in the biosynthesis of natural products leading to the production of 
unnatural or hybrid natural products in vivo (Rix et al. 2002; Wohlgemuth 2005). 
In this emerging technology, whole cells are re-engineered by introducing 
genes/chimeras for carbohydrate-processing pathway enzymes from other 
organisms. So far, this approach has been mainly adopted for the biosynthetic 
pathways of the polyketide group of antibiotics such as erythromycin and 
vancomycin (Rix et al. 2002; Walsh et al. 2003) even though other examples have 
been reported. For example, in an attempt to produce a complex human N-glycan, 
the endogenous yeast glycosylation pathways of P. pastoris were replaced with 
chimeric GTs including mannosidases, N-acetylglucosaminyltransferases and the 
UDP-N-acetylglucosamine (GlcNAc) transporter (Hancock et al. 2006). However, 
in some cases, the low transformation efficiency coupled with conjugational 
incompetence of host strains may pose limitations to the size of the target 
gene/insert to be expressed (Hoffmeister et al. 2001). 
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1.3.2 DE of GTs 
DE techniques mimic natural evolution processes such as random mutagenesis 
and sexual recombination (Dalby 2007). It is the generation and selection of a 
molecular library of enzymes with sufficient diversity for the altered function to 
be represented and evolved variants are selected and used as templates for the next 
round of evolution (Cohen et al. 2001; Rubin-Pitel and Zhao 2006).  
In DE studies, gene fragments of interest can be engineered in vitro or in their 
natural cellular environments for glycosylated product synthesis. However, in the 
case of GTs, loss of enzyme activity does not result in a phenotypic change and 
therefore cannot form the basis of a cell-based selection method (Love et al. 
2006). 
1.3.2.1 In vitro DNA recombination and domain swapping 
GT engineering and domain swapping studies have guided the identification of 
specific side chain residues or peptide motifs that govern substrate specificity in 
addition to offering a greater understanding of intra- and inter domain interactions 
(Osmani et al. 2009). However, due to the complexity of substrate recognition 
where several regions are involved, chimeric GTs have been generated using                  
UGTs (Cartwright et al. 2008; Krauth et al. 2009). For example, based on 
previous knowledge of the specific protein region of 31 amino acids of UrdGT1b 
and UrdGT1c that defines both donor and acceptor recognition, Hoffmeister et al. 
(2002) created a chimeric gene library harbouring codons for the 10 non-identical 
residues in this region from both parental enzymes. In addition to exhibiting 
parental specificities for urdamycin synthesis, several variants displayed novel 
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glycosylation patterns and exclusively catalysed the synthesis of a derivative, 
urdamycin P that contained a branched saccharide appendage. 
However, recently, Hansen et al. (2009) successfully applied the domain-
swapping strategy to closely as well as distantly related family 1 plant UGTs. The 
chimeras were constructed based on sequence alignments and molecular 
modelling with known UGT structures and generated functionally active UGTs. 
For example chimeras constructed with AtUGT71C1 and AtUGT71C2 showed a 
three-fold increase in Kcat of etoposide glycosylation compared with the wild type 
enzymes. Increased catalytic efficiency towards etoposide and a novel 
regiospecificity towards trans-resveratrol was also observed for chimeras 
constructed with AtUGT71C1 and SrUGT71E1 even though these sequences 
displayed only 38% amino acid sequence identity. 
1.3.2.2 DE by random mutagenesis  
In random mutagenesis (RM), libraries containing random combinations of single 
and multiple point mutations across entire gene/gene fragment can be generated 
by techniques such as error-prone PCR (ep-PCR) using a low-fidelity DNA 
polymerase. Williams and co-workers (2007, 2008) evolved GTs involved in the 
glycosylation of specific macrolide antibiotics by random mutagenesis using ep-
PCR. In one such example, a triple mutant (P67T/S132F/A242V) of the 
oleandomycin GT (OleD) from Streptomyces antibioticus showed a ~30 fold 
higher specific activity value against the fluorescent acceptor 4-
methylumbelliferone (4-Mu) as compared to wild-type OleD (Williams et al. 
2007). Following this, another triple mutant P67T/I112K/A242V of OleD was 
created with a 150-fold improved specific activity towards the nonnatural acceptor 
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novobiocic acid. It was found that Pro67 present in the N3 loop region and Ile112 
were associated with substrate specificity and acceptor binding respectively. 
These mutants consisted of a polar/charged residue at position 112 and 
hydrophobic residue at position 242 which were found to contribute to enhanced 
activity (Williams et al., 2008). 
1.3.2.3 Challenges for the DE of GTs 
A hurdle to the scope of DE experiments involving enzymatic and 
chemoenzymatic in vitro synthesis of glycoforms is created by the limited 
availability of NDP-sugar donors. However, recent work has suggested 
improvements in chemical methods of NDP-sugar synthesis, as well as enzyme-
based approaches for the synthesis and regeneration of sugar nucleotides (Mao et 
al. 2006; Masada et al. 2007; Pesnot and Wagner 2008; Ruffing et al. 2006). One 
such method for glycodiversification is glycorandomization which uses the 
inherent or engineered promiscuity of anomeric kinases and 
nucleotidyltransferases for the in vitro synthesis of accessible NDP-sugar donor 
libraries (Williams et al. 2007). However, the feasibility of the use of such 
methods requires further validation. 
Also, most DE and genetic engineering platforms require an efficient screening 
system for evolved variants. However, due to the magnitude of the library 
generated (103-107 variants); the exploitation of RM studies is solely dependent on 
the availability of a robust HTS methodology based on a simple selection for 
glycosidic bond formation. Currently, for in vitro evolution studies, the lack of 
suitable and efficient high-throughput screening systems to select for the desired 
activity is well documented and represents the main focus of research for 
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expanding the scope of GTs. The majority of the current screening methodologies 
either involve linking the aglycone to a surrogate fluorescent acceptor 
(Trubetskoy and Shaw 1999) or derivitization of the acceptor (Cowan et al. 2008; 
Warnecke et al. 1999), which in both cases, leads to a detectable change linked 
with product formation. A few recent studies have however, reported the 
development of colorimetric screens for the rapid screening of GT activity (Deng 
and Chen 2004), the wider scope of which needs to be further assessed.   
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1.4 Aims and objectives 
Glycosylation of drugs, which includes a major class of glycosylated steroids, 
significantly improves their stability, overall bioavailability and pharmacokinetic 
properties. However, the chemical synthesis of such compounds is a laborious and 
industrially unfeasible process and as such, paves the way for molecular based 
approaches for novel glycosylated product synthesis. 
Family 1 UGTs comprise of a class of USGTs and can therefore be exploited for 
the biosynthesis of steroidal glycosides. The major aim of this study was to isolate 
and characterize the function of putative eukaryotic USGTs for the synthesis of 
glycosides from steroids and steroid derivatives. Warnecke et al. (1999) have 
experimentally shown that the majority of the N-terminal domain of ScUGT51 
was not required for USGT activity. In addition to retaining its functional activity, 
the N-terminally truncated gene product was soluble and functionally stable when 
expressed in E. coli. The shortest C-terminal domain of ScUGT51 vital for 
enzyme function consists of sequence of 476 amino acids resulting from a 
deletion of the first 722 N-terminal amino acids (Warnecke et al. 1999).  
This study has attempted to exploit the observation that ScUGT51’ and related 
UGTs with N-terminal deletions could be available to detailed biochemical 
analysis as pure enzymes against a select panel of steroidal acceptors. 
Furthermore, at present no structure is available for USGTs which limits their 
detailed functional analysis. This study also aimed to study the function of the 
isolated USGTs by employing DE studies by RM. 
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The following table (Table 2.1) lists manufacturers (and the abbreviated form) 
that were used to source chemicals, reagents and enzymes used within this study.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.1 Manufacturers and their abbreviations used within the thesis. 
 
 
 
 
 
Manufacturer Abbreviation 
Acros ACR 
Alfa Aesar AE 
Amersham Biosciences AB 
Bioline BL 
Bio-Rad BR 
Brunswick Scientific BRS 
Fisher FIS 
Invitrogen INV 
Melford Laboratories Ltd. MEL 
MWG Biotech AG MWG 
National Diagnostics ND 
New England Biolabs NEB 
Novagen NOV 
Oxoid OX 
Perkin Elmer PE 
Sigma SIG 
Start Labs SL 
Stratagene STR 
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The following Materials section (2.1) details the recipes of reagents and media 
used throughout this study. Protocols used for DNA extraction, cloning and 
protein expression as well as UGT assay protocols are detailed in the Methods 
section 2.2. 
 
2.1 Materials 
2.1.1 Equipment  
All general use equipment is listed in Appendix D. 
 
2.1.2 Media 
Unless otherwise stated all solutions were made up with 18.2 MΩ/cm H2O 
purified by a Millipore Direct-Q® water purification system and were stored at 
room temperature. All media was prepared using distilled H2O and sterilised by 
autoclaving at 121°C. Liquid media was stored at room temperature, and solid 
media at 4°C. All adjustments to the pH of solutions were achieved using 1 M 
HCl or 1 M NaOH unless stated otherwise. 
2.1.2.1 Liquid media 
LB (Luria-Bertani) broth 
 
 
 
 
                     Component                             Amount (g)/L distilled  H2O 
Tryptone (OX)          10 
                      Yeast extract (OX)                    5 
 NaCl (SIG)                    10 
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Components were sequentially dissolved and adjusted to pH 7.0 followed by 
autoclave sterilisation. 
Low salt LB broth 
Used for the preparation of electrocompetent cells for transformation. 1 g low salt 
LB (SIG) was dissolved in 50 ml LB media in a 250 ml conical flask and 
autoclave sterilised. 
 
Liquid media for growing yeast cultures 
All liquid media was autoclaved at 121 oC prior to use. For the growth of yeast 
and bacterial strains on solid media, plates were prepared with the addition of 2% 
w/v Agar (OX). 
 
 
(a) YEPD broth 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                       Component                           Amount (g)/L distilled  H2O 
                        Bacto-Peptone (BD)              20 
                        Yeast extract (OX)   10 
                        Glucose (SIG)    20 
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(b) YM Broth 
 
 
 
 
 
 
 
(c) 393/YPD Broth (pH 6.5) 
 
 
 
 
 
 
 
(d) Broth 186 
 
 
 
 
 
 
 
 
                         Component                         Amount (g)/L distilled  H2O 
                         Yeast Extract                              3 
 Malt Extract (OX)                3 
 Peptone (OX)                 5 
                          Glucose (SIG)                                      10 
                        Component                          Amount (g)/L distilled  H2O 
                           Peptone                          20 
                           Yeast extract                         10 
                           Glucose                                     20 
                    Component                   Amount (g)/L distilled  H2O 
                           Yeast extract                                    3 
                           Malt extract                          3 
                           Glucose                          10 
                           Peptone (soybean)                            5 
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2.1.2.2 Solid media 
LB agar 
For the preparation of agar plates 2% (w/v) agar (bacteriological agar No 1) (OX) 
was added to sterile LB broth. Agar was then made soluble by autoclaving the 
media and poured into Petri dishes upon cooling to 50°C.  
2.1.2.3 Selective media 
Antibiotics, IPTG, X-Gal 
Antibiotics were made up at stock concentrations in sterile 18.2 MΩ/cm H2O 
unless stated otherwise and were diluted to the appropriate concentration in media 
(Table 2.2). 
 
Antibiotic/IPTG Stock 
concentration 
Dilution 
of stock  
Final 
concentration 
in media 
Storage 
of stocks 
Kanamycin (SIG) 10 mg/ml 1:100 100 ȝg/ml 4°C for 
up to 3 
days 
Chloramphenicol 
(SIG) 
34 mg/ml in 
100% (v/v) 
ethanol 
1:1000 34 ȝg/ml -20°C 
Streptomycin (SIG) 10 mg/ml 0.75:100
0 
75 ȝg/ml -20°C 
Ampicillin 10 mg/ml 1:100 100 ȝg/ml 4°C 
Isopropyl-beta-D-
thiogalactopyranoside 
(IPTG) (SIG) 
24  mg/ml 1:100 240 ȝg/ml 4°C 
X-Gal 40 mg/ml in 
100% (v/v) 
dimethyl 
formamide 
1:500 80 ȝg/ml -20°C 
 
Table 2.2 Stock concentrations and final concentrations of antibiotics in media 
 
For the addition of antibiotics to molten agar the media was cooled to ~55°C. 
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2.1.3 AGE -buffers, dyes and reagents 
2.1.3.1 TAE running buffer (50x) (TRIS-HCl (2 M), Glacial acetic acid (1 M), 
EDTA (0.05 M)) 
 
                Component                                                per L 18.2 MΩ/cm H2O 
                TRIS (SIG)                                            242 g 
                Glacial Acetic acid (17.51 M) (FIS)                  57.1 ml 
                EDTA (SIG) (0.5 M) solution pH 8.0          100 ml 
 
Running buffer was diluted down to 1x with distilled H2O prior to use for the 
preparation of agarose gels and use as reservoir buffer in gel tanks. 
 
2.1.3.2 Ethidium bromide (EtBr) (SIG) 
EtBr (10 mg/ml) was used diluted with 18.2 MΩ/cm H2O to a working 
concentration of 10 ȝg / ml prior to use. 
 
2.1.3.3 Sample loading buffer 
Bromophenol blue (6x) sample loading buffer 
 
                      Component                                           Amount 
                      Bromophenol blue (SIG)  0.25% w/v 
                      Glycerol (FIS)               30% v/v 
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DNA loading buffer without bromophenol blue (6x) (for DNA bands < 1Kb) 
 
                      Component                                           Amount 
                      Xylene cyanol (SIG)           0.25% w/v 
                      Glycerol (FIS)               30% v/v 
 
Loading buffer was diluted down to 1x with the sample prior to loading on an 
agarose gel. 
 
2.1.4 General buffers and reagents and size standards 
2.1.4.1 TE buffer (TRIS-HCl 10 mM, EDTA 1 mM pH 8.0) 
            Component                                  Volume (ml)/ L 18.2 MΩ/cm H2O                     
 TRIS (SIG)-HCl (0.5 M) pH 7.5                  20 
            EDTA (0.5 M) pH 8.0 solution                                        2 
 
 
2.1.4.2 STET Buffer 
                        Component                                           Amount/volume/L 
                         Sucrose                          80 g 
                         Triton X-100                         50 ml             
                         0.5 mM EDTA (pH 8.0)                           100 ml 
                        TRIS-HCl                                                   6.06 g  
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2.1.4.3 Size Standards 
 
DNA size standards 
For agarose gels, Hyper Ladder I® (Bioline) was used (m.wt. 200, 400, 600, 800 
1000, 2000, 2500, 3000, 4000, 5000, 6000, 8000, 10000 bp)  
Protein size standards 
High molecular weight range (SIG) (m.w. 36, 45, 55, 66, 84, 97, 116 and 205 
kDa) 
Low molecular weight range (SIG) (m.w. 20, 24, 29, 36, 45 and 66 kDa). 
Lyophilised standards (SIG) were reconstituted with 100 ȝl of sterile 18.2 MΩ/cm 
H2O to give a final concentration of ~2.0-3.5 mg / ml and separated into 4 ȝl 
aliquots and stored at –20°C. 
 
2.1.4.4 MgCl2-CaCl2 solutions  
For the preparation of chemically competent E. coli cells for transformation 
MgCl2 (SIG) (80 mM) solution  
(3.3 g/ 200 ml 18.2 MΩ/cm H2O) 
CaCl2 (SIG) (20 mM) solution 
(2.94 g/ 200 ml 18.2 MΩ/cm H2O) 
The two solutions were mixed in a 1:1 ratio and separated into 20 ml aliquots 
followed by autoclave sterilization. The aliquots were then stored at 4°C. 
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For final re-suspension of chemically competent cells 1 M CaCl2 was prepared by 
dissolving 14.7 g of CaCl2 in 100 ml 18.2 MΩ/cm H2O. The solution was 
separated in 1 ml aliquots and stored at 4°C. 
 
2.1.5 SDS-PAGE reagents and buffers 
12% (w/v) acrylamide resolving gel components 
 
                        Component                                                             Volume 
40% (w/v) solution (37.5:1 acrylamide: bisacrylamide) (SIG)      3 ml 
Buffer B*                            2.5 ml           
18.2 MΩ/cm H2O                                                                          4 ml 
Ammonium persulphate (APS) 10% (w/v) (SIG)              50 ȝl 
(TEMED)  (SIG) 
N,N,N',N'-Tetramethylethylenediamine                                    10 ȝl 
 
 
*Buffer B  
              Component                               Volume (ml)/ 100 ml 18.2 MΩ/cm H2O 
      TRIS-HCl (2 M) pH 8.8 (SIG)   75 
      10% (w/v) SDS (SIG)      4 
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Acrylamide stacking gel components 
 
Component                                                                   Volume 
40% (v/v) solution (37.5:1 acrylamide: bisacrylamide)         0.5 ml   
Solution C*                     1 ml 
18.2 MΩ/cm H2O                  2.5 ml 
10% (w/v) APS (SIG)                                                30 ȝl 
TEMED (SIG)                    10 ȝl 
 
5 ȝl of 2% (w/v) Bromophenol blue dye was added to the stacking gel to give a 
blue colour to distinguish between wells while loading samples. 
 
*Buffer C  
              Component                               Volume (ml)/ 100 ml 18.2 MΩ/cm H2O 
                      TRIS-HCl (2 M) pH 8.8 (SIG)   50 
                      10% (w/v) SDS (SIG)      4 
 
 
SDS - PAGE running buffer 10x (Stock) 
 
                             Component                       Amount (g)/L 18.2 MΩ/cm H2O 
                               TRIS        0.3 
Glycine (SIG)           144 
SDS (SIG)            10 
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The pH of the TRIS-HCl and glycine was adjusted to pH 8.0 in a volume of ~900 
ml prior to the addition of SDS. 
Running buffer was made up at 10 x stock concentration and diluted 1:10 with 
18.2 MΩ/cm H2O prior to use. 
 
SDS - PAGE sample loading dye 
 
              Component                                                     Volume (ml)/10 ml 
TRIS-HCl (60 mM) pH 6.8        0.6 
50% (v/v) Glycerol (SIG)    5.0 
10% (w/v)SDS     2.0 
β-Mercaptoethanol (14.4 mM) (SIG)   0.5 
                 Bromophenol blue (0.1%) (w/v) (SIG)                  1.0 
                18.2 MΩ/cm H2O                                0.9 
Loading dye was stored at –20°C in 0.4 ml aliquots. 
 
Solublising SDS - PAGE sample buffer (cracking buffer) 
2.4 g Urea (SIG) was added to 7.6 ml SDS-PAGE sample loading dye 
(section 2.1.3.4) and stored at 4°C. 
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Coomassie blue SDS-PAGE gel staining solution 
 
            Component                                        Per L 18.2 MΩ/cm H2O 
                Coomassie Blue R-250 (FIS)  1 g 
                Glacial acetic acid           100 ml 
                Methanol (FIS)                      450 ml 
 
Coomassie blue SDS-PAGE gel destaining solution 
 
                  Component                          volume (ml)/ L 18.2 MΩ/cm H2O 
                    Acetic acid     100 
                     Methanol    100 
 
 
 
2.1.6 Buffers for protein purification 
2.1.6.1 Ni2+ affinity chromatography purification buffers (for automated 
purification, gradient elution) 
 
Start buffer (Na2HPO4 (50 mM), NaCl (0.5 M), imidazole (10 mM)) pH 7.4. 
  
 
                    Component                            Amount (g)/ L 18.2 MΩ/cm H2O 
                    Na2HPO4 (SIG)                                     7.1 
                    NaCl                                                    29.2 
                    Imidazole (ACR)                                 0.68 
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Elution buffer (Na2HPO4 (50 mM), NaCl (0.5 M), imidazole (500 mM)), pH 7.4 
Refer recipe for start buffer except 0.68 g Imidazole was replaced with 34 g 
Imidazole.  
 
2.1.6.2 Buffers for MS analysis of digested peptides 
LC-MS grade H2O and Acetonitrile (ACN) (FIS) were used to prepare buffers for 
mass spectrometry analysis of peptides. Buffers were made up fresh prior to use. 
 
Start buffer A  
 
                               Component                         % (v/v) 
                                18.2 MΩ/cm H2O                 95 
                                 ACN                                     5  
                                Formic acid                          0.1 
 
 
 
Start buffer B 
 
                               Component                         % (v/v) 
                                18.2 MΩ/cm H2O                    5 
                                ACN                                      95  
                                Formic acid                           0.1 
 
2.1.7 In-gel protein digestion reagents  
100 mM NH4HCO3 (pH 8.0) 
79 mg NH4HCO3 was dissolved in 10 ml 18.2 MΩ/cm H2O. A 1:2 dilution of 100 
mM NH4HCO3 was prepared in 18.2 MΩ/cm H2O to prepare 50 mM NH4HCO3. 
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Trypsin solution  
A 1 ȝg/µl stock solution of Trypsin (Trypsin Gold, Mass spectrometry grade, 
Promega) was prepared by dissolving 100 ȝg of the lyophilised powder in 100 µl 
50 mM glacial acetic acid. Stock solutions were either stored at -20°C for use 
within one month or at -80°C for future use. 
 
 
2.1.8 Yeast and E. coli (DE3) strains  
All yeast strains were sourced from suppliers as detailed in Table 2.3. 
 
Table 2.3 Summary of yeast host strains used in this study. a Received as a gift from 
Agriculture Research Service Culture Collection, U.S. 
 
Organism Type Supplier and 
collection no. 
GenBank Accession 
Nos. of UGTs 
Saccharomyces cerevisiae 
(Sc) strain S288C 
Yeast ATCC 204508 NP_013290 
Pichia pastoris (Pp) strain 
GS115 
Yeast ATCC 201178 AAD29570 
Pichia guilliermondii (Pg) Yeast DSM 6381 XP_001482815 
Kluyveromyces polysporus 
(Kp) 
Yeast DSM 70294 XP_001646967 
Pichia angusta (Pa) Yeast DSM 70277 ABO31066 
Kluyveromyces lactis (Kl) Yeast DSM 70799 XP_452287 
Debaromyces hansenii 
(Dh)  
Yeast CBS 767a XP_460322 
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Stocks of all E. coli (DE3) strains were maintained at –80°C in 50% (v/v) glycerol 
and were used as detailed in Table 2.4. Antibiotic requirements for each strain 
used are listed in Table 2.5. 
 
 
Table 2.4 E. coli strains and their applications in this study. (b  pET system manual, 
1999). c Glycerol stocks provided by Structural Biology Lab, York University 
E. coli strain and 
source 
Application Genotype b 
TOP10 (INV) Cloning host F- mcrA Δ(mrr -
hsdRMS-mcrBC) 
φ80lacZΔM15 
ΔlacX74 recA1 
araD13λ Δ(araleu) 
7697 galU galK rpsL 
(StrR) endA1 nupG 
 
DE3 strains :  
BL21  (NOV) 
 
B834 (NOV) 
 
 
 
C41 (NOV) 
 
 
C43 (NOV) 
 
 
BL21-Codon Plus –RP 
(CP-RP) c 
 
 
 
BL21-Codon Plus –
RIPL (CP-RIPL)c 
 
Optimising soluble 
protein expression 
 
F-ompT hsdSB (rB-mB) 
gal dcm (DE3) 
F– ompT hsdSB (rB– 
Mb–) gal dcm met 
(DE3) 
 
F- ompT hsdSB (rB- mB-) 
gal dcm (DE3) 
 
F-ompT gal hsdSB (rB-
mB-) dcm lon Ȝ DE3 
 
B F– ompT hsdS(rB– 
mB–) dcm+ Tetr gal 
Ȝ(DE3) endA Hte 
[argU proLCamr] 
 
B F– ompT hsdS(rB– 
mB–) dcm+ Tetr gal 
Ȝ(DE3) endA Hte 
[argU proL Camr] 
[argU ileY leuW 
Strep/Specr] 
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E. coli 
strain 
Antibiotic Required for growth (liquid/solid media) 
TOP 10 None 
BL21 None 
B834 None 
C41 None 
C43 None 
CP-RP chloramphenicol  
CP-RIPL Chloramphenicol in liquid media prior to induction 
with IPTG and for preparation of chemically 
competent cells 
Chloramphenicol and streptomycin for growth in solid 
and liquid media (preparation of glycerol stocks etc.) 
 
Table 2.5 Antibiotic growth requirements for E. coli (DE3) strains. 
 
 
2.1.9 Enzymes 
All enzymes, buffers and reaction co-constituents were maintained at –20°C. 
Enzymes and reaction constituents are listed in Table 2.6. 
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Enzyme Suppliers Co-constituents 
Polymerases: 
 
T4 DNA Polymerase 
 
KOD Hot Start DNA 
Polymerase (kit) 
 
Taq DNA 
Polymerase (kit) 
 
 
Mutazyme II® DNA 
polymerase, 
EZClone DNA 
polymerase (kit) 
 
 
NOV 
 
 
 
BL 
 
 
 
STR 
 
Reaction buffer (recipe 
undisclosed by 
manufacturer) 
 
25 mM MgSO4, reaction 
buffer (recipe undisclosed 
by manufacturer) 
 
50 mM MgCl2, NH4 reaction 
buffer (160 mM (NH4)2 SO4, 
670 mM TRIS-HCl (pH 8.8) 
 
Supplied reaction buffers 
(recipes undisclosed by 
manufacturer) 
 
Restriction enzymes 
XbaI and XhoI 
NEB Bovine serum albumin 
(BSA)e, reaction buffer 2 
(10 mM TRIS-HCl, 50 mM 
NaCl, 10 mM MgCl2, 1mM 
Dithiothreitol (DTT), pH 7.9 
at 25°C). 
 
 
Lysozyme (from hen 
egg white) 
FIS None 
Lyticase  
(Arthrobacter luteus)  
SIG Sorbitol buffer (1M sorbitol 
(FIS); 100 mM sodium 
EDTA; 14 mM β-
mercaptoethanol) 
RNase  SIG None 
DpnI NEB None 
Trypsin (Mass 
spectrometry grade) 
Promega 50 mM glacial acetic acid. 
 
Table 2.6 Enzymes and co-constituents. eBSA (NEB) was supplied at 10 mg/ml 
(100x) and was diluted to 10x with 18.2 MΩ/cm H2O prior to use. 
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2.1.10 Kits 
The molecular biology kits employed in this study are listed in Table 2.7. All kits 
and components were stored at room temperature, except the cell re-suspension 
buffer of plasmid purification kits, which was maintained at 4°C. 
 
Kit Application 
DNeasy Blood and Tissue 
Kit® (Qiagen) 
Extraction of genomic 
DNA from host 
Miniprep kit (NZytech) Extraction of plasmid 
DNA (pDNA) from E. coli 
(DE3) 
PCR purification kit 
(Qiagen) 
Purification of double 
stranded DNA (dsDNA) 
from a PCR. 
Nucleotide removal kit 
(Qiagen) 
Removal of nucleotides 
following LIC-T4-
polymerase reactions. 
 
Table 2.7 Molecular biology kits and applications. 
 
 
2.1.11 Oligonucleotide primers (MWG) 
Oligonucleotides were received as lyophilised pellets, which were centrifuged at 
13000 x g for 4 min and were made up to a stock concentration of 100 pmol/l 
(100 M) with the appropriate volume of 18.2 MΩ/cm H2O as indicated by the 
supplier. Forward (CGCGCCTTCTCCTCACTGTTCCA) and reverse 
(TGTGGTGGTGGTGATGATGGCTG) primer sequences were used for PCR 
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amplification of the LIC vector. Primer stock concentration was 100 M (each of 
forward and reverse). All primers were maintained at -80°C. 
 
2.1.12 Vectors 
pET-YSBLIC (LIC) vector was used for cloning all gene fragments, pET- 28a 
was used as a control for transformation and in high throughput screening 
procedures. 
 
2.1.13 Substrates 
All acceptor and donor substrates are listed in Table 2.8 (a) and (b) respectively. 
Acceptor stock solutions of 2-4 mM were prepared in 100% (v/v) ethanol. Donor 
sugar solutions were prepared as 40 mM stocks in sterile 18.2 MΩ/cm H2O and 
were separated as 50 µl aliquots and stored at -20°C. 
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Table 2.8 (a) Chemical structures of acceptor aglycones. 
 
 
 
 
 
Acceptor substrate Structure 
ergosterol 
(SIG) 
 
cholesterol 
(SIG) 
 
testosterone 
(SIG) 
 
5-alpha-cholestan-3-beta-ol 
(dihydrocholesterol) (AE) 
 
4-methylumbelliferone (4-
MU) (SIG) 
 β-naphthol 
(SIG) 
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Table 2.8 (b) Chemical structures of donor sugars. 
 
  
Donor 
substrate 
structure 
UDP-
glucose (S. 
cerevisiae) 
(UDPG) 
(SIG) 
 
UDP-
galactose 
(UDPGA) 
(SIG) 
 
 
 
O 
O H H O 
O 
P 
O 
O H 
O 
P 
O 
O H 
O 
OH 
H O 
O H 
O 
O H 
N 
H 
N O O 
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2.2 Methods 
 
All basic molecular biology techniques including cloning and protein expression 
and purification were followed as described in Sambrook and Russell (Editions 1, 
2 and 3; 2001). 
 
2.2.1 DNA Methods 
2.2.1.1 Growth of yeast starter cultures for DNA extraction 
Growth conditions of each of the yeast strains are detailed in Table 2.9. A loopful 
of each of the yeast cultures provided was inoculated in 5 ml appropriate media in 
a sterile glass universal and left to grow overnight at 100 rpm at the corresponding 
temperature. Recipes of media are detailed in section 2.1.2.1. 
2.2.1.2 Growth of E. coli (DE3) starter cultures for plasmid DNA (pDNA) 
extraction 
E. coli (DE3) were grown in 28 ml sterile glass universals containing 5/10 ml of 
LB broth (depending upon the volume of inoculum required for the next stage) 
supplemented with the appropriate antibiotic, the resistance gene for which is 
encoded on the plasmid to be purified or expressed. For crude extraction of 
pDNA, cultures were inoculated from a single colony on an agar plate using a 
sterile wire loop whereas for standard extraction of pDNA (spin DNA), cultures 
were inoculated from an agar plate, glycerol stock or liquid culture using a sterile 
wire loop. Cultures were grown overnight at 37°C with orbital shaking at 200 
rpm. 
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2.2.1.3 Growth of E. coli (DE3) for the preparation of cell free extracts 
(CFEs) 
A 5/10 ml starter culture (as described above) for clones harbouring recombinant 
plasmids was prepared. Starter cultures were then inoculated at a 1% (v/v) ratio to 
a conical flask containing LB broth supplemented with the appropriate antibiotic 
(See Table 2.5 for antibiotic growth requirements of E. coli strains). Small scale 
expression was performed to study protein expression level profiles when using 
different DE3 hosts or auto-induction media (Appendix C.) and scaled up to 
achieve large amounts of protein for further analysis. Table 2.10 lists the scales of 
expression used and the volume of broth. 
 
 
Organism Media    Growth temperature 
Sc YEPD 30°C 
Pp YEPD 30°C 
Pg YM 26°C 
Kp 393/YPD 25°C 
Pa 186 25°C 
Kl 186 25°C 
Dh YM 25°C 
 
Table 2.9 Growth conditions for yeast strains for genomic DNA extraction.   
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Scale of 
expression 
Volume of 
broth (ml) 
Maximum 
capacity of 
conical flask 
(ml) 
Volume of 
inoculum (ml) 
Small 50 250 0.5 
Large 1000 2500 10 
  
Table 2.10 Scales of protein expression.  
 
 
The inoculated culture was grown and allowed to grow at 37°C orbital shaking at 
200 rpm for approximately 2-3 h till exponential phase with an O.D600nm= 0.7 read 
by spectrophotometer previously zeroed with LB media. The cells were then 
induced for protein expression by the addition of 240 µg/ml IPTG (final 
concentration) and allowed to grow overnight at 23°C shaking at 100 rpm.  
2.2.1.4 Extraction and purification of genomic DNA from yeast cultures 
Genomic DNA was extracted from overnight grown yeast cultures (section 
2.2.1.1) using a kit (Table 2.7). The recipes for the buffers used in the kit are 
undisclosed by the manufacturer. 
Overnight cultures (0.5 ml) were harvested in a 1.5 ml micro-centrifuge tube by 
centrifuging for 10 min at 5000 x g. The resulting supernatant was discarded and 
the pellet re-suspended in Sorbitol buffer (Recipe in Table 2.6) followed by the 
addition of 200 U lyticase (430 U/ml) and incubation at 30°C for 30 min. The 
cells were centrifuged for 10 min at 300 x g and re-suspended in 180 µl buffer 
ATL (cell re-suspension buffer). 20 µl proteinase K was then added to the cell 
mixture mixed by vortexing prior to incubation at 55°C for approx. 3 hr to ensure 
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complete tissue lysis. Cells were vortexed for 15 s followed by the addition of 200 
µl buffer AL (for precipitation of chromosomal DNA), mixed by vortexing and 
incubated at 70°C for 10 min. 200 µl ethanol (100% v/v) was added to the sample 
and mixed thoroughly by vortexing. The resulting mixture from step was then 
transferred to a DNeasy Mini spin column placed in the provided collection tube. 
Cells were then centrifuged for ≥6000 x g for 1 min and the flow-through 
discarded. Sample was then washed by the addition of 500 µl buffer AW1 
followed by an additional wash with 500 µl buffer AW2 to the spin column, both 
washes were performed by centrifugation for 3 min at 20,000 x g and the flow-
through discarded in both cases. The DNeasy column was placed in a clean 
microcentrifuge tube and 100 µl buffer AE (5 mM TRIS-HCl, pH 8.0) was then 
added directly in the centre of the DNeasy membrane. This was followed by an 
incubation step at room temperature for 1 min and centrifugation at 14, 000 x g. 
This step was repeated and the resulting 200 µl of eluant was stored at -20°C until 
further use. 
2.2.1.5 Extraction of pDNA from bacteria 
Crude extraction of pDNA from bacteria using STET Buffer (to screen for 
plasmids carrying inserts) 
All centrifugation steps were performed at 14,000 x g. A 3 ml E. coli culture 
(section 2.2.1.2) was pelleted by repeated centrifugation for 1 min. The 
supernatant was discarded followed by pulsed to remove any residual supernatant. 
The resulting pellet was re-suspended in 150 µl STET Buffer (section 2.1.4.2) 
ensuring complete re-suspension of cells by vortexing. 10 µl of 10 mg/ml 
lysozyme (prepared fresh on the day) was then added to cells and samples were 
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mixed by gentle inversion of the tube about 6-7 times. The cells were incubated at 
room temperature for 15 min and immersed in a boiling water bath for 40 s. 
Samples were immediately centrifuged at 14000 x g for 15 min. The resulting 
viscous pellet was then removed gently using a pipette tip and discarded. 150 µl 
chilled isopropanol was then added to the remaining supernatant and mixed. The 
cells were incubated at -20°C for 1 h to allow precipitation of DNA followed by 
centrifugation of cells for 5 min. The resulting supernatant was discarded and the 
pellet pulsed to ensure removal of any residual supernatant. The pellet was 
washed with 500 µl 100% (v/v) ethanol and centrifuged for 3 min. The resulting 
supernatant was discarded and the residual supernatant was carefully removed 
using the pipette. Samples were then air-dried for 10 min to allow evaporation of 
any latent ethanol. The dried pellet was re-suspended in 30 µl of TE Buffer 
(section 2.1.4.1) containing 100 µg/ml RNase. 
Standard extraction of pDNA from bacteria (Spin DNA)  
Spin DNA was extracted from bacterial cultures (section 2.2.1.2) using a kit 
(Table 2.7). The recipes for buffers used are undisclosed by the manufacturer. All 
centrifugation steps were performed at 11,000 x g unless stated otherwise. A 3 ml 
(from 5 ml) volume of overnight grown bacterial cell culture was pelleted in a 1.5 
ml micro-centrifuge tube by repeated centrifugation for 30 s and the supernatant 
discarded. The pellet was then pulsed and residual supernatant removed. The 
pellet was then re-suspended by vortexing in 250 ȝl of buffer A1 (cell re-
suspension buffer). 250 ȝl of buffer A2 (cell lysis buffer) was then added and the 
sample was mixed by gentle inversion 5-6 times, prior to incubation at room 
temperature for 5 min. 300 ȝl of buffer A3 (precipitation of proteins and 
chromosomal DNA) was then added to the sample and the sample was again 
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mixed by gentle inversion 5-6 times Precipitated material was then separated by 
centrifugation for 10 min and the supernatant was transferred to a spin column 
placed in a 2 ml receptacle collecting tube. The DNA was then loaded onto the 
filter by centrifugation for 1 min and the flowthrough discarded and washed with 
500 ȝl buffer AY, followed by an additional wash with 600 ȝl of buffer A4 (50% 
ethanol), both washes were performed by centrifugation at 14000 x g for 1 min 
and in each case the flowthrough discarded. Prior to elution, the empty spin 
column was centrifuged for 2 min in order to remove any residual ethanol. The 
spin column was then transferred into a sterile 1.5ml micro-centrifuge tube and 
the DNA eluted from the filter by centrifugation at 14000 x g for 1 min after the 
addition of 50 ȝl of AE (5 mM TRIS-HCl, pH 8.0) and incubation at room 
temperature for 1 min. For extraction of DNA for sequencing reactions, the same 
procedure was followed except: 9 ml overnight starter culture was pelleted 
(instead of 3 ml) and twice the volume of each buffer was used in each step. In the 
final step, DNA was eluted in 50 ȝl sterile 18.2 MΩ/cm H2O (pH 8.0).  
2.2.1.6 PCR Purification (PCR products, DpnI digested LIC vector) 
Purification of double stranded DNA (dsDNA) following a PCR was achieved 
using a kit (Table 2.7). The method is detailed as follows: All centrifugation steps 
were performed at 13,000 x g. Recipes for buffers used are not known. 
5 volumes of buffer PB were added to 1 volume of the PCR sample and mixed. A 
spin column was placed in a 2 ml collection tube following the application of the 
sample to the column. The column was then centrifuged for 60 s to bind the DNA. 
The flow-through was discarded and the column was placed back into the same 
tube. 0.75 ml buffer PE (wash buffer) was added to the spin column and 
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centrifuged for 60 s. The flow-through was discarded and the column placed 
backed into the same tube. The column was centrifuged for an additional 1 min to 
evaporate the residual ethanol from buffer PE. The spin column was placed in a 
sterile 1.5 ml microcentrifuge tube. To elute DNA 50 µl sterile 18.2 MΩ/cm H2O 
(pH 8.0) was added to the centre of the column membrane and the column was 
centrifuged again for 1 min. For elution of LIC vector following PCR, the elution 
step was performed using 100 µl TRIS-HCl (pH 8.0) and was repeated. 
2.2.1.7 AGE and gel visualization 
Agarose (1% w/v) gels were prepared in TAE buffer (section 2.1.3.1) in a total 
volume of 30/120 ml (depending upon the size of the tank used). The mixture was 
then boiled over a Bunsen burner until the agarose powder had completely 
dissolved in the buffer. This was confirmed by holding the conical flask against 
light to check no agarose particles remained. Once the mixture cooled to around 
60°C, it was poured into an agarose gel casting tray, a well comb inserted and the 
gel allowed to set for approx. 20 min. The casting tray with the ‘set’ agarose gel 
was then transferred into a gel electrophoresis tank and the tank filled with TAE 
buffer till it submerged the gel. The samples were then loaded onto the gel along 
with a DNA size standard (section 2.1.4.3). The electrophoresis tank was then 
connected to a power pack and electrophoresis carried out at 120 mA and 200 V 
for 30 min when using the small tank and 50 min while using the large tank. The 
gel was then transferred to a staining tray and filled with freshly made 10 g/ml 
EtBr solution (section 2.1.3.2) until the solution just submerged the gel. The tray 
was placed on a bench-top orbital shaker and the gel allowed staining for 15 min 
at 100 rpm. After staining, the EtBr solution was disposed by charcoal filtration 
and the gel rinsed with distilled H2O. After electrophoresis, the gel was visualised 
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using a gel documentation system using Quantity One™ software. Hard copies of 
the gel picture were produced using a Mitsubishi Video Copy Processor (Model 
P91 attached to the gel doc system), with Mitsubishi thermal paper (K65HM-CE / 
High density type, 110 mm x 21 m).  
2.2.1.8 Preparation of competent E. coli (DE3) cells for transformation 
Preparation of chemically competent E. coli (DE3) 
From a glycerol stock of E. coli (DE3) cells, a scrapping of cells was taken using 
a sterile loop and streaked onto a 4% w/v agar plate supplemented with the 
appropriate antibiotic if required (Table 2.5) and incubated overnight at 37°C. 
Approximately 1 cm of cell scrapping was then taken with a sterile loop from the 
agar plate and inoculated into 50 ml LB broth (section 2.1.2.1). For E. coli (DE3) 
strains Codon Plus CP (RP) and CP (RIPL), appropriate antibiotic was added to 
the liquid media prior to inoculation (Table 2.5 lists antibiotic growth 
requirements of different strains). The cultures were incubated at 37°C orbital 
shaking at 200 rpm for approx. 2 h till O.D600nm was between 0.35 and 0.40 as 
read by a spectrophotometer previously blanked with LB broth. At this point, the 
cultures were kept on ice for approx. 30 min and pelleted by centrifugation in two 
pre-chilled 25 ml sterile polystyrene universals at 2000 x g for 10 min at 4°C. The 
supernatant was discarded and the tubes were briefly inverted on tissue to drain 
the liquid ensuring that cells were not left off ice for more than a few seconds. 
One of the pellets was re-suspended by flicking the tube gently in 15 ml of ice 
cold sterile pre-chilled MgCl2-CaCl2 solution (section 2.1.4.4). The re-suspended 
pellet was then transferred to the second tube and the pellet re-suspended 
similarly. The cells were centrifuged again and the pellet drained as described 
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earlier. The pellet was then re-suspended in 1 ml ice cold 100 mM CaCl2 (section 
2.1.4.4). Chemically competent cells for expression hosts (BL21 etc) could be 
prepared and frozen at -80°C in 15% (v/v) glycerol for future use. 
Preparation of electrocompetent E. coli (DE3) cells for transformation 
An agar plate of the glycerol stock of the required cell type was prepared and 
incubated overnight at 37oC (see preparation of chemically competent E. coli). 
After overnight growth, using a sterile loop, approximately 1 cm of cell scrapping 
was inoculated into 50 ml of sterile pre-warmed low salt LB broth (section 
2.1.2.1) in a 250 ml conical flask. The culture was then grown at 37 oC with 
orbital shaking at 200 rpm until the cells reached an O.D600nm of 0.5~0.7. The 
culture was then placed on ice for 30 minutes and centrifuged at 4000 x g for 15 
min at 4oC and the supernatant discarded. The pellet was then gently re-suspended 
(by gentle vortex, never more than 3 sec at a time off ice) in 25 ml of ice cold 
filter sterilized 18.2 MΩ/cm H2O. The suspended cells were then centrifuged as 
before and the supernatant discarded. The cell pellet was then re-suspended (by 
gentle vortex never more than 3 sec at a time off ice) in 12 ml of ice cold filter 
sterilized 18.2 MΩ/cm H2O. The centrifugation and re-suspension was repeated 
twice but with the re-suspension volume decreasing each time with the next 
volume being 15 ml followed by re-suspension in 2 ml. A final centrifugation and 
re-suspension step followed with a volume of 0.2 ml of ice cold filter sterilized 
18.2 MΩ/cm H2O after which the cells were separated into pre-chilled 
microcentrifuge tubes in 40 µl aliquots.  
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2.2.1.9 Spectrophotometric quantification of DNA 
Plasmid DNA was quantitatively determined by transferring 60 ȝl neat sample to 
a sterile disposable plastic cuvette (UVette®, Eppendorf) fitted in an appropriate 
adapter for the UV-vis spectrophotometer (Ultrospec 2000 spectrophotometer, 
Pharmacia Biotech). In cases where the sample was highly concentrated or < 60 ȝl 
in volume, appropriate dilutions were prepared in 18.2 MΩ/cm H2O. A260 value 
was then recorded by a UV-visible spectrophotometer previously zeroed with 
water. The optimal wavelength for contaminating protein was assumed to be 280 
nm. The concentration and purity of the DNA was then determined as detailed 
below: 
[dsDNA] ȝg/ȝl = (A260) x 50 x (dilution factor) / 1000. 
DNA purity ratio = (A260)/ (A280) 
A DNA purity ratio of >1.8 was accepted as minimal protein contamination. 
2.2.1.11 Restriction endonuclease digests 
Restriction enzyme digestion of pDNA (section 2.2.1.5) was performed based on 
the knowledge of restriction sites present at the 5’ and 3’ ends of the gene of 
interest as described in section 2.2.1.11. The following were added to a 1.5 ml 
microcentrifuge tube (Table 2.11) for restriction endonuclease reactions. 
Restriction enzymes were added in the end and mixed by gently swirling the 
pipette tip. 
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Table 2.11 Restriction enzyme digestion conditions of plasmid DNA. 1 Recipes in 
Table 2.6.  
 
Each reaction was incubated for 2 h in a 37oC water bath. 2 ȝl of DNA loading 
dye was added to the 10 ȝl of each digest and analysed by gel electrophoresis as 
on a 1% (w/v) agarose gel. 
 
2.2.1.12 Transformation of recombinant plasmids into E. coli (DE3)   
Transformation using chemically competent E. coli (DE3) 
Transformations of insert-LIC constructs and r-plasmid DNA were performed 
using prepared chemically competent E. coli cells (see section 2.2.1.8 for 
preparation of competent E. coli). 5 ȝl pDNA was added to 50 ȝl chemically 
competent E. coli cells (if made fresh on the day) or 75 ȝl cells (previously made 
and frozen in 15% (v/v) glycerol). ) in a 1.5 ml microcentrifuge tube and mixed 
gently with a pipette tip. The mixture was then incubated on ice for 30 min. The 
cells were then transferred to a water bath at 42°C and heat shocked at this 
Component Volume (ȝl) Final 
concentration  
pDNA (30-120 ng/µl) 5 15-60 ng/µl 
XbaI (20,000 U/ml) 0.5 10 U 
XhoI (20,000 U/ml) 0.5 10 U 
Restriction Enzyme Buffer 2 1 1  
10 x BSA 1 1  1x 
18.2 MΩ/cm H2O to a final 
volume of 10 ȝl 
2   
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temperature for 90 s and immediately transferred on ice for 2 min. The cells were 
then recovered by the aseptic addition of 200 ȝl of sterile LB media (section 
2.1.2.1), and incubated at 37°C for 1 h. Recovered cells were then aseptically 
plated on agar plates supplemented with kanamycin (see Table 2.2). Plates were 
then incubated for 16 h at 37°C to allow the growth of bacterial colonies. 
Apart from the conventional expression strain, BL21 (DE3), other host E. coli 
strains were also used with antibiotic selection requirements as stated in Table 
2.3. 
Transformation of mutant library DNA into electrocompetent E. coli cells 
(by electroporation) 
Transformations were performed using prepared electrocompetent cells. 40 µl 
aliquots of cells were placed on ice and 2 µl of ligation or pDNA was added and 
mixed gently with a pipette tip. The cells and DNA mix was incubated on ice for 
at least 1 min. The mix was then transferred to an ice cold sterile 2 mm 
electroporation cuvette (BR) and the contents tapped gently down to the bottom of 
the cuvette until it entirely covered the bottom of the cuvette. The outside of the 
cuvette was dried thoroughly and the cuvette placed into a BioRad ShockPad and 
the lid closed. The BioRad PulseXcell was set to 2.5 kV and the voltage applied 
across the cuvette. Immediately following electroporation 1 ml of LB broth was 
added to the cuvette and transferred using a sterile glass pipette to a sterile 1.5 ml 
microcentrifuge tube. The cells were incubated at 37 oC for at least 1 hour and 
then plated onto an appropriate antibiotic LB agar plate. Plates were then 
incubated inverted for ~16 h at 37 oC.  
                                                                  Chapter 2 Materials and Methods 
 
75 
 
2.2.1.13 Plating bacteria 
Prior to plating, LB agar plates were surface dried by placing open face down at 
65°C for 10 min. A glass spreader was sterilised by immersion in 70% (v/v) 
ethanol, followed by removal of excess ethanol by passing quickly through a blue 
Bunsen flame, and used to spread 50-200 l of bacterial suspension evenly over 
the surface of the agar. When all the liquid had been absorbed into the agar, the 
plate was incubated inverted at 37°C for ~ 16 h.  
 
2.2.2 Protein Methods 
2.2.2.1 SDS-PAGE electrophoresis 
SDS – PAGE was conducted according to the method of Laemmli (Laemmli 
1970). 
SDS - PAGE gels were cast between two clean glass plates of dimensions (10.1 x 
7.2 and 10.1 x 8.2 cm) separated by a 1 mm spacer ridge on the larger of the two 
plates. The plates were clamped together and checked to ensure the bottoms were 
flush, prior to securing the gel with vertical downward pressure in a casting stand 
on a rubber gasket. The components for the resolving gel (section 2.1.5) were then 
added together, mixed, and then pipetted (using a 5 ml Gilson) into the space 
between the plates, until the solution was approximately 2 cm below the top of the 
smallest plate. In order to prevent oxygen from inhibiting polymerisation, a small 
volume of 18.2 MΩ/cm H2O was then added to the top of the solution. The 
resolving gel was then allowed to polymerise for 20 min. Once set, the H2O on 
top of the gel was removed by adsorbing with filter paper, and the components of 
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the stacking gel were added (section 2.1.5), mixed, and pipetted up to the top of 
small plate. A 10 toothed comb was then immediately inserted into the gap 
between the plates displacing some of the un-polymerised stacking gel. The 
stacking gel was then allowed to polymerise for 20 min prior to removal of the 
comb to reveal the wells, which were subsequently rinsed with H2O to remove 
any gel debris. The gel was then placed vertically into the buffer tank secured in a 
holder with, another gel constructed in exactly the same manner secured to the 
opposite side. SDS-PAGE 1 x running buffer (section 2.1.5) was then poured into 
the tank ensuring the level of buffer in the space between the two gels was higher 
than the level on the outside of the gels. Samples were then prepared by the 
addition of 5 ȝl of 6 x loading buffer (section 2.1.5) to 20 ȝl of sample, which was 
then pulsed briefly prior to boiling for 2 min. Size standards were prepared in the 
same way, except 8 ȝl of loading dye was added to 4 ȝl of size standard (section 
2.1.4.3). All samples and standards were then centrifuged at 14000 x g for 1 min 
prior to loading 20 ȝl of all samples and 10 ȝl of all standards into the wells using 
a Hamilton syringe. Finally the pair of gels was run at 120 mA, 200 v for 45 min. 
Gels were carefully removed and transferred to a staining tray after which 
Coomassie blue staining solution (section 2.1.5) was poured till it submerged the 
gels. The tray was placed on a bench-top orbital shaker and the gel allowed staining for 
15 min at 100 rpm after which the staining solution was removed and disposed by funnel 
filtration and the gels rinsed with distilled H2O. The tray with gels was filled with gel de-
staining solution (section 2.1.5) and left shaking overnight at 100 rpm to 
completely remove the staining solution. Stained gels were then analysed by a 
densitometer (section 2.1.1.7). 
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2.2.2.2 Preparation CFEs 
500 l of each of the induced overnight E. coli cultures (section 2.2.1.3) was 
centrifuged at 4000 x g for 1 min, the supernatant decanted. The pellet was 
maintained as the insoluble protein fraction and was resolubilised in 300 l of 
solubilising buffer (section 2.1.5). 
The overnight cultures were then concentrated at 4000 x g, 4oC for 15 min, the 
supernatant decanted and the pellets re-suspended in 5 ml start (section 2.1.6). 
Cells were then lysed in 5 ml volumes by sonication on ice at amplitude 14000 
microns for 2 min in 10 s bursts with 10 s intervals. The lysate was then decanted 
into centrifuge tubes and centrifuged at 4°C for 20 min at 24000 x g. After 
centrifugation the soluble fraction was maintained on ice as the CFE.  The CFE 
and insoluble protein fractions were then analysed for protein expression by SDS-
PAGE (section 2.2.2.1).  
2.2.2.3 Protein Purification via Nickel affinity chromatography 
N-terminally his-tagged protein was purified from cell free extract (section 
2.2.2.2) by automated Immobilised Metal Affinity Chromatography (IMAC) 
using automated gradient elution using a Ni Sepharose High Performance resin 
(AB). This was performed using the Akta Prime Plus 5.0 FPLC system™. In this 
programmed method, the gradient elution column was prepared by calibration 
with 100 ml start buffer (section 2.1.6). 5-10 ml of CFE was then loaded onto the 
column. The protein was finally eluted at a flow rate of 2 ml/min by passing 
through 200 ml elution buffer (section 2.1.6) with a linear imidazole gradient (10-
500 mM). The elution time of the protein was monitored at 280 nm using an inline 
UV spectrometer connected to the FPLC after which fractions (5 ml) were 
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collected by a fraction collector. To confirm purity, a 20 l aliquot from each 5 ml 
fraction thought to contain the target protein was analysed by SDS-PAGE (section 
2.2.2.1) and the pure fractions pooled. 
2.2.2.4 Concentration and buffer exchange of protein 
Concentration of protein was performed at 4°C by centrifugation at 4000 x g in 30 
kDa cut-off concentrator units. Solution was washed three times with start buffer 
(section 2.1.6) and stored at 4°C in 5 mM TRIS-HCl (pH 8.0) at a concentration 
of 1 mg/ml for future use. 
2.2.2.5 Spectrophotometric quantification of protein 
A 60 µl protein sample aliquot was transferred to a sterile synthetic Quartz cuvette 
(Uvette, Eppendorf) and absorbance at 280 nm was recorded by a UV-visible 
spectrophotometer after the instrument was zeroed with 5 mM TRIS-HCl (pH 
8.0). The concentration of proteins was determined as detailed below: 
[Protein] ȝg/ȝl = (A280) x m.wt of protein x (dilution factor)/Molar extinction 
coefficient 
 
2.2.3 UGT activity assays using UDP-[U-14C] glucose (UDPG) followed by 
liquid scintillation counting (LSC) of extracted glycosides. 
All pre-assay enzyme dilutions were prepared in 100 mM TRIS-HCl; pH 8.0. A 2 
mM stock solution for testosterone and 1 mM stock solution for cholesterol was 
prepared in ethanol (99% v/v). UDPG (PE) was supplied at 0.02 mCi/ml (specific 
activity 302 mCi/mmol) in 7:3 (v/v) ethanol: water. A 1:5 dilution of the stock 
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was prepared in H2O for each ~ 5 µl dilution = 50,000 dpm (0.07 µM). This was 
confirmed by liquid scintillation counting (LSC). Diluted solution was separated 
as 200 µl aliquots and stored at -20°C.     
All reactions were set in triplicate along with a blank which consisted of 75 µl 
buffer and a negative control consisting of all constituents except the acceptor 
substrate which was substituted with 18.2 MΩ/cm H2O.  Assay constituents using 
purified GTs and CFEs are listed in Table 2.12 (a) and (b) respectively. All 
components except UDPG were added and mixed. Upon the addition of UDPG 
(0.07 µM), samples were immediately vortexed and incubated for the required 
time intervals at 30°C. After each sample was incubated for exactly the desired 
duration (by keeping 15 s intervals between samples for the addition of radio-
labelled substrate and then maintaining the same time gap to stop the reaction), 
reactions were terminated by the addition of 125 µl 0.45% (w/v) NaCl. Glycosides 
were extracted by adding 300 µl of H2O saturated ethyl acetate to each reaction 
followed by vortexing for 10 s to separate the aqueous (bottom) and organic 
solvent (top) layers. 150 µl (of a total of 300 µl) of the extracted radiolabelled 
material was mixed with 4 ml Ecoscint liquid scintillation fluid (ND) in a 6 ml 
polyethylene vial (PE). Each sample was counted for 3 min by the Tricarb 2200 
CA liquid scintillation counter (PE) against a stored quench curve prepared using 
commercially supplied standards (PE) with known quench values in each vial. 
The incorporation of UDPG was determined by subtracting counts present in 
control assays (incubations in the absence of acceptor), which were typically less 
than 100 dpm per assay using CFEs as well as purified UGTs. 
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Table 2.12 (a) Assay constituents for UGT activity using UDPG and purified UGTs. 
 
 
Table 2.12 (b) Assay constituents for HTS for active UGTs using CFEs. Sample and 
control reactions were set up and incubated for 30 min at 30°C. 
 
Component Volume 
(µl) 
Final amount/ 
concentration 
(in 75 µl) 
1-2 mM substrate (acceptor)  0-200 µM 
50,000 dpm UDPG (0.07 µM, 
specific activity 302 mCi/mmol) 
  
100 mM TRIS-HCl; pH 8.0  50 67 mM 
1 mg/ml purified enzyme in (5 mM 
TRIS-HCl; pH 8.0)  
 0.5 µg 
18.2 MΩ/cm H2O to a final volume 
of 75 µl 
  
Component Volume 
(µl) 
Final amount/ 
concentration 
(in 75 µl) 
1 mM cholesterol (acceptor) 2.8 37 µM 
50,000 dpm UDPG (0.07 µM, 
specific activity 302 mCi/mmol) 
  
 CFE   60               
100 mM TRIS-HCl; pH 8.0  to a 
final volume of 75 µl 
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3.1 Introduction 
 
Owing to its relatively smaller size, the S. cerevisiae genome was the first 
eukaryotic genome to be sequenced (Klionsky et al. 2003). Due to the presence of 
homologs of yeast genes in other eukaryotes, gene products of which are 
functional homologs in many cases, the role of yeast genes and gene products may 
be directly applied to other organisms. 
The autophagy-related protein Atg26, ORF YLR189C from S. cerevisiae has been 
previously characterised as a USGT and was designated as UGT51 (Warnecke et 
al. 1999). UGT51 from S. cerevisiae (ScUGT51) is located on chromosome XII, 
which is approx. 1.1 Mb in length and consists of 534 ORFs (Johnston et al., 
1997). Fig. 3.1 shows the map of chromosome XII of S. cerevisiae highlighting 
the location of ScUGT51. Autophagy is a conserved process in eukaryotes and 
helps in nutrient recycling during starvation and stress as well as being involved 
in pathogen defence (Grille et al. 2010; Meijer et al. 2007). Although the 
homologs of ScUGT51 in Pichia pastoris and Yarrowia lipolytica have been 
shown to be involved in cellular degradation of proteins and pexophagy (Nazarko 
et al. 2007a; Nazarko et al. 2007b; Stasyk et al. 2003) recent studies have shown 
that ScUGT51 is not involved in such pathways and as such its role needs to be 
further elucidated (Cao and Klionsky 2007). 
Warnecke et al. (1999) have experimentally shown that the majority of the N-
terminal domain of ScUGT51 was not required for USGT activity. In addition to 
retaining its functional activity, the N-terminally truncated gene product was 
soluble and functionally stable when expressed in E. coli. The shortest C-terminal 
domain of ScUGT51 vital for enzyme function consists of sequence of 476 amino 
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acids resulting from a deletion of the first 722 N-terminal amino acids (Warnecke 
et al. 1999). The truncated form of ScUGT51 will hereby be designated as 
ScUGT51’.  
This study has attempted to exploit the observation that ScUGT51’ and related 
UGTs with N-terminal deletions could be available to detailed biochemical 
analysis as pure enzymes. 
This chapter will describe the identification and characterisation of ScUGT51’and 
putative USGTs from related organisms based on primary sequence similarity 
with ScUGT51’.  
In keeping with the nomenclature proposed for the yeast autophagy-related 
proteins (Klionsky et al. 2003), all UGTs described here will be denoted with a 
genus (capital) and species (lower case) prefix for example ScUGT51’ for the S. 
cerevisiae UGT and the corresponding gene/gene fragments will be indicated in 
italics for example ScUGT51.  
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Fig. 3.1 Map of chromosome XII of S. cerevisiae. ScUGT51 (ATG26) is located on the 
Crick strand (blue) with chromosomal coordinates 534393-530797 bp. It is flanked by 
MDL1 and MMR1, inner and outer mitochondrial membrane proteins respectively on the 
Watson (red) strand. The black dot represents the location of the centromere. (Figure 
taken from the Saccharomyces genome database (SGD), Stanford University). 
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3.2 Materials and Methods 
 
3.2.1 Bacterial and yeast strains 
The required media and growth conditions of bacterial and yeast strains described 
in this chapter are detailed in section 2.2. 
 
3.2.2 Identification and bioinformatic analysis of putative UGT encoding 
ORFs  
All identified ORFs, their corresponding amino acid sequence and other relevant 
information of the source organism and the genes of interest were obtained from 
the National Centre for Biotechnology Information (NCBI) database 
(http://www.ncbi.nlm.nih.gov/).  
Amino acid sequences of all ORFs were probed for the presence of signal 
peptides, trans-membrane spanning domains and probable sites for restriction 
endonucleases as follows:  
(a) The amino acid sequence encoded by each ORF was searched for the 
presence of signal peptides using the Technical University of Denmark’s 
Centre for Biological Sequence Analysis (CBS) web server, SignalP 3.0 
(http://www.cbs.dtu.dk/services/SignalP/) (Emanuelsson et al. 2007). 
(b) The amino acid sequences of each ORF were scanned for the presence of 
any trans-membrane helices (TMHs) using the CBS web server TMHMM, 
v.2.0 (http://www.cbs.dtu.dk/services/TMHMM/) and the Phobius tool 
(European Bioinformatics Institute (http://www.ebi.ac.uk/Tools/phobius/). 
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Protein localisation sites in the amino acid sequences were predicted and 
analysed using the PSORT Server (University of Tokyo, available at 
http://psort.ims.u-tokyo.ac.jp/). 
 
(c) The deduced gene fragments were checked for the presence of internal 
restriction sites for XbaI and XhoI using the NEB Web Cutter 2.0 program 
(http://tools.neb.com/NEBcutter2/). 
ClustalW web program (http://www.ebi.ac.uk/Tools/msa/clustalw2/) was used 
to determine primary sequence alignments. The Pfam database 
(http://pfam.sanger.ac.uk/) was used to determine organisation of UGT 
domains. 
 
3.2.3 PCR amplification and LIC-cloning of gene fragments 
Full length nucleotide and amino acid sequences of gene fragments as well as the 
map and cloning region of the pET-28a derived LIC vector are included in 
Appendix A.  
3.2.3.1 PCR for gene fragments 
Two primers were designed for each ORF under investigation, a forward primer 
and a reverse primer. These were designed using the Web primer program 
(http://www.yeastgenome.org/cgi-bin/web-primer). Primers were selected such 
that each primer was a minimum of 18 nucleotides in length and that the 
difference in Tm (DNA melting temperature) values of the forward and reverse 
primers was kept to a maximum of 5oC.  
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For all ORFs, the forward primer is identical to the first 19-21 nucleotides in the 
5’3’ direction on the ‘sense’ strand. Reverse primers designed are reverse 
complimentary to the last 18-22 bases on the ‘sense’ strand. To enable cloning of 
the PCR products into the LIC vector, LIC-specific ends (Table 3.1 in bold) were 
added to the 5’ end of each of the forward and reverse primers. The Tm values 
were then calculated for each of the primers including and excluding the LIC-
specific sequences using the following equation and are recorded in Table 3.2 (a).  
Tm= 69.3+ 0.41 x GC% - (650  total length of sequence) 
Primers were paired together for the PCR resulting in an amplified gene that was 
annealed to the LIC vector such that an N-terminally hexahistidine-tagged protein 
could be expressed. 
The calculated and optimised primary and secondary annealing temperatures for 
PCR are summarised in Table 3.2 (b).  
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Table 3.1 Primer pairs for the PCR amplification and cloning of probable UGTs into the LIC vector. LIC-specific ends are shown 
in bold and lowercase.
ORF Forward Primer Reverse Primer 
    Sc 5’-caccaccaccacATGATTGATGAGAATCCGCAC-3’ 5’-gaggagaaggcgcgTTAAATCATCGTCCACCCTTCA-3’ 
Pp 5’-caccaccaccacatgAACCAGTATTCTACGTCAGA-3’ 5‘-gaggagaaggcgcgTTACACTTCAAACCATGATC-3’ 
Pg 5’-caccaccaccacatgTTAGAAGATTCACCACTCATC-3’ 
 
 
5’-gaggagaaggcgcgTTAGTCGTTAGTTGTCGTTG-3’ 
 
Kp 5’-caccaccaccacatgGTTGAGGATAATCCATATTTT-3’ 
 
 
5‘-gaggagaaggcgcgttAGACCATGCTGGTGAGCG-3’ 
 
Pa 5’-caccaccaccacatgATAGAAGAGCATCCATTGACC-3’ 
 
 
5’-gaggagaaggcgcgttAAACCAGTAACCACGAGCC-3’  
 
Kl 5’-caccaccaccacatgGTTGAAAAAAACCCGTATT-3’ 
 
 
5’-gaggagaaggcgcgTTATATCAGAAGCCAGGATC-3’ 
Dh 5’-caccaccaccacatgTTAGAAGATTCTCCATTCTAT-3’ 
 
 
5’-gaggagaaggcgcgttaTTATTTGTTAGCATCTGTAAC-3’ 
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Table 3.2 (a) Calculated Tm values of primers including and excluding LIC specific 
sequences in calculation. (FP- forward primer; RP-reverse primer) 
 
ORF 
source 
organism 
Tm of FP 
excluding 
LIC 
sequences in 
calculation  
     (oC)       
Tm of RP 
excluding 
LIC 
sequences in 
calculation 
    (oC) 
Tm of FP 
including 
LIC 
sequences in 
calculation 
(oC) 
Tm of RP 
including 
LIC 
sequences in 
calculation 
 (oC) 
Sc 53.0                         55.0 70.7                   72.9 
Pp 53.2                         51.5 70.6                   70.7 
Pp 53.9                         53.2 70.6                    71.9 
Kp 50.0                         56.6 68.3                    75.0 
Pa 55.9                          56.7 71.7                    74.2 
Kl 48.0                          53.2 68.3                     71.9 
Dh 50.0                          50.0 75.0                     72.8 
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Table 3.2 (b) Calculated (C) and optimised (O) primary and secondary annealing 
temperatures for paired primers. Temperatures were calculated by subtracting 5oC 
from the lower Tm value of primer pair (Table 3.2 (a)). Optimised temperature pair was 
used for PCR.                          
 
A 1:5 dilution of the primers (100 M) was prepared in 18.2 MΩ/cm H2O for the 
PCRs which were set up as follows: 
All components were pulsed by centrifugation for 5 s prior to use and were added 
to a PCR tube as shown in Table 3.3 (a). KOD Hot Start DNA polymerase was 
added in the end and was mixed by swirling the pipette tip in solution. The PCR 
tubes were then pulsed by centrifugation for 5 s. 
 
 
ORF 
source 
organism 
Primary annealing 
temperature (oC) 
          C                         O 
Secondary annealing 
temperature (oC) 
C                        O 
Sc 48.0 54.5 65.7 77.5 
Pp 46.0 51.0 65.5 72.4 
Pg 48.2 48.0 65.6 69.8 
Kp 45.0 48.5 63.3 71.5 
Pa 50.9 42.7 66.7 65.7 
Kl 43.0 48.5 63.3 71.5 
Dh 45.0 45.5 63.3 68.5 
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Table 3.3 (a) PCR components for amplification of DNA fragments and LIC vector.  
 
 
The PCR cycle used to amplify DNA fragments is tabulated in Table 3.3 (b) 
using the annealing temperatures described in Table 3.6.3 (c). KOD Hot Start 
DNA polymerase was used for PCR product amplification. 5 l of each PCR 
product was mixed with 1 l loading dye (section 3.1.3.3) and analysed by AGE. 
The samples were run with a DNA size standard. The target gene fragment was 
expected to be located at approx. 1431 base pairs (bp) for Sc; 1395 bp for Pp.; 
1602 bp for Pg; 1434 bp for Kp.; 1413 bp for Pa.; 1473 bp for Kl and 1632 bp for 
Dh. 
Component Volume 
(l) Final concentration (in 50 l reaction) 
1.0 U/l KOD Hot start DNA 
polymerase  
1  1 U 
10 x buffer for KOD Hot start DNA 
polymerase 
5  1 x 
Genomic template DNA (yeast 
genomic DNA- 0.1 g/l; LIC vector 
template- 1 ng/l.) 
0.5  1 ng (yeast genomic 
DNA); 0.01  ng/l 
(LIC vector template) 
20 mM Forward primer 1  0.4  mM 
20 mM Reverse primer 1  0.4  mM 
2 mM each dNTPs 5  0.2  mM (each) 
25 mM MgSO4 2  1  mM 
18.2 MΩ/cm H2O  34.5   
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Step Temp 
(oC) 
Time 
(h:min:s) 
Purpose 
1 95.0 00:02:00 Initial denaturation 
2 95.0 00:00:15 Denaturation 
3 X 00:00:30 Annealing 
4 72.0 00:01:38 Elongation  
5   Step 2- 4: repeated 4 times = 5 
cycles 
6 95.0 00:00:15 Denaturation 
7 Y 00:00:30 Annealing 
8 72.0 00:01:38 Elongation 
9   Step 6-8, repeated 24 times= 
25 cycles 
10 72.0 00:10:00 Final Extension 
11 10.0 Hold Storage 
  
Table 3.3 (b) PCR program used for the amplification of ORFs. X= Primary 
annealing temperature for primers (as indicated in Table 3.2 (b); Y= Secondary 
annealing temperature (as indicated in Table 3.2 (b). 
 
 
3.2.3.2 PCR amplification of LIC vector followed by DpnI digestion 
LIC vector sequence was amplified via PCR (See Table 3.3 (a) for PCR 
components) and the PCR cycle used for amplification is described in Table 3.3 
(c). 5 l of the PCR product was mixed with 1 l of loading dye and was analysed 
by AGE. 1 l of DpnI (20,000 U/ml, New England Biolabs) was then added to 45 
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l of the PCR product along with 5 l of 10 x Buffer 2 (recipe in Table 2.6) and 
incubated in a H2O bath at 37oC for 1 h.  
Target gene and LIC vector concentration was determined using the Bio-Rad 
DNA quantification software (Quantity One) using a DNA size standard (Hyper 
Ladder 1) with known amounts of DNA in each fragment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.3 (c) PCR program used for the amplification of LIC vector 
  
 
 
3.2.3.3 Ligation-independent cloning (LIC) 
3.2.3.3.1 T4 polymerase (LIC T4 pol) reaction for PCR products 
To enable ligation independent cloning (Bonsor et al., 2006), PCR products of 
amplified target inserts and LIC vector (section 2.2.1.13) were treated with LIC-
qualified T4 polymerase. Reaction components for LIC vector and target inserts 
are tabulated Table 3.4 (a) and (b).  
Step Temp (oC)  Time 
(h:min:s) 
Purpose 
1 95.0 00:02:00 Initial denaturation 
2 95.0 00:00:30 Denaturation 
3 75.0 00:00:30 Annealing 
4 72.0 00:06:00 Elongation 
5   Step 2-4, repeated 34 times 
6 72.0 00:10:00 Final Extension 
7 10.0 Hold Storage 
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Table 3.4 (a) T4 polymerase reaction of LIC vector. 
 
Table 3.4 (b) T4 pol treatment of target inserts 
 
For each reaction, the reaction constituents were mixed gently with a pipette tip 
and the reaction mixture was incubated at 22oC for 30 min followed by further 
Component Volume (ȝl) Final 
amount/ 
concentration 
(in 200 ȝl) 
Linearised LIC vector DNA (Section 
2.2.1.13) 25 ng/µl 
45  1.1 µg 
10x T4 polymerase buffer 20 1x 
25 mM dTTP 20  2.5 mM 
100 mM DTT 10  5 mM 
2.5 U/ȝl T4 pol (LIC-qual)   4  10 U 
18.2 MΩ/cm H2O to a final volume of 
200 ȝl 
       101  
Component Volume 
(µl) 
Final amount/ 
concentration (in 
20 µl) 
PCR product (insert) (10-100 ng/µl)  
(Section 2.2.1.13) 
14.6 0.2 pmol 
10x T4 polymerase buffer 2 1x 
25 mM dATP 2 2.5 mM 
100 mM DTT 1 5 mM 
2.5 U/ȝl T4 polymerase (LIC-qual) 0.4 1 U 
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incubation at 75oC for 20 min. Following LIC T4 pol treatment, LIC vector was 
purified as described section 2.2.1.6. 
 
3.2.3.3.2 Nucleotide removal following T4 polymerase (T4-pol) reaction 
This procedure was carried out for nucleotide removal following LIC-T4 pol 
reaction of LIC vector (section 2.2.1.14). This was achieved using a kit (Table 
2.7) and the following method: All centrifugation steps were performed at 10,000 
x g. 5 volumes of Buffer PN (recipe undisclosed by manufacturer) was added to 1 
volume the sample and mixed. A spin column was placed in the 2 ml collection 
tube and 600 µl of the sample applied to the spin column and centrifuged for 1 
min to bind DNA. The flow-through was discarded and the spin column placed 
back into the same collection tube. Note: for samples > 600 µl, the same spin 
column was re-loaded with the remaining mixture and centrifugation repeated. To 
wash the column, 750 µl of buffer PE (recipe undisclosed by manufacturer) was 
added and centrifuged for 1 min. The flow-through was discarded and the spin 
column was placed back in the same collection tube and centrifuged for an 
additional 1 min. The spin column was then placed in a sterile 1.5 ml 
microcentrifuge tube. To elute DNA, 100µl of sterile 18.2 MΩ/cm H2O (pH 8.0) 
was added to the centre of the column membrane and the column was centrifuged 
for 1 min. This step was repeated and the resulting 200 µl of eluant was stored at -
20°C until further use. 
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3.2.3.3.3 Ligation of target inserts into LIC vector followed by 
transformation in cloning host E. coli TOP10  
Each of the T4 pol treated reactions (2 ȝl; 50-100 ng/µl) was added to 1 ȝl of the 
T4 pol treated LIC vector (192 ng/ȝl) and the reaction mixture incubated at room 
temperature for 10 min. 1 ȝl of 100 mM EDTA was then added to the reaction 
mixture and mixed with a pipette tip and the solution incubated at room 
temperature for further 10 min. To check E. coli transformation efficiency, 2 ȝl 
pET-28a vector DNA (0.01 ng/ȝl) was used as a control reaction. 
4 ȝl of each of the LIC annealing products were transformed into to 50 ȝl of 
freshly prepared E. coli TOP 10 chemically competent cells as described in 
section 2.2.1.12. 
 
3.2.4 In-gel trypsin digestion and identification of r-proteins by peptide mass 
fingerprinting 
Protein bands of interest were excised from polyacrylamide gels following SDS-
PAGE (section 2.2.2.1) and were cut into 1 mm x 1 mm slices using a sterile 
scalpel. These were then transferred to clean siliconized 0.5 ml tubes and could be 
stored at -20°C until future use. All incubation steps were performed at room 
temperature unless stated otherwise. Gel slices were washed three times by adding 
100 ȝl of 100 mM NH4HCO3, pH 8.0 (section 2.1.7) and 60 ȝl ACN and left 
orbitally shaking for 30 min. The liquid was discarded in between each wash step. 
Following this, the gel slices were dehydrated by adding 100 ȝl of ACN and 
incubated for 5 min. This step was repeated following which gel slices were dried 
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by centrifugal evaporation for 15 min. The recovered peptides were digested with 
25 ȝl of 0.1 µg/µl trypsin (section 2.1.7) in 50 mM NH4HCO3  on ice for 30 min. 
30 ȝl of 50 mM NH4HCO3 was added to the tubes prior to incubation at 37 °C 
overnight. The peptides were extracted by incubating in 30 ȝl of a 50% (v/v) ACN 
with 5% (v/v) formic acid solution and the tubes were left shaking for 30 min. The 
solution containing the digested peptides was transferred to a clean 1.5 ml 
microcentrifuge tube. A 30 ȝl solution of 83% (v/v) ACN with 0.1% (v/v) formic 
acid was added to the original tube with gel slices followed by incubation for 
another 30 min. The liquid containing the leftover digested peptides (if any) was 
pooled with the initial collection of digested peptides. For protein identification, 
the samples were freeze-dried, dissolved in 10 ȝl of start buffer A (section 2.1.6.2) 
and the solution transferred into a microtitre well plate. Samples were analysed by 
an HCTUltra MS (Bruker Daltonics) via an electron spray ionisation (ESI) source. 
Instruments were controlled and the MS-MS spectrum obtained using HyStarTM 
3.2 software (Bruker Daltonics). Peptide analysis was performed at a flow rate of 
3 ȝl/min with a nebulizer pressure of 10 psi and a drying gas flow rate of 5.0 
L/min at a drying gas temperature of 300°C.  
Database searches were performed against NCBI non-redundant (nr) peptide 
database (http://ncbi.nlm.nih.gov/BLAST/) using the Mascot MS/MS ions search 
program (Matrix Sciences, UK; 
http://matrixscience.com/search_form_select.html). 
Preliminary qualitative UGT activity assays and TLC analysis were performed 
based on assay conditions stated in Madina et al., 2007 and Warnecke et al., 1999. 
Acceptor and donor substrates described in this chapter are listed in Table 2.8 (a) 
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and (b). Stocks of all acceptor aglycones were prepared in ethanol and made fresh 
on the day of use. UDPG/UDPGA stocks were prepared in 18.2 MΩ/cm H2O and 
stored at -20°C. These were diluted and kept on ice prior to assaying. The assay 
mixture constituents are summarised in Table 3.5. Reaction mixtures were scaled 
up if required (to a total reaction volumes of 200-300 µl) for HPLC separation and 
MS analysis as described in section 2.2.4. 
 
 
 
Table 3.5 Standard UGT activity assay constituents. 
 
All reactions were set in triplicate along with control reactions where 2 µl of 
UDP-sugar donor was substituted with 2 µl 18.2 MΩ/cm H2O. Reactions were 
also set up with 1M MnCl2 in the reaction buffer (0.1 mM final concentration). 
Component Volume 
(µl) 
Final amount/ 
concentration/amount 
(in 100 µl) 
4 mM substrate (acceptor) 20 0.8 mM 
40 mM UDP-sugar (donor) 2 0.8 mM 
100 mM TRIS-HCl; pH 8.0  10 10 mM 
1 mg/ml purified enzyme in (5 mM 
TRIS-HCl; pH 8.0)  
 2 µg 
18.2 MΩ/cm H2O to a final volume 
of 100 µl 
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For extraction of lipid products, reactions were incubated at 30°C for 2 h and were 
terminated by the addition of 0.9 ml of 0.45% (w/v) NaCl solution and 4 ml of 
chloroform: methanol, 2:1 v/v. The reactions were vortexed for 20 s after which 
the aqueous phase (top layer) was discarded and the organic phase (bottom layer) 
containing the reaction product was collected and dried at room temperature using 
a sample concentrator with an external N2 gas supply. The samples were re-
constituted in 30 µl chloroform: methanol, 2:1 (v/v) and spotted on a TLC plate 
(silica gel 60, F254) and run using a mixture of 85:15 (v/v) chloroform: methanol 
as the mobile phase. For lipid detection, plates were developed with spray of 15% 
(w/v) phosphotungstic acid (SIG) in ethanol and visualised by charring using a 
heat gun. Samples were analysed against an authentic testosterone glycoside 
standard (ProStrakan). 
 
3.2.6 HPLC-MS analysis of reaction products 
HPLC-MS analysis of standard assay reaction products was performed on a Luna 
CN Phenomenex column (5.0 cm x 2 mm 5µm) using a Thermo Finnigan 
Surveyor with analytes detected by an ion-trap mass-spectrometer (Thermo 
Finnigan LCQ Advantage). MS detection was performed in selected ion 
monitoring (SIM) mode with an ion spray voltage of 4.5 kV and capillary 
temperature of 230°C. 100 µl of post assay reactions (section 2.2.3.1) after 2-3 h 
incubation periods were terminated by the addition of 100 µl 0.3 M HCl and  were 
mixed with 800 µl distilled H2O prior to loading using an autosampler at an 
injection volume of 20 µl and flow rate of 150 µl/min. The eluant was 30% (v/v) 
acetonitrile, 1% (v/v) acetic acid used in an isocratic mode with a run time of 5 
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min. Glycosides were identified using mass spectral data visualised using the 
Xcalibur software suite. The identity of the testosterone glycoside was confirmed 
by comparison with an authentic standard kindly provided by ProStrakan 
(Galashiels, UK). 
 
3.2.7 Kinetic analysis of UGTs  
Kinetic parameters (Vmax, KM and Kcat) of UGTs against different acceptor 
substrates were determined using UDPG as the donor substrate. For all kinetic 
analysis, 4 - 5 substrate concentrations (determined empirically) in the limiting 
range were chosen and reactions were performed as detailed in section 2.2.3. 
Michaelis-Menten and Lineweaver-Burk plots were prepared using GraphPad 
Prism software version 5.04 for Windows (GraphPad Software, San Diego 
California USA). Specific activities (SpA) of UGTs were determined under 
standard assay conditions by measurement of an initial reaction rate at saturating 
substrate concentration.  
Raw dpm data was treated as follows: 
Data from LSC was expressed in dpm as described in section 2.2.3. Amount of 
product (sterol glycoside) formed in pmol was calculated as follows: 
a) Measured dpm (x) was converted to curies (Ci) as 1Ci= 2.22 x 1012 dpm; 
therefore dpm value/ 2.22 x 1012  = y Ci 
b) Amount of radiolabelled product formed (y) was then converted to amount 
(in mmol)  
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y/specific activity of UDPG (0.302 Ci/mmol) = z mmol 
z x 109 = Amount of product formed (pmol). 
Therefore, x x 109/ 0.302 x 2.22 x 1012 = x x 670.4 
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3.3 Results  
 
The molecular weight and extinction coefficient values of proteins were predicted 
based on the identified amino acid sequences including the N-terminal 
hexahistidine tag. These analyses were performed using the ProtParam tool within 
the web program ExPASy (expert protein analysis system; Swiss Institute of 
Bioinformatics, http://expasy.org/tools/protparam.html). 
The nucleotide sequences corresponding to each truncated amino acid sequence 
were then searched to check for the presence of restriction sites of restriction 
enzymes XbaI and XhoI using the NEB v2.0 web program (NEBcutter, 
http://tools.neb.com/NEBcutter2/).  
 
3.3.1 Identification and investigation of ORFs 
A Pfam database (http://pfam.sanger.ac.uk/) analysis (Finn et al. 2008) of the 
ScUGT51 sequence revealed the presence of the pleckstrin homology (PH) 
domain (PF00169), GRAM domain (PF02893), a GT family 28 (GT28) domain 
and a UDP-glucoronosyl/UGT (UDPGT) domain (PF00201) (Fig. 3.2 A.). 
Warnecke et al. (1999) showed by successive deletions of the N-terminus of 
ScUGT51 followed by in vitro analysis that only the GT28 and UDPGT C-
terminal domains was required for the synthesis of several steryl glycosides 
including the natural ergosteryl-β-glucoside. The shortest, truncated functional 
UGT sequence, ScUGT51’ consisted of 476 amino acids following the deletion of 
722 N-terminal amino acids.  
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In an attempt to identify and characterise novel UGTs on the basis of sequence 
similarity approaches and to analyse the function of conserved residues and 
motifs, a BlastP (Altschul et al.,1997) search was performed using ScUGT51’ as a 
template to probe the sequenced protein database.  At the time of conducting the 
BLAST search at the beginning of this study, ScUGT51’ displayed a high 
percentage of overall sequence identity, ranging between 63-69% with the 
characterised UGTs isolated from other yeasts such as the UGT51B1 of P. 
pastoris (Pp), UGT51 from Candida albicans, a putative USGT from Yarrowia 
lipolytica as well as protein products Atg26p from Pichia angusta (Pa) and 
AFR681Wp from Ashbya gossypii and uncharacterised protein products 
Kpol_2000p77 from Kluveromyces polysporus (Kp), ‘unnamed’ product from 
Kluveromyces lactis (Kl), PGUG_04770 from Pichia guilliermondii (Pg) and 
DEHA0E25168g from Debaromyces hansenii (Dh). However, the pairwise 
sequence identities of the non-truncated sequences as compared with ScUGT51 
were between 33-45%, implying that the majority of the differences existed as a 
result of the variations within the N-terminal regions. This is further indicated by 
the organisation of the N-terminal PH and GRAM domains differs in all the 
identified sequences (Fig. 3.2 B.). 
Among the first ten hits that displayed significant sequence identities, the 
sequences that were selected for further investigation in this study, in addition to 
the ScUGT51’ were those of Pp, Pg, Pa, Kl, Kp and Dh (Table 3.6). Among 
these, only UGT51B1 from Pp had been previously characterised as a USGT 
(Warnecke et al. 1999).  
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An amino acid sequence alignment was performed using the ClustalW2 web 
alignment program (European Bioinformatics institute, 
http://www.ebi.ac.uk/Tools/msa/clustalw2/) with ScUGT51’ and the selected 
sequences identified using Blastp searches. This allowed identification of the 
exact regions of all sequences that aligned with ScUGT51’. Following this, 
truncated versions of all identified sequences with appropriate N-terminal amino 
acid deletions made, were produced. Fig. 3.2 C. shows the sequence alignment of 
ScUGT51’with the BLAST-identified sequences. Regions of highly conserved 
amino acids were noted in all sequences (indicated by black boxes). In addition, 
all sequences also contain the USS (underlined), a characteristic feature of the 
GT-B fold UGT superfamily (Hu and Walker 2002). The presence of highly 
conserved residues in the C-terminal domain across all identified sequences 
strongly suggested that these could be functional homologues.  
All deduced sequences were checked for the presence of N-terminal putative 
signal peptide and trans-membrane helices in order to avoid improper folding of 
the expressed proteins. This is because expressing proteins with a signal peptide 
could lead to the formation of insoluble aggregates which prevents them being 
studied in detail (Simonen and Palva, 1993). As expected, none of the selected 
sequences indicated the presence of TMHs or signal peptides. 
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Table 3.6 Summary of yeast host strains used in this study.  
 
 
 
 
 
 
 
 
Organism GenBank Accession 
Nos. of UGTs 
Reference 
Saccharomyces cerevisiae (Sc) 
strain S288C 
NP_013290 Johnston et al., 
1997 
Pichia pastoris (Pp) strain GS115 AAD29570 Warnecke et al., 
1999 
Pichia guilliermondii (Pg) XP_001482815 Birren et al., 
unpublished data 
Kluyveromyces polysporus (Kp) XP_001646967 Scannell et al., 
2007 
Pichia angusta (Pa) ABO31066 Meijer et al., 
2007 
Kluyveromyces lactis (Kl) XP_452287 Dujon et al., 2004 
Debaromyces hansenii (Dh)  XP_460322 Dujon et al., 2004 
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Fig. 3.2 Schematic showing overall organisation of UGT domains. A. Domains of 
ScUGT51. The extent N-terminal truncation of ScUGT51 is indicated by arrows and was 
conserved in all sequences. ScUGT51 consists of the PH and GRAM domains (G) 
involved in protein localisation; a GT family 28 sequence and the UDPGT domain; 
(Distances are not drawn to scale). B. PH, GRAM, GT28 and UDPGT domains of Pp, Pa, 
Pg, Kl, Kp and Dh (top to bottom) (Figures taken from Pfam database (Finn et al., 2008).  
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C.             10        20        30        40        50        60        70        80        90       100 
                |         |         |         |         |         |         |         |         |         | 
Pp     ---ENQYSTSEIRSKRRYKFVLLTIGSRGDVQPYISLAKGLLAENHKVKIVTHEEFKPWVESYGIEFATIAGNPAELMSLMVTHKSLSVGFLKEAKEKFT 
Pa     IIEEHPLTKTKVRPLKSYRFTLLTIGSRGDVQPYIALGKALMKEGHQVRIVTHAEFEPWIKKHGIRFASIAGDPSELMALMVTHPTINYNFIKEAKSKFR 
Pg     LLEDSPLIKTEVRPSTSFKFTLLTIGSRGDVQPYLALAKGLQEEGHDVTIATHSEFKEWIEGHNVKFREIAGNPTELMALMVRHGSMSVTFIKEASSKFR 
Dh     VLEDSPFYKTEIRPSTSFNFTLLTIGSRGDVQPYIALGKGLLNEGHNVTIATHSDFEEWIVGHGIKFKTIAGNPVELMSLMVTHGSMSLSFLKEASSKFR 
Sc     MIDENPHYKTSIKPNKSYKFGLLTIGSRGDVQPYIALGKGLIKEGHQVVIITHSEFRDFVESHGIQFEEIAGNPVELMSLMVENESMNVKMLREASSKFR 
Kp     LVEDNPYFKTKIMPTKSYNFGFLTIGSRGDVQPYIALAKGLIQEGHSVTIITHREFKSFVECHGIDFKEIAGDPTKLMSLMVEHEAINVGMLMEASSKFR 
Kl     IVEKNPYFTTVIKPSKSYKFGLLTIGSRGDVQPYIALAKGLQAEGHEVIILTHGEFKDWIVSHNIGFREISGNPAELISLMVQHGSMNMGLLRDASTNFS 
          .    .: : .   :.* :************::*.*.*  *.*.* * ** :*. ::  :.: *  *:*:* :*::*** : ::.  :: :*. :* 
  
              110       120       130       140       150       160       170       180       190       200 
                |         |         |         |         |         |         |         |         |         | 
Pp     GWIGELLQSSWDACQD--ADVLIESPSAMAGIHIAEKLQIPYFRAFTMPWTRTRAYPHAFVVPEQKRGGSYNYLTHIIFENVFWKGISGEVNKWREQVLM 
Pa     SWIDDLLVTSWKACQD--TDILIESPSSICGIHIAEKLQIPYFRAFTMPWTRTRAYPHAFMVPDQKLGGAYNYMTHVAFENGYWRGTAHQVNKWRVETLG 
Pg     SWITELLSSSWDACQG--TDILIESPSAMGGVHIAEALGIPYMRAFTMPWTRTRAYPHAFIVPDQKKGGSYNYLTHVMFETLFWKGISGQVNRWRQNELG 
Dh     GWIQELLDTSWKACQG--SDILIESPSAMVGAHIAEALGIPYIRAFTMPWTRTRAYPHAFIVPDKKKGGSYNYITHLMFETVLWKGISSQVNKWRRELLG 
Sc     GWIDALLQTSWEVCNRRKFDILIESPSAMVGIHITEALQIPYFRAFTMPWTRTRAYPHAFIVPDQKRGGNYNYLTHVLFENVFWKGISGQVNKWRVETLG 
Kp     GWIHDLLVTTWEACKNLKLDILIESPSAMAGIHISEALQIPYFRAFTMPWTRTRAYPHAFIVPDQKRGGSFNYLTHVIFENVFWRGICSQVNKWRVQTLG 
Kl     TWISSLLDTAWEGCQG--IDILIESPSAMAGIHIAEALRIPYFRAFTMPWTRTRAYPHAFIVPDQKRGGNYNYFTHVLFENIFWKGISGKVNEWRETKLK 
        **  ** ::*. *:    *:******:: * **:* * ***:*****************:**::* ** :**:**: **.  *:* . :**.**   * 
 
              210       220       230       240       250       260       270       280       290       300 
                |         |         |         |         |         |         |         |         |         | 
Pp     LPKTNLERLEQNKVPFLYNVSPTVFPPSMDFPHWVKVVGYWFLDEGEADSYDPPKPLLEFMEKAKTDGKKLVYIGFGSIVVSDPKQLTEAVIDAVLSADV 
Pa     LPKTSLAEMKQNNVPFLYNVSPTVFPPSVDFAEWVKVTGYWFLDESE--TYQPPEVLTKFIEQARKDGKKVVYIGFGSIVVSKPSELTQAVVDAVLEADV 
Pg     LPRTSLLKLQQTKIPFLYNISPSIFPPSVDFPDWVKVTGYWFLNEGGSN-FNPPPELLEFLSLAKENGKKVVYIGFGSIVVKNAKSLTKAIVEAVQEADI 
Dh     LPRTNLYRLAQYDIPFLYNISPTIFPPSVDFPDWVKVTGYWFLDEGAADDFEPLKELVEFMNKARADDKKVVYIGFGSIVVEDAKSLTKAIVEAVLNADV 
Sc     LGKTNLFLLQQNNVPFLYNVSPTIFPPSIDFSEWVRVTGYWFLDDKST--FKPPAELQEFISEARSKGKKLVYIGFGSIVVSNAKEMTEALVEAVMEADV 
Kp     LEKTNLAQLQQNKIPFLYNISPVIFPPAIDFDEWIKVTGYWFLDESES--FEPSQELETFISKARKLGKKLVYIGFGSIVVNNAKEMTRAVIDSVLETDI 
Kl     LPKTNLVSMQQNRVPFLYNVSPIVFPPSVDFNEWIKVTGYWFLDEKRS--YKPPAEFMEFLNKARELKKKVVYIGFGSIVVNDPEKMTDTIIEAVRDAGV 
       * :*.*  : *  :*****:** :***::** .*::*.*****::     :.*   :  *:. *:   **:**********.....:* :::::* .:.: 
 
              310       320       330       340       350       360       370       380       390       400 
                |         |         |         |         |         |         |         |         |         | 
Pp     RCILNKGWSDRL------GKQTGVEVELPEEIYNSGNVPHDWLFGKIDASVHHGGSGTTGATLRAGIPTIIKPFFGDQFFYANRVEDIGVGIGLRKLNSK 
Pa     RCILNKGWSDRL------GTKTEIEVVLPPEIYNAGSVPHDWLFPQIDAAVHHGGSGTTGASLRFGVPTIIKPFFGDQKFYAGRVEDLGCGVSLKDLNYK 
Pg     YCILNKGWSDRLLDSDDKAEKEKPEIDLPPEVFNSGAVPHDWLFPRIDAAVHHGGSGTTGATLRAGLPTIIKPFFGDQFFYASRVEQMGVGLSLKKLNSK 
Dh     RCILNKGWSDR--NSSPAKDNAEPEVELPEEIYNSGSIPHDWLFPKIDAAVHHGGSGTTGATMRAGIPTIIKPFFGDQFFYSSRIEDIGAGIGLKKLNAR 
Sc     YCILNKGWSER---LGDKAAK-KTEVDLPRNILNIGNVPHDWLFPQVDAAVHHGGSGTTGASLRAGLPTVIKPFFGDQFFYAGRVEDIGVGIALKKLNAQ 
Kp     FCILNKGWSER---LGKEELRYEEEPEYPETIFLCDSIPHDWLFPKVDAAVHHGGSGTTGATLKAGTPVVIKPFFGDQFFFASRIEDIGAGIALKKLNVS 
Kl     YCVLNKGWSNR---FGDPLAK-KIDKELPSYIYNSGDVPHDWLFTKIDATVHHGGSGTTGASLRAGLPTIIKPFFGDQFFYASRVEDIGAGVALKKLNRS 
          *:******:*         .   :   *  :   . :****** ::**:***********::: * *.:******** *::.*:*::* *:.*:.** 
   
              410       420       430       440       450       460       470       480       490       500 
                |         |         |         |         |         |         |         |         |         | 
Pp     SLSKAIKEVTTNTRIIEKAKEIGKQIQSENGVSAAIRCLYQEMEYAKKLSKSKQK-Y--------------------WDNQSEDISDDSVSGSWFEV--- 
Pa     SLARALKEVTTNTRIIEKAKLVGARIRSETGVQTAIETIYNEMEYARSLSISKVKQVSV----------------VKSDEEFDDDKDEEVEGSWLLV--- 
Pg     SLTKALNTVTSDFKMIEKCRSISERINHEDGVSAALEAIYSELEYAKHLSISRRALGYE---ASGLQTPVVYEQSDESDESGYDDEDESEETETDEESTD 
Dh     SLCTALKTATSDAKMITKAKKISERLKQENGVLNAIEAIYYELEYARSLILAKQHENTKHDLKSGTQTPVVNETNEYFDSDTYDADHDSDKESDHDQTYE 
Sc     TLADALKVATTNKIMKDRAGLIKKKISKEDGIKTAISAIYNELEYARSVTLSRVKTPRK-----------------KEENVDATKLTPAETTDEGWTMI- 
Kp     SLSNAIKKVLTDKSIKRKAVSLKKRVAKENGVTTAINCIYSELEYARSLVVKKNHKSSN-----------------IEFIQHPNNVNDTTKTVIPLTSMV 
Kl     SLAKALKEVTTNTRIIQKARQIGESISKEHGVATAIGAIYSELGYARSLIKTKNPVDDK-----------------EMEAASTKLSNDAVVTAKGNEKEE 
       :*  *:: . ::  :  :.  :   :  * *:  *:  :* *: **: :   : 
                                                
               510       520       530       540 
                 |         |         |         | 
Pp      ------------------------------------------------- 
Pa      ------------------------------------------------- 
Pg      NEDITEIENVPHLDYVQNHRKSLESSSEEDVAIATTTTND--------- 
Dh      QDNHSDYDVANDDNMTEIVEPSLEDGND-TVRIAPDSGNDNTTVTDANK 
Sc      ------------------------------------------------- 
Kp      ------------------------------------------------- 
Kl      YSSEGSGSNDGSWLLI--------------------------------- 
 
 
 
Fig. 3.2 C. ClustalW 2.0.12 alignment of ScUGT51’ with deduced yeast sequences. 
Black boxes indicate identical amino acids in all 7 sequences. Grey boxes indicate 
identical amino acids in 5 or 6 sequences; the USS is underlined in red.  The first amino 
acid residue of ScUGT51’ shown here corresponds to the 723rd residue in the ScUGT51 
and aligns with residues 748, 772, 1067, 1032, 741 and 491 in the deduced sequences of 
Pp, Pa, Pg, Dh, Kp and Kl respectively.  
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3.3.2 Cloning, UGT expression and purification 
The ORFs of the gene fragments of interest were amplified by PCR and cloned 
into the LIC vector. The LIC vector is a modification of the pET-28a vector where 
the gene of interest can be inserted into the vector alleviating the need for time 
consuming and unreliable ligation steps for cloning (Bonsor et al. 2006). The LIC 
vector also encodes a hexa-histidine tag that can be incorporated at the N-terminus 
of the protein of the encoded gene thereby allowing one-step r-protein purification 
using IMAC. 
 
3.3.2.1 PCR amplification of target genes followed by LIC 
ORFs of gene fragments hypothesised to encode putative UGTs were amplified 
by PCR from chromosomal DNA extracted from the respective yeast strains (See 
Fig. 3.3 for visualisation of DNA by AGE). Forward (F) and reverse (R) primer 
pairs that included LIC specific ends (section 3.2.3.1) were used to generate PCR 
fragments (Fig. 3.4 A-C) corresponding to polypeptides with N-terminal deletions 
as described in section 3.1.1. Optimised annealing temperatures for PCR are listed 
in Table 3.2 (b). In all cases except for P. guilliermondii, it was observed that 
increasing the initial primary and consequently secondary annealing temperatures 
(Table 3.7) contributed to specific primer annealing thereby generating a cleaner 
target gene product. 
LIC vector was prepared by PCR amplification where at the optimised annealing 
temperature of 75°C, a dense PCR band is observed (Fig. 3.4 D) between 5 Kb 
(Kilo bases) and 6 Kb when compared to the DNA size standard (L). Since the 
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size of linear LIC vector was expected to be approx. 5.4 Kb (See Appendix A), 
these results indicate the successful PCR amplification of the LIC vector. PCR 
amplified LIC vector was treated with DpnI in order to digest the original 
circularised vector DNA template and prevent it from being preferentially 
transformed in E. coli. 
Following PCR cleanup (section 2.2.1.6), PCR products and LIC vector were 
treated with T4 pol (section 3.2.3.3.1), that cleaved DNA fragments to result in 
the formation of 12-15 base 5’3’ specific non-complementary single-stranded 
overhangs to enable LIC. Treated products were annealed and transformed into 
chemically competent E. coli TOP 10 as described in section 2.2.1.12. A 
transformation efficiency of 50-60 CFUs per 192 ng LIC vector was achieved 
compared to the pET-28a positive control where 270 CFUs per 0.02 ng vector 
(expected 100-200 CFU) were noted. 
 
ORF of 
source 
organism 
1 
P                S 
2 
P                S 
3 
P               S 
 
4 
P              S 
Kp 28.9         51.9 38.2         61.2 48.5        71.5  
Pa 33.1         56.1 42.7         65.7 53.4        76.4  
Sc 35.6         58.6 45.5         65.5 54.5        77.5  
Kl 28.9         51.9 38.2         61.2 48.5        71.5  
Dh 28.9         51.9 35.6         58.6 45.5        68.5  
Pp 28.9         51.9 35.6         58.6 45.5        68.5 51.0       72.4 
Pg 40.7         63.3 48.0         69.8 45.2        67.3  
  
Table 3.7 Optimisation of (P) and secondary (S) annealing temperatures (oC) for 
PCR. The corresponding results are shown in Fig. 3.4 (A-C). 
 
                     Chapter 3 Cloning, expression and characterisation of UGTs 
 
110 
 
 
 
 
 
      
 
Fig. 3.3 Visualisation of genomic DNA of yeasts following AGE. Sc, Pp, Pa, Pg, Kl, 
Dh, Kp (Lanes 1-7). L= m.wt DNA size standards ranging between 200 bp and 10 Kb. 
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Fig. 3.4 Visualisation of gene fragments following PCR. Annealing temperature sets 
used are listed in Table 3.7. A. Lanes 1-3: PCR products for Kp at annealing temperature 
set 1-3 (expected size 1434 bp + LIC ends); Lanes 4-6: PCR products for Pa at annealing 
temperature set 1-3 (expected size 1413 bp +LIC ends); Lanes 7-9: PCR products for Sc 
at annealing temperature set 1-3 (expected size 1431 bp + LIC ends); Lanes 10-12: PCR 
products for Kl at annealing temperature set 1-3 (expected size 1473 bp + LIC ends); 
Lanes 13-15: PCR products for Dh using annealing temperature set 1-3 (expected size 
1632 + LIC ends); B. Lanes 16-19: PCR products for Pp at annealing temperature set 1-3 
(expected size 1395+ LIC ends). L= DNA size standards ranging between 200 bp and 10 
Kb.  
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Fig. 3.4 C. Visualisation of gene fragments following PCR. Annealing temperature sets 
used are listed in Table 3.7 Lanes 20-22: PCR products for Pg using annealing 
temperature set 1-3 (expected size 1602 bp + LIC ends). L= DNA size standards ranging 
between 200 bp and 10 Kb. 
  
                     Chapter 3 Cloning, expression and characterisation of UGTs 
 
113 
 
 
 
 
 
                                                     
 
Fig. 3.4 D. PCR amplification of LIC vector. Gel image following AGE shows a 
fragment between 5 and 6 Kb (expected size 5.4 Kb representing the size of pET-28a 
vector was expected.). The concentration as determined by spectrophotometric 
quantification was found to be 50 ng/µl. 
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UGT fragments were cloned such that recognition sites for XbaI and XhoI flanked 
the upstream and downstream regions of the target sequences respectively. This 
was confirmed by restriction endonuclease digestion of isolated pDNA (see 
section 2.2.1.5 for crude pDNA prep) from a single clone by XbaI and XhoI (see 
section 2.2.1.11 for reaction conditions). Fig. 3.5 A and B show AGE images of r-
plasmids harbouring target gene inserts. Internal restriction recognition sites were 
present in gene fragments of Pg (XbaI and XhoI recognition sites present at 
position 759 and 1136 respectively), Pp (XhoI recognition site present at position 
68) and Dh (XbaI recognition site present at position 717) as determined by the 
NEBcutter program (http://tools.neb.com/NEBcutter2/). As shown from Lanes 7-
9, due to the presence of an Xba  I recognition site in the case of Dh, two 
fragments are observed approx. 900 bp and over 1000 bp. Similarly, in the case of 
Pg three fragments at approx. 800, 600 and 400 bp are observed as expected based 
on the positions of recognition sites. In all other cases, bands of the expected gene 
size were observed with the addition of approx. 100 nucleotides which includes 
LIC specific ends as well as addition of nucleotides until the restriction site for 
Xba I is included in the insert. Linearised LIC vector appeared as a band of 
approx. 5 Kb in all cases. Results of successful cloning of target inserts are 
tabulated in Table 3.8. These results clearly indicate that target inserts from all 
sources were successfully cloned in the LIC vector. 
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Organism 
Total pDNA 
preps screened 
for inserts 
No. of r-
plasmids 
Recombination 
efficiency (%) 
 Kp  7 1 14  
Pa 5 4 80  
Sc 4 3 75  
Dh 4 3 75  
 Kp 5 5 100 
Pg 8 7 88  
 Pp 6 6 100 
 
 
Table 3.8 Recombination efficiency of plasmids. Constructs were transformed in E. coli 
(TOP10) and efficiency verified by restriction endonuclease digestion.  
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Fig. 3.5 A. AGE gel image showing gene fragments following endonuclease digestion 
of pDNA. Lanes 1-5: Pa gene fragments (expected size 1513 bp); Lanes 6-9:Dh gene 
fragments; Lane 10: Kl gene fragments (expected size 1573 bp); Lane 11: Kp gene 
fragment (expected size 1534 bp); Lane 12-14: Sc gene fragments (expected size 1531 
bp); Lanes 15-20: Pp gene fragments (expected size 1495 bp); Lanes 4, 6:  pDNA lacking 
target gene fragments. L= DNA size standards ranging between 200 bp and 10 Kb. 
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Fig. 3.5 B. AGE gel image showing fragments following endonuclease digestion of 
pDNA. Lanes 1-8: Pg digested DNA showing multiple fragments due to presence of 
internal restriction endonuclease sites. 
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3.3.2.2 Native target gene expression and protein purification 
A single r-plasmid of each gene was transformed into chemically competent E. 
coli (DE3) for protein expression. All clones were transformed in E. coli (DE3) 
strains BL21, C41, C43, B834, CP (CP) and CP (RIPL) in order to optimise 
protein expression. Additionally, in order to determine optimum growth 
temperature for maximal protein expression, E. coli cultures were grown at 23oC, 
30oC and 37oC post induction with IPTG. This is because change in incubation 
temperature can significantly alter protein expression (Yu et al. 2006). The 
optimum temperature for protein expression in all cases was found to be 23oC.  
Protein expression profiles were compared to determine the most appropriate E. 
coli (DE3) strain for maximal expression. Fig. 3.6 shows SDS-PAGE analysis of 
solubilised proteins from overnight cultures of DE3 strains harbouring the 
pPpUGT51’. The PpUGT51’ (m.wt 54 kDa) was expressed, with the highest level 
of expression observed from CP (RP, RIPL) strains. E. coli CP (DE3) strains are 
engineered to contain additional t-RNA encoding genes to increase heterologous 
protein expression in E. coli as has been shown previously (Singh et al. 2009). 
Small scale protein expression levels in LB and auto-induction media (section 
2.2.1.3) were compared to check if media could affect protein hyper-expression. It 
was found all r-proteins expressed as insoluble inclusion bodies using auto-
induction media as compared with LB media which proved better for soluble 
protein expression (SDS-PAGE gel image using auto-induction media in 
Appendix C.). Furthermore, membrane fractions and CFEs of samples harvested 
3 h post induction with IPTG in addition to overnight incubation post induction 
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were analysed and in all cases it was found that soluble protein expression 
increased post overnight incubation following IPTG induction. 
Negative controls were performed wherein no IPTG was added to induce protein 
expression. In these cases no protein over-expression was observed as compared 
to cultures induced with IPTG. Table 3.9 indicates the most appropriate E. coli 
strain for maximal protein expression for each construct (See Appendix E. for 
SDS-PAGE gel images for r-proteins of Sc, Pa, Kl, Kp, Pg and Dh preferentially 
over expressed in indicated strains). In each case, optimised strains were then used 
for consequent protein expression and purification. 
CFEs (section 2.2.2.2) were prepared from IPTG induced overnight E. coli 
cultures harbouring r-plasmids. N-terminally histidine tagged r-proteins were 
purified from CFEs using gradient elution IMAC with a Ni Sepharose high 
performance resin. An automated gradient elution technique (as described in 
section 2.2.2.3) was used wherein relatively low imidazole concentration (10 mM) 
was used to eliminate E. coli native proteins while the N-terminal hexa-histidine 
tag engineered on the r-proteins chelates to the Ni+2 ions and is eventually eluted 
by introducing a linear gradient of 10-500 mM imidazole (Yang et al. 2007). This 
automated purification method proved highly efficient in protein purification. 
Even though KpUGT51’ was solubly expressed, it could not be purified 
successfully via IMAC. All other r-proteins were purified to near homogeneity. 
Pooled purified fractions were pooled, visualised by SDS-PAGE as shown in Fig. 
3.7. These fractions were concentrated and protein yields were between 4-6 mg/L. 
All enzymes were stable for up to 4 months at 4oC. 
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Table 3.9 E. coli (DE3) strains for soluble protein hyper expression. E. coli strains 
showing the maximal soluble protein expression levels for each r-plasmid. It is worth 
noting that no expression was detected in the conventional E .coli (BL21) for PpUGT51’, 
PgUGT51’ and ScUGT51’. 
 
 
 
 
 
 
 
 
r-protein Optimised E. coli strain/strains for soluble protein 
expression 
PpUGT51’ CP (RP, RIPL) 
PgUGT51’ CP (RP, RIPL), B834 
PaUGT51’ CP (RP, RIPL), B834, BL21 
ScUGT51’ CP (RP, RIPL) 
KlUGT51’ CP (RP, RIPL), BL21 
KpUGT51’ B834, BL21 
DhUGT51’ CP (RP, RIPL), BL21 
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Fig. 3.6 Optimisation of protein expression levels in E. coli (DE3) strains. SDS-PAGE 
analysis of membrane fractions of E. coli (DE3) (indicated above lanes) following 
expression of the Pp r-plasmid. Higher expression levels can be seen in case of E. coli CP 
(RP, RIPL). Predicted m.wt for PpUGT51’-54 KDa. 
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Fig. 3.7 SDS-PAGE analysis of IMAC purified UGTs. Elution of UGTs was achieved 
at imidazole gradient ranging between 10 and 500 mM. Purified protein bands are 
observed for A. ScUGT51’ (predicted m.wt-55 KDa); B. PaUGT51’ (predicted m.wt- 54 
KDa); C. PpUGT51’ (predicted m.wt 54 KDa) and D. KlUGT51’ (predicted m.wt 54 
KDa). Gel images for purified fractions of Pg and Dh r-proteins are included in 
Appendix E. 
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3.3.3 Determination of in vitro UGT activity and kinetic analysis 
3.3.3.1 In vitro UGT activity assays and LC-MS analysis 
To determine the preliminary activity and substrate specificity of UGTs, in vitro 
assays (section 3.2.5) were performed with the seven solubly expressed proteins, 
six of which could be successfully purified as described in section 3.3.3. For ease 
of reference, r-proteins produced using truncated sequences of identified yeasts 
will be designated as PpUGT51’, PaUGT51’, KlUGT51’, PgUGT51’, KpUGT51’ 
and DhUGT51’ isolated from Pp, Pa, Pg, Kp and Dh respectively. The respective 
r-plasmids will be denoted with a prefix ‘p’; for example, pScUGT51’ for the r-
plasmid of ScUGT51’. 
Protein concentrations were determined by measuring the A280 values as described 
in section 2.2.2.5. Based on previous studies of GTs isolated from eukaryotes, in 
vitro UGT activity assays were performed at pH 8.0 and a temperature of 30°C 
(Madina et al. 2007; Warnecke et al. 1999). No activity was observed when 
assays were performed at 37°C although blood group GTs have been previously 
assayed at this temperature (Persson and Palcic 2008). To test UGT activity and 
substrate specificity, assays were performed with a panel comprising mainly of 
steroidal acceptor substrates and UDPG and UDPGA as glycosyl donors. 
Structures of acceptors tested for UGT activity are depicted in Table 3.10 A. The 
range of acceptors served as examples with varying degree of steric hindrance 
apart from the difference in positioning of the –OH functional group for 
glycosidic bond formation. These were ergosterol, cholesterol, 
dihydroxycholesterol (cholestanol) and testosterone. β-naphthol, a non-steroidal 
acceptor substrate with a –OH functional group was also included to assess the 
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promiscuity of UGTs. It differed from steroidal substrates in that it consists of two 
fused benzene rings as opposed to four fused cycloalkane rings, a characteristic 
feature of steroids.  
Preliminary UGT activity results are summarised in Table 3.10 B. Assays 
(section 3.2.5) were set up in triplicate and incubated for 2 h following which the 
lipids were extracted, dried to evaporation and reconstituted in 2:1 (v/v) 
chloroform: methanol. The extracted lipids were then observed on a TLC plate 
following heat charring. KpUGT51’ could not be purified by IMAC and UGT 
activity assays were performed with 60 µl CFE in this case. As expected, 
ScUGT51’ displayed USGT activity. In addition, three r-proteins encoded by the 
selected gene fragments of Pp, Pa and Kl also displayed USGT activity with 
testosterone and/or ergosterol, cholesterol and cholesterol derivatives. No product 
was observed when assays were performed using non-steroidal aglycones such as 
beta naphthol. Furthermore, UDPG was shown to be the universal donor substrate 
that could not be replaced by UDPGA. UGT activities were further verified by 
assays with CFEs using UDPG as the donor and cholesterol as the acceptor 
aglycone (section 2.2.3). Untransformed E. coli BL21 (DE3) CFEs and crude 
membrane fractions were used as a control and it was found that these did not 
show background SG activity along with r-proteins from Pg, Dh and Kp with dpm 
counts typically less than 100. As expected, Sc, Pp, Pa and Kl UGTs were active 
with dpm counts between 1000-2000. 
The reaction products with cholesterol, testosterone and ergosterol, resolved by 
TLC in a 85:15 (v/v) chloroform: methanol solvent mixture are shown in Fig. 3.8. 
The reaction products with testosterone as substrate were co-chromatographed 
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with a chemically synthesised testosterone glycoside (TG) standard (ProStrakan) 
and were found to have identical Rf values. The standard and sample also had 
identical Rf values when co-spotted and visualised by TLC. Control reactions 
lacking UDPG showed the presence of the unused acceptor while lacking the 
formation of any other reaction products.  
Following in-gel trypsin digestion and MS analysis, the identity of the active r-
proteins could be verified by a Mascot nr peptide database search (described in 
section 3.2.4). The MS data subjected to searches against the nr protein sequence 
database confirmed the successful identification of Sc, Pp, Pa r-proteins based on 
the detection of 10, 14 and 10 peptide sequences respectively. The Mascot 
spectrum analysis reports are included in Appendix B.  
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Table 3.10 A. Structures of acceptor substrates used to study UGT activity. 
  
Code Acceptor 
substrate 
Structure 
E ergosterol 
 
C cholesterol 
 
 
T testosterone 
 
 
DC 5-alpha-
cholestan-3-
beta-ol 
(dihydrochol
esterol)  
 
B β-naphthol 
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Table 3.10 B. Summary of UGT activity against tested substrates. Acceptors utilized 
by UGTs as confirmed by TLC analysis are mentioned. Codes designated to acceptors are 
mentioned in Table 3.10 A. 
  
r-protein Acceptor substrates Glycosyl donor 
ScUGT51’ E,C, DC, T UDPG 
PpUGT51’ E,C, DC, T UDPG 
PaUGT51’ E,C, DC, T UDPG 
KlUGT51’ C, DC UDPG 
KpUGT51’ - - 
PgUGT51’ - - 
DhUGT51’ - - 
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Fig. 3.8 TLC resolution of extracted reaction products. Products were analysed 
following 2 h incubation of Sc, Pp, Pa and Kl UGT51’ reaction mixtures with A. 
cholesterol and B. testosterone and C. ergosterol acceptors. Lanes C and T are controls 
without UDPG. Lane TG depicts the authentic standard β-testosterone glycoside. Unused 
acceptor substrate and respective SGs are indicated by upper and bottom arrows and were 
detected by heat charring following staining with 15% (w/v) phosphotungstic acid. 
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For LC-MS analysis and verification of the TLC-resolved reaction products with 
testosterone as the acceptor (section 2.2.4), reaction volumes of the above 
described assays were doubled and after stopping the reaction after 2-3 h, half the 
volume of the reaction mixture, i.e. 100 µl was directly loaded for LC-MS 
whereas the other half was processed for TLC analysis. The expected m/z ratio for 
testosterone glycoside was 451.0 and 289.0 for testosterone (in the positive 
mode). The analysis was performed in the SIM mode (288.0-290.0; 450.0-452.0) 
for these ions and the chromatograms with the mass spectra for each UGT are 
shown in Figs. 3.9 (A.-C.). Retention times of reaction products were compared 
using standards of testosterone and testosterone glycoside (TG) which showed 
similar retention times of 2.0 and 1.3 min respectively. Also, control assay 
reactions with UDPGA as glycosyl donor or reactions in the absence of either 
substrate (acceptor or donor) showed no formation of a product peak. These 
results therefore confirmed TG synthesis by the action of UGTs of Sc, Pp and Pa. 
Following preliminary TLC analysis where no TG was noted using KlUGT51’, 
LC-MS analysis also did not yield a TG product peak following KlUGT51’ 
assays. Although LC-MS has been routinely used to detect testosterone and its 
metabolites, elongated run times have been reported (Li et al. 2002; Zea and Pohl 
2004). In this study, detection of testosterone and the corresponding conjugated 
product was achieved within a total run time of 5 min in isocratic mode thereby 
making this is rapid screening system for active GTs which may also be amenable 
to HTS. 
Glycosyl transfer reactions proceeded to completion as no characteristic peak was 
detected at m/z 289.0 following overnight incubation of reaction mixtures, thereby 
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indicating complete conversion of testosterone. This was additionally confirmed 
by the TLC resolution of the extracted reaction products where no remaining 
acceptor substrate was detected. The MS monitored increase in TG peak area 
using reactions stopped at different time intervals could therefore possibly be used 
for kinetic analysis of UGTs against a standard curve produced using known 
amounts of TG. A few studies have reported determination of GT kinetic 
parameters by LC-MS (Bothner et al. 2000; Cartwright et al. 2008; Hefner and 
Joachim 2003) and LC-MS (Offen et al. 2006). In one such study by Cartwright et 
al. (2008), an HPLC based assay was reported to determine kinetic parameters of 
flavonoid specific UGTs from A. thaliana . Each of these UGTs exhibit 
differential preferences towards the different –OH groups in quercetin and the 
differences in regiospecificity were exploited to determine kinetic parameters. 
However, the mentioned studies report significantly lower Kcat (< 2.9 s-1) and 
catalytic efficiency compared to USGTs in this study. This could be due to the 
high sensitivity of radiochemical assays over conventional methods for analysis 
(Brazier-Hicks et al. 2007). Also, in the absence of an internal standard, the 
requirement for manipulation for easy detection such as derivitization of either 
substrate coupled with lack of reproducibility make the accuracy of MS based 
quantification studies debatable (Higashi and Shimada 2004). Yang et al. (2005) 
have described the quantification of product accumulation over time catalysed by 
GT family 1 plant UGTs by using GDP as an internal standard. However, NDPs 
have been known to cause GT inhibition and this may limit their further use as 
internal standards for monitoring reactions in such cases (Potocka and Zimowski 
2008). LC-MS analysis could only be performed using testosterone as the 
acceptor as cholesterol represented a poor candidate for MS analysis due to its 
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ionization response. Even though gas chromatography coupled to mass 
spectrometry (GC-MS) has been earlier used to detect free sterols (Sugai et al. 
2009), monitoring the corresponding glycoside formation still represents a major 
challenge in analyzing GT catalysed reactions. 
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Fig. 3.9 A. LC-MS analysis of PaUGT51’- testosterone assay products. Products were 
analysed following a 2 h incubation of reaction mixture. A characteristic peak at m/z = 
451 [M + H] + at a retention time (R.T.) of 1.3 min confirms the synthesis of TG (inset); 
peak at R.T. 2.06 indicates unused testosterone. Ion with m/z=289 indicates the 
breakdown product ion of TG in the reaction.   
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Fig. 3.9 B. LC-MS analysis of ScUGT51’- testosterone assay products. Products were 
analysed following a 2 h incubation of reaction mixture. A characteristic peak at m/z = 
451 [M + H] + at a retention time (R.T.) of 1.4 min confirms the synthesis of TG (inset); 
peak at R.T. 2.06 indicates unused testosterone. Chromatogram below shows the TG ion. 
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Fig. 3.9 C. LC-MS analysis of PpUGT51’- testosterone assay products. Products were 
analysed following a 2 h incubation of reaction mixture. A characteristic peak at m/z = 
451 [M + H] + at a retention time (R.T.) of 1.27 min confirms the synthesis of TG (inset); 
peak at R.T. 1.77 indicates unused testosterone. Ion with m/z=289 indicates the 
breakdown product ion of TG in the reaction.   
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3.3.3.2 Kinetic analysis of UGTs with cholesterol and testosterone 
Assays for kinetic analysis were prepared using pure UGTs as described in section 
2.2.3. Kinetic parameters (KM, kcat) and catalytic efficiency of all active UGTs 
were determined as described in section 3.2.7 against a sterol (cholesterol) and 
steroidal (testosterone) acceptor with UDPG as the sugar donor. Kinetic analysis 
was performed using GraphPad Prism version 5.04 for Windows (GraphPad 
Software, San Diego California USA) and the results are tabulated in Table 3.11. 
All reactions followed typical Michaelis-Menten kinetics and the addition of 
MnCl2 in the reaction buffer did not alter enzyme activity. The Lineweaver-Burk 
plots for all UGTs against cholesterol and testosterone are shown in Figs. 3.10 
and 3.11 respectively. In all cases, under the current experimental conditions, 
cholesterol was at least two-fold more readily accepted compared to testosterone 
and this was further highlighted by at least four fold lower KM (high affinity) 
values for cholesterol. However, due to the lack of solubility of testosterone at 
higher concentrations in the aqueous reaction mixture, the KM values using 
testosterone (‘pseudo’ KM) were derived at less than saturating substrate 
concentrations. This high KM value therefore also suggests substrate inhibition. All 
USGTs exhibit preferential specificity towards the 3-hydroxy group in the A ring 
of the planar 4-ring system of cholesterol. PpUGT displayed the highest level of 
catalytic efficiency against both substrates with values of 111.7 s-1 µM-1 against 
cholesterol and 2.31 s-1 µM-1 against testosterone. 
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Table 3.11 Kinetic parameters of wt UGTs. Kinetic constants derived from assays 
using UDPG. Results are the means of triplicated determinations ± standard error (SE). 
  
UGT Acceptor KM  
(µM) 
Vmax  
(µmol min-1mg-1) 
kcat  
(s-1) 
kcat/ KM  
( s-1 µM-1) 
Sc C 
T 
79.9 ± 21.7 
362.5 ± 26.85 
1447.0 ± 218.2 
538.7 ± 23.75 
1319.2 
491.13 
16.5 
1.35 
Pp C 
T 
34.90 ± 10.80 
211.1 ± 27.5 
4337 ± 551.2 
288.7 ± 20.5 
3897.0 
488.67 
111.6 
2.3 
Pa C 
T 
67.2 ± 31.63 
837.9 ± 182.23 
719.1 ± 176.8 
540.1  ± 76.24 
650.6 
351.9 
9.7 
0.42 
Kl C 65.92 ± 31.09 509.0 ± 124.6 475.0 7.21 
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Fig. 3.10 Lineweaver-Burk plots against cholesterol. A. ScUGT51’, PaUGT51’ and 
KlUGT51’; B. PpUGT51’. Initial reaction rates were determined at [cholesterol] =12.5-
100 µM. Data points represent the mean of triplicates; error bars represent standard error 
of the mean (SEM) of triplicates. V= Rate/mg enzyme. 
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Fig. 3.11 Lineweaver-Burk plots against testosterone. Initial reaction rates were 
determined at [testosterone] =25-100 µM for ScUGT51’ and PpUGT51’ and at 
[testosterone] = 25-200 µM for PaUGT51’. Data points represent the mean of triplicates; 
error bars represent standard error of the mean (SEM) of triplicates. V= Rate/mg enzyme. 
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3.4 Discussion 
There is limited knowledge on detailed structural information as well as a lack of 
genetic approaches to elucidate functions of UGTs. ScUGT51’ and PpUGT51’ are 
classified as GT family 1 members and therefore can be assumed as inverting GTs 
that are proposed to adopt the GT-B fold in their tertiary structure. GT members 
from this family are known to embrace a diverse range of substrates and consist of 
the characteristic C-terminus USS that is involved in NDP-sugar binding (Hansen 
et al. 2009). For these reasons, characterised members of this family may be used 
to search sequence databases to identify novel and more promiscuous GTs as well 
as to understand catalytic domains for this important group of enzymes. 
Within the CAZy classification system, the same GT family may display 
variability in TM content (Rosen et al. 2004). Most GT family 1 UGTs 
characterised so far lack the presence of membrane spanning domains. They do 
however, contain several hydrophobic segments to enable association with the 
inner membrane, with the catalytic domain exposed to the cytoplasm 
(Brockhausen et al. 2008). PH and GRAM domains of UGTs from several yeasts 
such as P. pastoris have been shown to be involved in GT localisation to plasma 
and vacuolar membranes (Oku et al. 2003). In addition, the presence of these 
domains is vital for cellular processes such as pexophagy in yeasts such as P. 
pastoris and Y. lipolytica (Stasyk et al. 2003). 
The N-terminus PH and GRAM domains of ScUGT51’ are membrane localising 
elements and therefore are located in low levels in the soluble fractions. Grille et 
al., (2009) have recently reviewed that the majority of UGTs characterised so far 
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have been based on assays with crude cell homogenates or partially purified 
preparations which hampers their detailed biochemical and structural analysis.  
This study focussed on ScUGT51’, previously recognized as a USGT with known 
function (Warnecke et al. 1999) and the identified related UGTs. The full length 
ORFs of all sequences using ScUGT51’ as the query sequence consisted of the 
PH and GRAM domains; however, the 5’ truncated ORFs that did not encode 
these elements expressed soluble N-terminally histidine tagged soluble proteins 
that were amenable to purification and subsequent analysis. Based on this, apart 
from the previously characterised ScUGT51’ and PpUGT51’, the activity of two 
novel UGTs namely the PaUGT51’ and KlUGT51’ was described in this study. In 
all cases where activity was shown, it has confirmed that the majority of the N-
terminal domain is not required for UGT activity. Although the Atg protein 
homologs of Dh and Pg (DhUGT51’ and PgUGT51’ respectively in this study) 
have been implicated in autophagy and related processes (Bellu and Kiel 2003; 
Weijers et al. 2008), they do not demonstrate UGT activity as shown in this study. 
However, in the case of Pg, Kp and Dh r-proteins that lacked activity against the 
tested substrates despite significant sequence similarity with ScUGT51’, further 
structural information may be required to highlight the role of specific residues 
involved in acceptor specificity. 
Interestingly, Sugai et al. (2009) have recently reported the detection of an 
increased amount of total SG content detected in K. lactis strain M-16 as 
compared to strain NBRC 1267. The amino acid sequence of the latter is identical 
the sequence of the UGT of NRRL Y-1140 used in this study although they both 
differ from the UGT of M-16 in only one residue at position 620 which is 
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threonine (T) whereas the residue is methionine (M) in the case of M-16. Even 
though methionine has a more hydrophobic side chain as compared to threonine, 
the increased levels of SG in the case of M-16 is not clear. Moreover, the 
KlUGT51’ studied here was void of the N-terminus threonine residue and still 
displayed a relatively lower catalytic efficiency as compared to other UGTs and 
so the role of this residue in the regulation of SG cannot be confirmed. In 
addition, the possibility of M-16 being more resistant to conditions has been 
suggested as such conditions trigger activation of USGTs (Sugai et al. 2009). On 
the other hand, due to the identical primary UGT sequence of Kl strain NRRL Y-
1140 and NBRC 1267, other sterols involved in the yeast biosynthetic pathway 
such as lanosterol, zymosterol and episterol but not included in this study, may 
also be implied for SG synthesis in NRRL Y-1140 as shown in the case of strain 
NBRC 1267. 
Substrate specificity of UGTs and the effect of divalent cations 
In order to evaluate UGT specificity, in addition to the natural acceptor ergosterol, 
cholesterol and a panel of other such steroidal compounds were chosen as models 
for xenobiotic sterols in the current study. Sugar linked sterols have tremendous 
potential as drug delivery tools and as anticancer therapeutics. For example, 
Hahismoto et al. (2008), have successfully reported the inhibitory activity of 
mono-, di and tri-saccharide cholestanol compounds against mice tumour cell 
lines (Hahismoto et al. 2008). 
All active UGTs demonstrated exclusive substrate specificity towards their 
steroidal as well as sugar substrates. Hefner et al. (2003) have shown that a plant 
GT family 1 arbutin synthase involved in the synthesis of natural product O-β-D-
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glucosides was able to use β-naphthol as the acceptor substrate with UDPG, the 
most commonly utilized sugar donor in plants. This result is in agreement with the 
fact that plant natural product UGTs are largely specific to plant species only and 
display broad substrate specificity towards the acceptor aglycone (Thorsoe et al. 
2005).  
UGTs also show very high specificity towards their donor sugars. The most 
commonly used natural sugar is UDPG but others recognized include UDPGA, 
UDP-mannose, UDP-xylose and the commonly used sugar by mammalian UGTs, 
UDP-glucuronic acid (Osmani et al. 2009). GT family 1 glucuronosyltransferases 
are involved in the biotransformation of various steroid hormones including 
testosterone (Compain and Martin 2001). Conjugation with glucuronic acid during 
Phase II metabolism increases the polarity of the aglycone thereby facilitating its 
removal by excretion (Evans and O'reilly 1998; Jantti et al. 2007). Thus, UGTs 
responsible for testosterone conjugation could provide a basis for steroid based 
drug design and biotransformation. 
As expected, USGTs were highly specific to sterols and showed no activity 
against the non-steroidal β-naphthol. Previous studies have shown that ScUGT51’ 
and PpUGT51’ and other fungal USGTs with UGT51 homologs such as the 
UGT51E1 from Leptosphaeria maculans with a 38% primary sequence identity to 
PpUGT51’ were able to conjugate sterols such as the ergosterol, cholesterol and 
(Idnurm et al. 2003; Oku et al. 2003; Warnecke et al. 1999). In other cases, plant 
USGTs have been reported to utilise steroidal alkaloids such as tomatidine and 
solanidine acceptors (Moehs et al. 1997; Potocka and Zimowski 2008). However, 
all these compounds are hydroxylated at the C-3 position which USGTs are 
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commonly known to glycosylate and glycosylation at higher positions is rarely 
reported. In addition to the C-3 sterols, three USGTs in the present study 
glycosylated testosterone which consists of an –OH group at the C-17 position. 
Another plant derived USGT involved in secondary product metabolism has been 
reported to accept testosterone and higher steroids as acceptors (Madina et al. 
2007). With a KM value of 170 µM and kcat >5000 s-1 against testosterone, it 
displayed a much higher catalytic efficiency of 29 s-1 µM-1 as compared to the 
USGTs in this study where the highest catalytic efficiency of 2.3 s-1 µM-1 for 
testosterone conjugation was achieved in the case of PpUGT. On the other hand, it 
lacked any activity against the C-3 –OH sterols which were readily accepted by 
USGTs described in this study.  
The presence and/or position of double bonds within the steroid molecule as well 
as the presence and/or length of the acceptor hydrocarbon side chain has also 
shown to pose an effect on glycosylation rate with longer alkyl side chains acting 
as better sugar acceptors as compared with steroidal alkaloids (Potocka and 
Zimowski 2008). Cholesterol with a longer carbon side chain was found to be at 
least ten times more readily accepted compared to testosterone besides the fact 
that it consists of the USGT preferred C-3 –OH group.  
It is unclear why of the four tested USGTs only KlUGT51’ did not show activity 
towards testosterone (Fig. 3.8 B.) despite 64% sequence identity with ScUGT51’. 
Therefore, sequence similarity approaches alone cannot be used to predict 
substrate specificities and domain swap or site directed mutagenesis studies would 
be able to further elucidate the roles of specific amino acids in acceptor 
recognition. 
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The presence of Mn+2 did not affect UGT activity. This is in agreement with other 
family 1 UGTs that are not affected by the presence of Mn+2 and Mg+2. For 
example Madina et al. (2007) have reported that the presence of divalent metal 
cations of Mg and Mn did not affect a plant UGT activity. However, UDP was 
found to be a competitive inhibitor, suggesting that UDP may play an important 
role in plants. However, there have been several reports of UGT activity being 
enhanced in the presence of these cations. For example it has been previously 
shown that Ca+2 significantly enhanced a plant USGT activity as compared to 
Mg+2 (Staver et al. 1978). In another study, the rate of glucoside formation was 
enhanced by over two-fold by the addition of Mg+2 whereas Ca+2 inhibited a 
promiscuous plant UGT (Hefner et al. 2002). Further 3-D structural information 
and insight into the substrate specificity would be therefore required to better 
understand the affect of different metal cations on UGT activity. 
Role of SGs 
Ergosterol is the most abundant sterol in fungi where along with its biosynthetic 
precursors including lanosterol, zymosterol and episterol, it plays a major role in 
maintaining membrane integrity and function (Klutts et al. 2006; Stasyk et al. 
2003). However, a majority of the ergosterol exists in the free form, even though 
it is modified to steryl glycosides in a few yeasts where it may have a specific 
function. For example, in the case of P. pastoris, deletion of UGT51B1 
(PpUGT51’ in this study) resulted in a complete loss of ergosteryl glucoside 
synthesis and glucose dependent peroxisome degradation (Oku et al. 2003). In 
this study, all functionally active UGTs, apart from KlUGT51’ have shown 
positive activity towards ergosterol. Sugai et al. (2009) have reported ergosteryl 
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glucoside synthesis in K. lactis M-16, even though SGs from the other studied 
strain NBRC 1267, identical to NRRL Y-1140 in this study, were not 
characterised although they report abundance of free ergosteryl in NBRC 1267. 
This study therefore further highlights the diverse roles of steryl glycosides in M-
16 and NBRC 1267/NRRL Y-1140 and in other fungi in general. 
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4. Random mutagenesis and 
functional analysis of UGTs 
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4.1 Introduction 
As highlighted in the previous chapters, GTs may possess distinct substrate 
specificities despite a high percentage of sequence similarities. Thus for a broader 
scope in drug development, GTs, especially members of the GT-B family 
represent an ideal candidate for DE and engineering platforms due to the diversity 
of substrates utilised (Love et al. 2006). In order to highlight the role of specific 
residues in substrate binding and monosaccharide transfer, several mutagenesis 
studies in the past have focussed on creating point mutations based on solved 
crystal structures (Shao et al. 2005; Thorsoe et al. 2005). Even though these 
studies have highlighted the role of specific conserved residues within the C-
terminal domain, the highly variable N-terminal substrate recognising domains 
remain relatively poorly understood even though novel specificities have been 
achieved by several domain swapping studies (Hansen et al. 2009; Truman et al. 
2009).    
The aim of the studies described in this chapter was to generate random mutant 
libraries of the isolated ScUGT51’, PpUGT51’, PaUGT51’ and KlUGT51’ and to 
use these as a resource to screen for mutants with significantly improved catalytic 
activity compared to the parental enzymes. Beneficial mutations within the 
truncated versions of the USGTs studied here could provide a better insight into 
the involvement of specific amino acids in substrate recognition and saccharide 
transfer to the aglycone. Moreover, as previously described, due to low protein 
expression levels and GTs being membrane bound, it is important to create 
variants with significantly improved catalytic activities. Furthermore, due to the 
high conservation of secondary and tertiary structure among the UGTs, 
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comparative modeling with solved 3-D structures in the form of homology 
modeling was also explored in this study. Homology modeling represents an 
attractive tool for biochemical and functional characterisation as well as for 
rational engineering of GTs for desired properties (Osmani et al. 2009). 
Herein, mutant libraries of parental UGT encoding gene fragments were generated 
by ep-PCR using low fidelity DNA polymerases. This was approached in two 
different ways. One such approach involved ep-PCR of the wild type (WT) 
ScUGT51’, PpUGT51’, PaUGT51’ and KlUGT51’ sequence using Taq DNA Pol 
along with unequal amounts of dNTPs, whereas in the other approach, ep-PCR of 
the WT ScUGT51’, PpUGT51’, PaUGT51’ and KlUGT51’ sequence was 
performed using the Genemorph II EZClone Domain Mutagenesis kit (STR), 
which contains Mutazyme.  
The generation of plasmids with expected high rate of mutation frequencies (upto 
9-16 mutations/Kb of gene) in the UGT domains involved two rounds of PCRs. 
The general scheme followed in RM experiments is depicted in Figure 4.1. The 
ep-PCR stage or the mutant megaprimer (MM) synthesis involved the 
amplification of the target gene from the original plasmid (donor plasmid) by PCR 
using a low fidelity DNA Pol (Taq or Mutazyme). The second stage or the PCR 
cloning stage where PCR products, i.e. mutant megaprimers (MM) from the first 
round were used as primers to anneal to the original donor plasmid was followed 
by extension using a high fidelity DNA Pol. While using MMT (megaprimers 
generated using Taq DNA pol), KOD was used for PCR cloning and this was 
termed as an EZK reaction. While using MMM (megaprimers generated using 
Mutazyme DNA pol), EZC enzyme mix (Genemorph II EZClone Domain 
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Mutagenesis kit (STR), was used for PCR cloning and this was termed an EZC 
reaction. 
A HTS system based upon the desired activity of the evolved enzyme represents a 
major challenge for screening RM created libraries. The action of a GT in the 
formation of a glycosidic bond is accompanied by a stoichiometric proton release 
(Yao et al. 1998). For example: 
UDPGA + N-acetylglucosamine N-acetyllactosamine +UDP+ H+ 
 It has previously been shown that this pH perturbation can be used as a sensitive 
colorimetric assay for galactosyltransferases and other GTs using readily available 
pH indicators such phenol red and bromothymol blue to follow the progress of the 
reaction (Deng and Chen 2004; Park et al. 2009a; Persson and Palcic 2008). It has 
been postulated that this methodology would be more widely applicable to other 
GTs and therefore could be amenable to rapid screening of GT activities using a 
96-well plate reader. 
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Fig. 4.1 General scheme of RM experiments. Adapted from Genemorph II EZClone 
Domain Mutagenesis kit instruction manual  
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4.2 Materials and Methods 
4.2.1 Bacterial strains, r-plasmids and sequencing 
The r-plasmids pScUGT51, pPpUGT51’, pPaUGT51’ and pKlUGT51’ used are 
described in Chapter 3. Bacterial growth conditions are described in section 2.2. 
DNA was sequenced by GATC Biotech, U.K. For all sequencing reactions, 30 µl 
DNA prep (50-100 ng/µl) was prepared and samples sequenced using T7 
promoter forward (5’-TAATACGACTCACTATAGGG-3’) and pET-28a reverse 
(5’-CTAGTTATTGCTCAGCGG-3’) primers.  
4.2.2 ep-PCR for MM synthesis using Taq and Mutazyme DNA pol  
Primers stated in section 3.2.3.1 were used for ep-PCRs. Stock solutions (100 
µM) were diluted to 125 ng/µl (~12 µM). DNA concentration from agarose gels 
was determined by the Bio-Rad DNA quantification software (Quantity One) 
against a DNA size standard (Hyper Ladder 1) with known amounts of DNA in 
each fragment. 
4.2.2.1 ep-PCR for the generation of MMT using Taq DNA pol (BL) 
Constituents for Taq ep-PCR are listed in Table 4.1 (a) and details of the PCR 
program used is provided in Table 4.1 (b). A template DNA amount of 5 ng was 
used for high mutation frequency (9-16 mutations/Kb gene fragment). 
 dNTPs (100 mM each, BL) were diluted prior to use as follows: dATP- 1:10 
dilution with H2O, all other dNTPs- 1:5 dilution with H2O. 
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Table 4.1 (a) PCR components for ep-PCR using Taq DNA pol. 1 Recipe in Table 
2.6. 
 
 
 
 
 
 
 
 
Component Volume 
(l) Final amount (in 50 l reaction) 
5.0 U/l BIOTAQ DNA 
polymerase  
0.5 2.5 U 
10x NH4 buffer 1 5 1x 
wt r-plasmid DNA (template) 
(10-30 ng/µl) 
 5 ng 
 125 ng/µl forward primer 1 125 ng 
 125 ng/µl reverse primer 1 125 ng 
10 mM dATP 1.1 220 µM 
20 mM dCTP 2 0.8  mM 
20 mM dGTP 2 0.8  mM 
20 mM dTTP 2 0.8  mM 
50 mM MgCl2 solution 3 3  mM 
18.2 MΩ/cm H2O (to a final of 
50 µl) 
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Step Temp (oC)  Time 
(h:min:s) 
Cycle 
1 94.0 00:03:00 Initial denaturation 
2 94.0 00:01:00 Denaturation 
3 A 00:01:00 Annealing 
4 72.0 00:01:40 Elongation 
5   Step 2-4, repeated 29 times = 
30 cycles 
6 72.0 00:10:00 Final Extension 
7 10.0 Hold Storage 
 
Table 4.1 (b) PCR program for ep-PCR for random mutagenesis. A = optimised 
annealing temperature as listed in Table 3.2 (b). Elongation time was based on 1min/Kb 
gene fragment to be amplified. 
 
4.2.2.2 ep-PCR for MMM synthesis using Mutazyme (Genemorph II EZClone 
Domain Mutagenesis kit) 
All reactions and PCRs were set up as described in the kit instruction manual. 
Constituents for Mutazyme ep-PCR are listed in Table 4.2 (a). A control reaction 
was also set-up using the positive control plasmid DNA supplied within the kit. 1 
µl of the supplied positive control primer mix (125 ng/µl each primer) was used. 
Also 2 µl of 0.5 ng/µl positive control plasmid DNA was used for a final template 
amount of 1 ng. 
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Table 4.2 (a) PCR components for ep-PCR using Mutazyme 
 
The PCR program used is detailed in Table 4.1 (b) with amendments listed in 
Table 4.2 (b).  
Following ep-PCR, MMs generated were purified as detailed in section 2.2.1.6. 
 
 
 
 
 
 
 
Table 4.2 (b) PCR program for ep-PCR for RM using Mutazyme. A= optimised 
annealing temperature as listed in Table 3.2 (b) 
Component Volume 
(l) Final amount/ concentration (in 50 l reaction) 
2.5 U/µl Mutazyme II DNA 
polymerase  
1 2.5 U 
10x 
 
 Mutazyme II  reaction 
buffer  
5 1x 
WT r-plasmid DNA (template) 
(10-30 ng/µl) 
 5 ng 
 125 ng/µl forward primer  1 125 ng 
 125 ng/µl reverse primer 1 125 ng 
40 mM dNTP mix 1 200 µM (each) 
18.2 MΩ/cm H2O (to a final of 
50 µl) 
  
Step Temp (oC)  Time 
(h:min:s) 
Cycle 
1 95.0 00:02:00 Initial denaturation 
2 95.0 00:0:30 Denaturation 
3 A 00:00:30 Annealing 
Follow from step 4 (Table 4.2) 
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4.2.3 PCR cloning of MMs followed by transformation in E. coli 
Purified MMs generated by ep-PCR (section 4.1.1) served as primers for the PCR 
synthesis of plasmids harbouring mutations in the UGT domains.  
4.2.3.1 PCR cloning of mutants using MMT as primers- EZK reaction 
In this reaction, MMT (section 4.1.1.1) were annealed to donor plasmids followed 
by extension using KOD DNA pol. PCR constituents and PCR program are 
tabulated in Table 4.3 (a) and (b) respectively. 
 
Table 4.3 (a) EZK reaction constituents 
 
 
 
Component Volume 
(l) Final amount/ concentration (in 50 l reaction) 
1.0 U/µl KOD DNA pol  1 1.0 U 
10x 
 
KOD DNA pol reaction 
buffer  
5 1x 
wt r-plasmid DNA (template) 
(10-30 ng/µl) 
 50 ng 
 MMT (50-70 ng/µl)  500 ng 
dNTP mix (2 mM each) 5 200 µM (each) 
18.2 MΩ/cm H2O (to a final of 
50 µl) 
  
                 Chapter 4 Random mutagenesis and functional analysis of UGTs 
 
156 
 
 
 
Step Temp (oC)  Time 
(h:min:s) 
Cycle 
1 95.0 00:01:00 Initial denaturation 
2 95.0 00:00:50 Denaturation 
3 60.0 00:00:50 Annealing 
4 68.0 00:13:48 Elongation 
5   Step 2-4, repeated 24 times = 
25 cycles 
7 10.0 Hold Storage 
 
Table 4.3 (b) PCR program for generation of plasmids harbouring mutant UGTs. 
Elongation time was based on 2 min/Kb fragment amplification. 
 
4.2.3.2 PCR cloning of mutants using MMM as primers- EZC reaction 
In this reaction, MMM (section 4.1.1.2) were annealed to donor plasmids 
followed by extension using EZClone enzyme mix (Genemorph II EZClone 
Domain Mutagenesis kit). PCR constituents for this reaction are tabulated in 
Table 4.4. A control reaction was also prepared using 5 µl of the supplied positive 
control plasmid DNA template and 250 ng of the positive control MMM 
generated as described in section 4.1.1.2. PCR conditions are detailed in Table 
4.3 (b). 
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Table 4.4 EZC reaction constituents. 
 
Following PCR cloning, EZC and EZK reaction products were digested with 1 µl 
DpnI at 37oC for 2 h. Digested reaction products were transformed by 
electroporation into E. coli (TOP 10 and BL21) as described in section 2.1.1.17. A 
transformation control was also set up for both sets of reactions with 1 µl of pET-
28a (1 ng/µl) (expected to result in approx 4000 CFUs upon transformation). In 
the case of EZC reactions, an additional control transformation was also 
performed using the supplied positive control plasmid (Genemorph II Domain 
Mutagenesis kit) containing the lacZ gene. In this case, the reactions were plated 
onto low-salt LB agar supplemented with Amp, IPTG and X-gal. 
 
4.2.3.3 DNA analysis and sequencing 
10 single colonies derived for each clone following RM (section 4.1.2) and 
transformation in E. coli TOP 10 were picked and cultured for extraction of spin 
Component Volume 
(l) Final amount/ concentration (in 50 l reaction) 
2x EZClone enzyme mix 25 1x 
EZClone enzyme solution 3  
wt r-plasmid DNA (template) 
(10-30 ng/µl) 
 50 ng 
MMM (50-70 ng/µl)  500 ng 
18.2 MΩ/cm H2O (to a final of 
50 µl) 
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DNA as described in section 2.1.1.5. Each DNA prep (2 µl) was digested with 
restriction endonucleases (section 2.2.1.11) to confirm the presence of the insert. 
The samples were then sent for DNA sequencing.  
 
4.2.4 Screening for UGT activity following RM 
4.2.4.1 Colorimetric assays for HTS 
Colorimetric assays were performed with cresol red (CR), phenol red (PR) and 
bromothymol blue (BB) as the absorbance change indicators. Stock solutions of 
colour indicators were prepared in appropriate buffers adjusted to the required pH 
and were stored at room temperature. Assay conditions for each indicator are 
listed in Table 4.5. All components except the UDP donor were added to a 96-
well flat-bottom microtitre plates and mixed. The plates were then pre-incubated 
for 5 min at 30°C in a Microtek Synergy-HT Microplate reader equipped with an 
internal temperature control chamber. Following this, the UDP donor was added 
and absorbance monitored at 1 min intervals for a period of 3 h. 
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Table 4.5 pH change colour assays using colour indicators. Assays were maintained at 
a constant pH 8.0 in the case of CR and PR and pH 7.3 in the case of BB. Control 
reactions were prepared where the UDPG was substituted with UDPGal. Blanks were 
prepared with 200 µl 18.2 MΩ/cm H2O. The wavelength of absorbance for each colour 
indicator is stated.  
 
 
4.2.4.2 Screening RM libraries by radioactivity assays with UDPG 
For screening, 1 ml LB supplemented with 50 µg/ml kanamycin was added to 
each well of as many sterile 96-deep-well microtitre plates as required. Individual 
colonies derived for each clone following RM and transformation in E. coli BL21 
(DE3) were picked and inoculated into 94 out of 96 wells in each plate. A positive 
(wt UGT transformed in BL21(DE3)) and negative (pET-28a transformed in 
Component Final concentration (wavelengths 
used) 
  PR  (A557)    CR  (A436)     BB (A615) 
10 mM Na2HPO4 buffer; pH 
8.0/ MOPS buffer; pH 7.3 
2 mM 1 mM 2 mM 
2 mM colour indicator 0.01 mM 0.05 mM 0.1 mM 
4 mM acceptor sterol 0.3 mM 0.4 mM 0.8  mM   
40 mM UDPG/UDPGal 2 mM 2 mM 2 mM 
purified UGT in 5 mM 
TRIS-HCl pH 8.0 
1-2 µg 1-2 µg 1-2 µg 
18.2 MΩ/cm H2O to a final 
volume of 200 µl 
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BL21(DE3)) control was included in the remaining two wells of each plate 
following which the plates were sealed with a breathable self adhesive film (SL). 
After cell growth at 37oC for 18 h with shaking at 350 rpm, 100 µl of each culture 
was transferred to a fresh deep-well plate containing 1 ml LB medium 
supplemented with 50 µg ml-1 kanamycin. The original ‘master’ plate was then 
sealed and stored at 4oC. The freshly inoculated plates were incubated at 37oC for 
2-3 h with shaking at 350 rpm at which point the OD600 was approximately 0.7. 
IPTG was then added to a final concentration of 0.4 mM followed by the 
incubation of plates for 18 h at 23oC. 
Cells were harvested by centrifugation at 3,000 x g for 10 min at 4oC and the 
pellets re-suspended in chilled 50 mM TRIS-HCl (pH 8.0) containing 10 mg/ml 
lysozyme. Plates were then frozen at -80oC and thawed at room temperature. Cell 
debris was collected at the bottom of each well by centrifugation at 3,000 x g for 
20 min at 4oC. The resulting clear supernatant (CFE) from each well were 
screened for UGT activity based on assays with UDPG and analysis by LSC as 
described in section 2.2.3. CFEs with significantly evolved activity towards 
cholesterol compared to wt UGTs were identified and selected for DNA 
sequencing. For DNA sequencing, 50 µl of culture from a selected well of the 
stored ‘master’ plate was inoculated and cultured in 5 ml LB medium for 
preparation of spin DNA as described in section 2.2.1.5. Spin DNA was then 
transformed into chemically competent E. coli TOP 10 (as described in section 
2.2.1.12). An individual colony was picked, inoculated and cultured in 10 ml LB 
medium for spin DNA preparation for sequencing. 
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4.3 Results 
 
4.3.1 HTS method development 
This study had aimed to exploit the postulated colour change associated with a GT 
catalysed reaction for HTS. However, limited success was achieved in this 
methodology following which RM libraries were screened for GT activity by the 
widely used, reliable and sensitive radiochemical assay. Results from both these 
approaches are described in the following sections. 
 
4.3.1.1 Colorimetric assay method development 
In order to establish a simple and rapid screening system for active UGTs 
following RM, a pH responsive method based on colour and corresponding 
absorbance change was employed to test wt UGTs wherein three different colour 
indicator/buffer combinations (CR/PR and Na2HPO4 pH 8.0; BB and MOPS; pH 
7.3) were evaluated. However, the sensitivity and reproducibility of this technique 
relies on a number of factors. Firstly, the buffer strength proves crucial in these 
assays as weak buffers may increase the sensitivity of the system and lead to pH 
drops upon enzyme or substrate addition and strong buffers may not yield any 
colour change due to the increase in buffering capacity of the system (Chapman 
and Wong 2002). Secondly, the pH range for colour change of the indicator 
should include the optimum pH range for enzyme activity (Banerjee et al. 2003). 
Also, the number of protons released during the reaction progress may not be 
sufficient to yield a colour change from red to orange/yellow in the case of PR 
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and CR and blue to green/yellow in the case of BB. In order to confirm that the 
buffering capacity of the screening system was appropriate for a 
colour/absorbance change and to estimate the amount of H+ required to yield this 
change, a calibration curve was generated with PR assay components (section 
4.2.4.1) omitting the enzyme and consisting of known amounts of HCl (0-0.2 
mM). As shown in Fig 4.2, a decrease in A557 confirmed that assay components 
and solvents including ethanol, used for the preparation of acceptor stocks did not 
interfere with the buffering capacity of the mixture. In addition, a steady colour 
change from red ([HCl] =0 mM) to yellow ([HCl] =0.2 mM) was also observed in 
these reactions. However, when assays were performed with pure wt UGTs, no 
significant absorbance change was noted following 3 h incubation. In addition, 
control reactions where UDPG was substituted with UDPGal also showed no 
difference in absorbance. Moreover, no apparent colour difference was noted 
between reactions and control samples. Fig. 4.3 shows the BB assays prepared in 
a 96-well plate format. Negative controls were also prepared with UDPGal as the 
sugar donor and the r-proteins from Dh and Pg. Again, no apparent colour change 
was observed in the case of reactions with PgUGT51’ and DhUGT51’ following 3 
h incubation at 30oC. Even though KlUGT51’ and PpUGT51’ reactions show a 
slight colour change from blue to green, no differences were observed for 
ScUGT51’ and PaUGT51’ reactions. Furthermore, in all cases, no colour 
differences were observed between reactions and corresponding negative controls. 
These experiments were repeated and similar results were obtained indicating that 
the buffering capacity of the system could have been affected upon enzyme 
addition. On the other hand, CR and PH based assays displayed a better contrast 
between controls and reactions. This could be due to the fact that CR and PR turn 
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from red to yellow within a pH range of 8.8-7.0 and 8.0-6.6 (Moris-Varas et al. 
1999) respectively which better correlates with the optimum pH range for UGT 
activity as opposed to BB that turns from blue to yellow within pH 7.6-6.0. 
However, these results were not reproducible further highlighting the fact that the 
addition of purified enzyme solution may cause sudden pH perturbations. 
Therefore, in order to avoid precipitation, r-protein solutions were maintained in 5 
mM TRIS; pH 8.0 and a 1:200 (v/v) dilution was prepared in 2 mM Na2HPO4 
buffer; pH 8.0 prior to addition to the assay mixture. However, this further did not 
translate into a colour change following 3 h incubation at 30oC. These results 
clearly suggest that a high level of UGT activity is required in order to produce a 
significant pH shift leading to a colour change. Following assays with pure UGTs 
without yielding an appreciable colour change, the amenability of this approach 
for HTS for UGT activity using CFEs could not be validated in my hands.  
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Fig. 4.2 Calibration curve for HCl. Relationship between proton concentration and 
absorbance at 557 nm. Samples contained (in a total volume of 1 ml): 0.01 mM PR, 2 
mM Na2HPO4 buffer, 0.3 mM cholesterol and 2 mM UDPG.OD557 was recorded after 
addition of different amounts of HCl (0-0.2 mM). 
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Fig. 4.3 Colorimetric assay screening using BB. Reactions were performed against 
cholesterol as acceptor and maintained at pH 7.3. A615nm was measured at t=0 (above) and 
t=3 h (below) at 30oC. C= control reactions where UDP donor was absent. 
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4.3.1.2 Screening ep-PCR library for enhanced UGT activity using UDPG 
The ep-PCR library generated (section 4.3.2) for each clone was screened for 
significantly improved UGT activity compared to wt UGTs against cholesterol as 
the acceptor substrate using UDPG as donor. Cholesterol was chosen as the 
acceptor candidate for screening as all WT UGTs were active against this sterol 
which was not the case for testosterone.  
Since transformation rate for HTS is critical, RM reactions were transformed in 
electrocompetent BL21 (DE3) (section 2.2.1.12). This resulted in at least tenfold 
higher transformation efficiency (4000-5000 CFUs) of EZC reactions as 
compared to EZK reactions (100-350 CFUs) for each clone.  
For each variant library, 94 individual colonies following transformation were 
picked, cultured and CFE extracts prepared using sterile 96-well deep well plates 
as described in section 4.2.4.2. A similar screening approach has been recently 
undertaken to identify GT variants from an ep-PCR library with improved activity 
towards UDPG by using a 4-methylumbelliferone, a fluorescent acceptor 
(Williams and Thorson 2008). However, an advantage of the Williams and 
Thorson (2008) study was that the screening procedure could be entirely 
performed within a 96-well plate format since the quench in fluorescence 
following a GT reaction could be recorded using a plate reader. In my study 
however, the final stage of screening involved the extraction of radiolabelled 
products for LSC measurements which required assays using CFEs to be 
performed in tubes.  
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Tables 4.6 (A.-D.) depict the HTS screening data following LSC whereas Table 
4.7 summarises the HTS figures of cholesterol active mutants. As expected, due to 
the different mutagenic rates produced by the regimes followed, a maximum of 
only 10% of the hits screened from the Mutazyme generated variant library were 
active as compared to upto 45% active hits obtained from the Taq pol generated 
library of mutants. These results suggest that the high rate of mutation employed 
in the former case resulted in a majority of inactive enzymes. On the other hand, a 
mega-library was obtained with different mutagenic rates. CFE from pET-28a 
vector transformed into E. coli (BL21) served as a negative control and provided 
negligible background of less than 100 dpm in all cases which was in line with 
past studies where E. coli cell free extracts have shown no background activity in 
a radio-labelled assay format (Warnecke et al. 1999).  
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Sc mutant library Dpm             fold increase 
Mutazyme   
WtScUGT51’ 505.86  
ScEZC24 1177.9 2.3 
ScEZC35 465.19  
ScEZC46 2197.1 4.3 
ScEZC82 1789.21 3.5 
Taq pol   
ScEZK1 675.4  
ScEZK6 1136.77  
ScEZK7 869.15  
ScEZK11 877.25  
ScEZK12 1065.45  
ScEZK15 1145.4  
ScEZK16 775.28  
ScEZK17 599.54  
ScEZK19 500.26  
ScEZK20 1166.14 2.3 
ScEZK21 501.93  
ScEZK23 971.13  
ScEZK24 731.23  
ScEZK27 627.48  
ScEZK28 983.31  
ScEZK31 1009.72  
ScEZK33 689.07  
ScEZK37 564.13  
ScEZK38 606.58  
ScEZK39 845.88  
ScEZK42 1103.5  
ScEZK44 952.95  
ScEZK45 762.41  
ScEZK47 1686.54 3.3 
ScEZK48 926.19  
ScEZK50 553.83  
ScEZK53 932.59  
ScEZK56 426.75  
ScEZK57 784.61  
 
Table 4.6 A. HTS screening data for Sc mutant libraries. Hits showing at least two-
fold increase in activity following LSC are indicated in bold and discussed in text. 
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Pp mutant library Dpm             fold increase 
Mutazyme   
WtPpUGT51’ 797.28  
PpEZC8 336.36  
PpEZC12 339  
Taq pol   
PpEZK1 1304.96  
PpEZK6 1409.51  
PpEZK7 1492.46  
PpEZK9 1846.16  
PpEZK12 945.11  
PpEZK15 4785.57 6 
PpEZK20 1139.43  
PpEZK22 1050.33  
PpEZK23 1475.67  
PpEZK30 2380.25 3 
PpEZK36 820.9  
PpEZK46 2477.69 3 
PpEZK50 847.24  
PpEZK58 950.14  
PpEZK59 1143.27  
PpEZK61 1625.13  
PpEZK66 1353.77  
PpEZK70 2129.7  
PpEZK75 1063.12  
PpEZK85 959.82  
PpEZK87 1196.96  
PpEZK89 748.6  
PpEZK93 573.6  
 
Table 4.6 B. HTS screening data for Pp mutant libraries. Hits showing at 
least two-fold increase in activity following LSC are indicated in bold and 
discussed in text. 
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Pa mutant library Dpm             fold increase 
Mutazyme   
WtPaUGT51’ 2395.17  
PaEZC6 832.88  
PaEZC11 685.68  
PaEZC17 458.19  
PaEZC20 768.83  
PaEZC22 538.61  
PaEZC36 429.99  
PaEZC47 6193.47 2.6 
PaEZC57 505.79  
Taq pol   
PaEZK2 1135.56  
PaEZK3 1032.59  
PaEZK4 875.14  
PaEZK5 721.73  
PaEZK6 529.5  
PaEZK8 1579.56  
PaEZK10 1774.08  
PaEZK13 2941.86  
PaEZK20 634.28  
PaEZK26 433.74  
PaEZK35 509.92  
PaEZK36 547.43  
PaEZK38 943.4  
PaEZK40 613.93  
PaEZK43 617.95  
PaEZK48 2158.22  
PaEZK49 570.28  
PaEZK50 1421.34  
PaEZK52 753.08  
PaEZK58 1798.91  
PaEZK61 1697.07  
PaEZK62 751.07  
PaEZK64 538.42  
PaEZK67 4177.28 1.7 
PaEZK72 1266.27  
PaEZK73 2780.18  
PaEZK74 490.04  
PaEZK76 905.62  
PaEZK77 598.43  
PaEZK86 896.17  
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PaEZK89 1042.82  
PaEZK91 1205.56  
PaEZK92 967.25  
PaEZK94 1956.55  
PaEZK95 1105.52  
PaEZK96 3341.57  
 
 
 
 
Table 4.6 C. HTS screening data for Pa mutant libraries. Hits showing at least two-
fold increase in activity following LSC are indicated in bold and discussed in text. 
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Kl mutant library Dpm             
Taq pol   
WtKlUGT51’ 782.83  
KlEZC4 1037.2  
KlEZC8 1180.44  
KlEZC10 1106.75  
KlEZC11 1216.48  
KlEZC13 894.07  
KlEZC14 1034.98  
KlEZC15 1144.97  
KlEZC17 1050.01  
KlEZC18 625.34  
KlEZC24 1203.44  
KlEZC26 1755.46  
KlEZC28 1207.04  
KlEZC31 935.88  
KlEZC33 1432.76  
KlEZC34 1256.03  
KlEZC35 1318.15  
KlEZC39 1113.39  
KlEZC40 734.43  
KlEZC41 1336.31  
KlEZC43 706.82  
KlEZC47 941.2  
KlEZC48 1223.83  
KlEZC50 1415.12  
KlEZC51 1628.34  
KlEZC52 917.26  
KlEZC56 899.4  
KlEZC58 1412.81  
KlEZC60 1430.08  
KlEZC62 1083.78  
KlEZC66 761.17  
KlEZC68 842.03  
KlEZC71 1345.09  
KlEZC73 931.49  
KlEZC75 1400.45  
KlEZC76 1229.31  
KlEZC77 970.11  
KlEZC79 1176.32  
KlEZC81 965.16  
KlEZC85 1267.98  
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KlEZC89 1199.36  
KlEZC90 1369.47  
KlEZC91 755.1  
 
Table 4.6 D. HTS screening data for Kl mutant libraries. Hits showing at least two-
fold increase in activity following LSC are indicated in bold and discussed in text. 
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Mutant 
library 
Mutazyme 
Total screened         Hits 
Taq pol 
Total screened           Hits 
ScUGT51’ 92 4 (3) 59 28 (2) 
PpUGT51’ 56 2 (-) 94 23 (3) 
PaUGT51’ 77 8 (1) 94 36 (1) 
KlUGT51’ 63 - 94 42 (0) 
  
Table 4.7 Comparison of active variants (hits) following ep-PCR with Mutazyme 
and Taq. Numbers within brackets represent the active mutants exhibiting at least 
double the amount of incorporation of UDPG as compared with wt UGTs as noted 
from the dpm values. Dpm values for the negative control were typically less than 100 
dpm whereas wt clones transformed in BL21 demonstrated activity in all cases. 
 
 
 
 
 
 4.3.2 RM, transformation and generation of UGT variants 
ep-PCR with Taq pol or Mutazyme was carried out with the aim of achieving 
different mutagenic rates. It has been previously shown that additional rounds of 
ep-PCR using Taq led to an increase in mutation frequencies in each successive 
round which was confirmed by the respective increase in thermostability of 
xylanases and loss of catalytic activity at a permissive temperature of 37oC  
(Andrews et al. 2004). However, only one round of ep-PCR was performed when 
using Taq pol in my studies. However, when using Mutazyme, conditions for high 
mutagenic frequency (9-16 mutations/Kb) were employed. 
Another crucial step when performing ep-PCR using Taq is the ligation of 
mutated gene fragments to the recipient vector that requires optimisation of the 
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ratio and concentrations of insert and vector (Hibbert and Dalby 2005; Miyazaki 
2002). However, in my study, I developed a PCR cloning stage using a high 
fidelity KOD DNA polymerase (EZK reaction), analogous to the PCR cloning 
stage of the Genemorph II EZClone kit. Thus, MMs generated for WT clones 
(pScUGT51’, pPpUGT51’, pPaUGT51’ and pKlUGT51’) were purified and these 
served as primers to replace the homologous region in the template plasmid via 
the EZK and EZC reactions (section 4.2.3). The high fidelity DNA polymerases 
were used to prevent incorporation of new mutations during amplification of the 
entire r-plasmids. The resulting mixture was then treated with DpnI in order to 
eliminate the original WT r-plasmids used as the donor template for PCR cloning 
reactions (Stage 2, Fig 4.1). 
For preliminary analysis of mutation frequency, DpnI-treated EZC and EZK 
reaction mixture for each library (2 sets of mutant libraries were generated for 
each wt clone) was transformed into chemically competent E. coli TOP10. To 
check the effectiveness of the EZC method, the supplied positive control plasmid 
containing the lacZ gene was used that resulted in a total of 535 CFUs of which 
435 were white and the remainder blue when plated on agar media substituted 
with 80 µg/ml Amp, 240 µg/ml IPTG and 100 µg/ml X-gal. This suggested that 
approx. 81% of the total clones were phenotypic mutants even though the actual 
mutation rate may be much higher as not all mutations may lead to a change in 
phenotype. Two randomly picked clones from each variant library (i.e. 4 clones 
for each target) were verified to contain target inserts by restriction endonuclease 
digestion. DNA sequencing data from these revealed an average rate of 2-5 
mutations/Kb for all target fragments generated by Taq and a relatively higher rate 
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of 3-9 mutations/Kb target fragment generated by Mutazyme. A low mutation 
frequency may not necessarily lead to an amino acid whereas several mutations 
could lead to a majority of inactive enzymes. Mutation rate (transitions or 
transversions) can be further increased by lowering the target DNA for ep-PCR to 
as low as 0.1 ng which is proposed to yield the highest mutation frequency. It has 
been previously shown that a mutagenesis frequency corresponding to 1-2 amino 
acid changes per target per round of ep-PCR using either Taq or Mutazyme was 
preferred in order to prevent accumulation of neutral mutations (Bulter et al. 
2003). 
Variants displaying the highest level of UGT activity as well as a few random 
variants displaying at least a two-fold increase in rate of incorporation with UDPG 
as compared with the corresponding parental enzyme were selected for mutational 
analysis. For this purpose, the extracted pDNA was transformed into chemically 
competent E. coli TOP10 cells prior to sequencing reactions. Variants with 
enhanced levels of UGT activity compared to native enzymes, listed in Table 4.8 
were found to contain substitutions in both the N- and C-terminal regions. Each 
variant is referred to by the respective organism abbreviation as the prefix 
followed by the method used to generate the mutant library followed by the 
unique number for the clone, for example ScEZC46. 
 
 
 
 
                 Chapter 4 Random mutagenesis and functional analysis of UGTs 
 
177 
 
 
 
 
 
Table 4.8 UGT variants with improved activity compared to respective native 
enzymes following RM. 
 
 
4.3.3 Structural homology and analysis of UGT variants 
4.3.3.1 Homology modeling and overall structure of ScUGT51’ 
When used as a query sequence to match 3-D structures within the RCSB Protein 
Data Bank (http://www.pdb.org/pdb), ScUGT51’ showed closest structural 
homology with family 1 glycopeptide antibiotic GTs (Gtfs) from A. orientalis 
giving E-values of 1.49x10-22, 8.37x10-20, 2.69 x10-18, and 3.0x10-14 against a 
chimeric GtfA (GtfA’; PDB idμ 3H4I ) (Truman et al., 2009), GtfB (PDB id: 1IIR) 
(Mulichak et al., 2001), GtfA (PDB id: 1PN3) (Mulichak et al., 2003) and GtfD 
(PDB id: 1RRV) (Mulichak et al., 2004), respectively. Primary sequences of all 
the Gtfs derived from the PDB database exhibited an overall 62% identity among 
them and ScUGT51’ displayed a 25-28% overall sequence identity to GtfA’, 
GtfA, GtfB and GtfD. GtfD and GtfA utilise vancosamine and epi-vancosamine 
sugars for vancomycin and choloroeremomycin biogenesis respectively whereas 
GtfB is specific for UDPG in choloroeremomycin biogenesis and utilise different 
Variant Mutation Activity  
(relative to native UGTs) 
ScEZC46 E61V two-fold 
ScEZC24 G189E Similar 
PaEZC62 V316A 
E433G 
six-fold 
PpEZK15 K207R 
N400S 
six-fold 
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NDP-sugars and acceptor aglycones. GtfA and GtfD are however, structural 
homologs and decorate the same monoglycosylated vancomycin intermediate- 
desvancosaminyl vancomycin (DVV) (Walsh et al. 2003). 
ScUGT51’ was modelled based on the crystal structure of GtfA, GtfA’, GtfB and 
GtfD as templates to gain further insight into substrate binding and catalytic 
mechanism. The secondary structure of ScUGT51’ was predicted by PSIPRED 
protein structure prediction program (UCL, http://bioinf.cs.ucl.ac.uk/psipred/) and 
was used as a guide to produce an optimal structural alignment with Gtfs (Fig. 
4.4.). For this purpose, the ScUGT51’ sequence was truncated at the N- and C-
terminus (final sequence: 18Y-Y439) to fit the template sequences. Molecular 
modeling was performed by Dr. Marcus Durrant, Northumbria University by 
using DeepView/Swiss-PDB Viewer (version 4.0.1; available at 
http://www.expasy.org/spdbv) to construct a valid model of ScUGT51' based on 
its optimally produced alignment. Loops were built using the DeepView loop 
database. Energy was minimised to 1 Kcal/Å in Hyperchem using AMBER force 
field. The ligands thymidine diphosphate (TYD) and DVV of the GtfD-complex 
(PDB id: 1RRV) were used for ligand docking in the ScUGT51’ model. 
GtfB, GtfA and GtfD are all GT-B fold members with a bi-lobed 3-D structure 
adopting a GT-B fold (Mulichak et al. 2003; Mulichak et al. 2001; Mulichak et al. 
2004). The ScUGT51’ model based on the structural alignment is shown in Fig. 
4.5. Consistent with the structures of the Gtfs (Mulichak et al. 2001)., the 
structure of ScUGT51’ also belonged to the typical GT-B fold where both the N 
and C- terminal domains consist of a core structure of parallel β-sheets numbered 
as Nβ1-7, Cβ1-5. In addition, as in the case of other GT-B fold GTs, a long helical 
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tail of three consecutive helices is present at the end of the C-terminus and is 
shown to be involved in hydrophobic interactions linking the two domains (Wang 
2009). GT-B fold-characteristic glycine-rich motifs such as those harboured 
within the USS, are associated with donor sugar binding and are present in all 
sequences as shown. Based upon these observations, all UGTs in this study may 
therefore adopt a similar core structure.  
Flexible loop regions in the 3-D structure of all Gtfs correspond with 
hypervariable sequence regions (Fig. 4.4.) and are responsible for the optimal 
binding positioning of the vancomycin aglycones (Mulichak et al. 2001). Only the 
GtfA, GtfA’ and GtfD structures were available in NDP and/or aglycone bound 
forms where the conformation as expected was cleft-closed which allows the N-
terminus N3 and N5 loops (Fig.4.5) following the Nβ4 and Nβ5  respectively to 
form the acceptor binding crevice as well and promotes donor sugar interactions 
with both domains. On the other hand, both the N3 and N5 loops were disordered 
in the ScUGT51’ model similar to the non ligand-bound GtfB structure further 
confirming that these are involved in interactions with the acceptor.  
GtfD has more elaborate interdomain contacts where specific residues within the 
flexible loops have been shown to interact with the C-terminal domain (Mulichak 
et al. 2004).  
As the interdomain linker is immediately followed by a helix in Gtfs that also 
corresponds to a helix in the predicted secondary structure of ScUGT51’, this 
suggests that the position of the linker may be similar in ScUGT51’. However, the 
length of the interdomain linker is variable in plant UGTs and Gtfs, where it is 
much shorter in the latter. Differences in length and composition of linker region 
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serve to define domain positioning and substrate accommodation (Osmani et al. 
2009). 
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A.                                               
                                      * 
ScUGT51’   1     YKFGLLTIGSRGDVQPYIALGKGLIKEGHQVVIITHSEFRDFVESHGIQFEEIAGNPV 
GtfA’      2      GVLITGCGSRGDTEPLVALAARLRELGADARMCLPPDYVERCAEVGVPMVPVG--RA 
GtfB       1     MRVLLATCGSRGDTEPLVALAVRVRDLGADVRMCAPPDCAERLAEVGVPHVPVG--PR 
GtfA       1     MRVLITGCGSRGDTEPLVALAARLRELGADARMCLPPDYVERCAEVGVPMVPVG--RA 
GtfD       1     MRVLLSVCGTRGDVEIGVALADRLKALGVQTRMCAPPAAEERLAEVGVPHVPVG--LP 
            Nβ1            Nα1         Nβ2         Nα2     Nβ3 
 
ScUGT51’  59     ELMSLMVENESMNVKMLREASSKFRGWIDALLQTSWEVCNRRKFDILIESPSAMVGIH 
GtfA’     57     VRAGAREP----GELPPGAAEVVTEVVAEWFDKVPAAIEGCDAVVTTGLLPAAVAVRS 
GtfB      64     AKPL----------TAEDVRRFTTEAIATQFDEIPAAAEGCAAVVTTGLLAAAIGVRS 
GtfA      57     VRAGAREP----GELPPGAAEVVTEVVAEWFDKVPAAIEGCDAVVTTGLLPAAVAVRS 
GtfD      57     QHMMLQEGMPPP--PPEEEQRLAAMTVEMQFDAVPGAAEGCAAVVAVGDLAAATGVRS 
                                        Nα3              Nβ4      Nα4 
                                                                    * 
ScUGT51’  117   ITEALQIPYFRAFTMPWTRTRAYPHAFIVPDQKRGGNYNYLTHVLFENVFWKGISGQVN 
GtfA’     111   MAEKLGIPYRYTVLSPDHLPSEQSQ----------------AERDMYNQGADRLFGDAV 
GtfB      112   VAEKLGIPYFYAFHCPSYVPSPYYPPPP---------IDIPAQWERNNQSAYQRYGGLL 
GtfA      111   MAEKLGIPYRYTVLSPDHLPSEQSQ----------------AERDMYNQGADRLFGDAV 
GtfD      113   VAEKLGLPFFYSVPSPVYLASPHLPPAYDEPTTPGVT-DIRVLWEERAARFADRYGPTL 
                         Nβ5                              Nα5           Nα5a 
                                   * 
ScUGT51’  176   KWRVETLGLGKTNLFLLQQNNVPFLYNVSPTIFPPSIDFSEWVRVTGYWFLDDKSTFKP 
GtfA’     154   NSHRASIGLPPVEHLYDYGYTDQPWLAADPVLSPLRPT-DLGTVQTGAWILPDQRPL-- 
GtfB      171   NSHRDAIGLPPVEDIFTFGYTDHPWVAADPVLAPLQPT-DLDAVQTGAWILPDERPL-- 
GtfA      154   NSHRASIGLPPVEHLYDYGYTDQPWLAADPVLSPLRPT-DLGTVQTGAWILPDERPL-- 
GtfD      171   NRRRAEIGLPPVEDVFGYGHGERPLLAADPVLAPLQPD--VDAVQTGAWLLSDERPL-- 
                 Nα5b     Nβ6   Nα6          Nβ7 
 
ScUGT51’  235   PAELQEFISE--AR-SK-GKKLVYIGFGSIVVSNAKEMTEALVEAVMEADVYCILNKGW 
GtfA’     210   SAELEGFLRA--GS-PP-----VYVGFGSG--PAPAEAARVAIEAVRAQGRRVVLSSGW 
GtfB      227   SPELAAFLDA--GP-PP-----VYLGF---G--APADAVRVAIDAIRAHGRRVILSRG- 
GtfA      210   SAELEAFLAA--GS-TP-----VYVGFGSSSRPATADAAKMAIKAVRASGRRIVLSRGW 
GtfD      226   PPELEAFLAA--GS-PP-----VHIGFGSSSGRGIADAAKVAVEAIRAQGRRVILSRGW 
               CαA            Cβ1                 Cα1          Cβ2 
                              * 
ScUGT51’  290   SERLGDKAAKKTEVDL------PRNILNIGNVPHDWLFPQVDAAVHHGGSGTTGASLRA 
GtfA’     259   AG-LG--------R-IDE----GDDCLVVGEVNHQVLFGRVAAVVHHGGAGTTTAVTRA 
GtfB      275   -W-ADL-------VLPDD----GADCFAIGEVNHQVLFGRVAAVIHHGGAGTTHVAARA 
GtfA      261   AD-L---------VLPDD----GADCFVVGEVNLQELFGRVAAAIHHDSAGTTLLAMRA 
GtfD      277   TE-L---------VLPDD—RD---DCFAIDEVNFQALFRRVAAVIHHGSAGTEHVATRA 
                                    Cβ3       Cα3    Cβ4      Cα4 
                                                          * 
ScUGT51’  343   GLPTVIKPFFGD----QFFYAGRVEDIGVGIALKKLNAQTLADALKVATTNKIMKDRAG 
GtfA’     304   GAPQVVVPQKAD----QPYYAGRVADLGVGVAHDGPTPTVESLSAALATALTPGIRARA 
GtfB      321   GAPQILLPQMAD----QPYYAGRVAELGVGVAHDGPIPTFDSLSAALATALTPETHARA 
GtfA      306   GIPQIVVRRVVDNVVEQAYHADRVAELGVGVAVDGPVPTIDSLSAALDTALAPEIRARA 
GtfD      322   GVPQLVIPRNTD----QPYFAGRVAALGIGVAHDGPTPTFESLSAALTTVLAPETRARA 
           Cβ5              Cα5      Cβ6         CαB    CαC 
   * 
      ScUGT51’  396   LIKKKISKEDGIKTAISAIYNELEY 
      GtfA’     359   AAVAGTIRTDGTTVAAKLLLEAISRAKLAAALEHH 
      GtfB      376   TAVAGTIRTDGAAVAARLLLDAVSRE 
      GtfA      365   TTVADTIRADGTTVAAQLLFDAVSLEK 
      GtfD      377   EAVAGMVLTDGAAAAADLVLAAVGR- 
                                     CαD 
 
 
 
Fig. 4.4 Structure-based sequence alignment of ScUGT51’ and Gtfs. The secondary 
structure elements of GtfA (PDB idμ 3H4I); GtfB (PDB idμ 1IIR); GtfA’ (PDB idμ 1PN3) 
and GtfD (PDB id: 1RRV) are indicated below the alignment and underlined. Conserved 
residues (pink), glycine-rich regions in the C-terminal (blue) and N-terminal (green) are 
highlighted. Catalytic residues (discussed in text) are shown in red. Interdomain linker 
peptide is underlined (orange). Disordered N3 (magenta) and N5 (yellow) loop regions in 
Gtfs and corresponding sequence elements in ScUGT51’ are highlighted. Stars above the 
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sequence represent locations of substitutions in ScUGT51’ (red), PaUGT51’ (blue) and 
PpUGT51’ (green) mutants. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                 Chapter 4 Random mutagenesis and functional analysis of UGTs 
 
183 
 
 
 
                                              
                       
Fig. 4.5 ScUGT51’ model and fitted DVV and TDP. A., B.: Different views of the 
structure showing the long C-terminal helical tail joining the N-terminus in A.DVV 
(green) and TDP (orange) ligands fitted from the superposition with GtfD:DVV:TDP 
complex (PDB id: 1RRV ) are displayed as stick models. Hypervariable loops N3 (pink), 
N5 (yellow) are shown. The USS is coloured in grey. The figure was prepared using 
RasMol. 
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4.3.3.2 Acceptor and NDP-sugar interactions 
The ligand docking study and comparison with previously reported GT-B 
structures indicated that D13, S10, D103, S259, H330, D354 and Q355 were the 
key catalytic residues of ScUGT51’. The catalytic site harbouring these residues is 
shown in Fig. 4.6. 
The general catalytic base 
D13, corresponding to D13 in ScUGT51’ has been proposed as the catalytic base 
of glycosyl transfer in the case of GtfA, GtfA’ and GtfD (Mulichak et al. 2003; 
Truman et al. 2009; Mulichak et al. 2004). The D35 of HMT31, another chimeric 
antibiotic GT (Park et al. 2009b) was matched with the D13 as a catalytic general 
base and in fact the eight residue glycine-rich motif in the N-terminus 
(GS(T)RGDVQP) containing the catalytic base is common to many other putative 
and characterised sequences of GT-B members from plants, other fungi and 
viruses (Hacker et al. 2005) suggesting that it consists of residues important for 
glycosyl transfer. This also includes the highly conserved S/T10 residue that is 
involved in hydrogen bonding with the reactive –OH of GtfA and GtfD (Mulichak 
et al. 2003; Mulichak et al. 2004). However mutational analysis of this D13 in 
GtfB revealed that although the kcat displayed by the mutant reduced ten-fold, the 
Km value for UDPG remained unaffected. D332 (corresponding to D354 in 
ScUGT51’) was proposed as the catalytic base instead. On the other hand, the 
D13A GtfD mutant showed a 5500-fold drop in kcat confirming its role as the 
catalytic base. Moreover, its proximity to DVV as well as TDP strongly suggests 
this as the base. In plant UGTs however, for example UGT71G1 and UGT73A5, 
the corresponding Asp position is occupied by H22 which is close to the C1’ of 
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the bound UDPG (Hans et al. 2004). Also in this case, an acidic residue D121 
(corresponding to D103 in ScUGT51’) was proposed to be involved in forming an 
electron transfer chain to H22/D13 to assist deprotonation of acceptor (Shao et al. 
2005). It has been shown that the interaction of H22 and D121 is essential for 
enzyme activity (Brazier-Hicks et al. 2007). Interestingly, even though this Asp 
residue is absent in all Gtfs, the D103 residue in GtfD (corresponding to Leu in 
other Gtfs) has been suggested to create a hydrophilic catalytic pocket.   
Acceptor binding site 
Acceptor interactions are largely as a result of the distinct patches of hydrophobic 
and aromatic residues in the N3 and N5 loop regions that are involved in acceptor 
interactions (Mulichak et al. 2001). Interestingly however, the sequence and 
length of these loops greatly varies among other Gtfs, such as these loops in GtfD 
are much longer compared to GtfA and GtfB. ScUGT51’ although lacks the 
presence of hydrophobic residues involved in such interactions, the loop regions 
are similar in length to GtfD. On the other hand, certain interdomain interactions 
are conserved across Gtfs such as that of R11 and S230 in GtfA (corresponding to 
R11 and S25λ in ScUGT51’). Also, in addition to positive helix dipole 
interactions suggested for GT-B fold GTs, other residues in Gtfs are shown to be 
involved in ionic interactions to stabilise the thymine base of TDP such as that 
between R11 and E277 of GtfA and are not likely to be present in ScUGT51’ due 
to the presence of a conserved Asn residue in all yeast UGTs corresponding to 
E277. In this case positive helix dipole interactions of the Nα1 and Cα4 could 
contribute to hydrogen bonding interactions promoted by the highly conserved 
glycine residues across distantly related GT-B members.   
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It has been suggested earlier that acceptor selectivity could be altered in GT-B 
members by targeting the loop between Nβ5-Nα5 in the acceptor binding domain. 
This loop was conserved among MurG homologs that utilise the same acceptor 
and corresponded to the variant loop in the case of Gtfs that utilise subtly different 
acceptors despite high sequence homology (Hu and Walker 2002). The sequential, 
ordered reaction mechanism could also influence substrate recognition and 
binding. For example in the case of MurG, the NDP-sugar binds first whereas in 
the case of the related macrolide OleD, the acceptor binds prior to the NDP-sugar 
(Quiros et al. 2000). In Gtfs however, the order of substrate recognition is still 
unclear as for GtfB it was suggested that the binding of the UDPG ligand required 
prior aglycone binding whereas an independent substrate binding mechanism has 
been suggested for GtfA. 
NDP-sugar binding site 
In the ScUGT51’ model, the donor sugar moiety resides within the inter-domain 
cleft as has been earlier shown for GT-B structures. The closed confirmation of 
GT-B GTs allows for the pyrophosphate moiety of the NDP-sugar to interact 
simultaneously with the N- and C-terminal domains and therefore requires the 
prior binding of the NDP moiety (Mulichak et al. 2003).  
H330 and G334 of ScUGT51’ are part of the 329HHXXAGT335 loop which is a 
highly conserved glycine-rich motif among distantly related GT-B fold GTs (Fig. 
4.7) constituting a large part of the donor binding site ((Hu et al. 2003; Hu and 
Walker 2002; Rix et al. 2002). For example it is a binding site of α-phosphate of 
the NDP-sugar donor in GtfA (Mulichak et al. 2003). UDP-
glucuronosyltransferases that are involved in the glucuronidation of various 
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natural as well as foreign compounds including carcinogens and drugs also 
contain the consensus USS ((Mackenzie et al. 1997; Meech and Mackenzie 2010). 
The Q289 of MurG (corresponding to Q355 in ScUGT51’) located within this 
loop of the β/α/β motif was proposed to hydrogen bond with the -OH at the C-4 of 
the sugar which suggests that the isomer galactosamine may not be accepted. 
(Hoffmeister et al. 2001; Hu and Walker 2002) This is because the axial O-4 of 
UDPGal has been proposed to create steric hindrance with the acceptor oxygen 
even though it may fit into the active site (Thorsoe et al. 2005). Interestingly, as 
shown in the alignment in Fig. 4.7, GTs utilising UDPG or UDP-GlcNAc as the 
sugar donor have Gln as the conserved sugar recognition determinant whereas in 
the ceramide GalT (Kapitonov and Yu 1999), His occupies this highly conserved 
position. In one study, H374 of a plant GalT (corresponding to the highly 
conserved Q382) upon being replaced by Gln switched galactose preference to 
glucose (Shao et al. 2005). However, the glucose specificity for a flavonoid GT 
(UGT71G1) could not be altered when Q382 in this case was mutated to His, 
suggesting that other residues may be additionally play a role in dictating donor 
specificity (Shao et al. 2005). This study also showed that docking of UDPGal in 
the structure of UGT71G1 would prevent formation of hydrogen bonds with the 
adjacent E381, another key conserved residue, and therefore suggestive of a multi-
residue involvement in sugar recognition and specificity. In addition, this residue 
is conservatively replaced by Asp in several eukaryotic GT-B GTs including the 
UGTs in the present study, further highlighting its role in NDP-sugar recognition. 
A few conserved residues within the USS across GT-B members are directly 
involved in forming hydrogen bonds with the NDP-sugar moiety. Thorsoe et al. 
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(2005) established by mutational analysis of UGT85B1 that certain residues 
within the USS motif were critical for catalysis. For example the C-6 of UDPG 
hydrogen bonds with E410, Q411 (corresponding to D354 and Q355 in 
ScUGT51’). Interestingly, E410 in this case has also been shown to hydrogen 
bond with both the acceptor and donor which has not been reported in the case of 
Gtfs. Another critical hydrogen bonding interaction in this case involves the S391 
of UGT85B1 that interacts with pyrophosphate of donor. This residue corresponds 
to a conserved Thr residue among Gtfs (for example T296 of GtfA), as well as 
T335 of ScUGT51’. The conserved role of the Glu and Gln residues has also been 
confirmed in the case of other plant UGTs such as the arbutin synthase (AS) 
(Hefner et al. 2002). 
In the case of UGT71G1 (Shao et al. 2005), another plant UGT, it was shown that 
the phosphate of the sugar forms hydrogen bonds with H357 (corresponding to 
H330 in ScUGT51) and S285 (corresponding to S259), the only residue outside 
the USS which is directly shown to interact with the phosphate group as shown in 
Fig. 4.6.  
The nucleotide pocket environment however, differs between the plant UGTs and 
the Gtfs (Offen et al. 2006). Apart from the residues within the USS involved 
directly in NDP-sugar binding, other residues within the PSPG motif of plant 
sequences are shown to have been involved in creating a hydrophobic 
environment around the donor molecule. For example. the indole ring of the 
conserved tryptophan (W), the first residue of the PSPG motif is involved in 
donor recognition and hydrophobic interactions in all plant UGT structures solved 
so far (Osmani et al. 2009).  
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In UGT71G1 binding UDP-glucose, MurG binding UDP-GlcNAc, GtfD binding 
TDP, sugar donor molecules are positioned similarly despite low sequence 
identities and detailed interactions with sugar donors also vary.  
Interestingly, some residues present in vancosamine recognising Gtfs differ from 
those recognising UDPG as the donor. For example, hydrophobic residues (P126 
in GtfD and L124 in GtfA) favourably interact with vancosamine whereas a 
substituted H125 in GtfB was proposed to form H-bonds with UDPG. A T130 
residue in the ScUGT51’ may also offer potential H-bonding interactions with the 
6’–OH of UDPG. Also, S311 in GtfD involved in sugar binding is conserved in 
GtfA and is substituted with glycine in the case of GtfB and ScUGT51’ strongly 
suggesting its role in the exclusive recognition of UDPG. 
Residues involved in dictating catalytic mechanism 
Differences in specific residues among GT members may lead to difference in 
catalytic mechanism. For example, as described earlier, a His residue is located in 
the first position of the USS of GT-B fold GTs in the case of family 1 and family 
28 members. However, this position is occupied by Asp or Glu residues for GT 
family 4 and 20 members that catalyse sugar transfer by the retaining mechanism. 
Consequently, charge differences in these usually well conserved motifs may 
dictate catalytic mechanism (Rosen et al. 2004).  
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Fig. 4.6 Schematic showing significant active site residues and fitted DVV and TDP 
ligands in the ScUGT51’ model.  DVV and TDP (fitted from the superposition with 
GtfD: DVV: TDP complex; PDB id: 1RRV) are indicated and proposed residues involved 
in glycosyl transfer reactions are shown as CPK models. The figure was prepared using 
RasMol. 
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UGT3A             366 HGGQNSIMEAIQHGVPMVGIPLEG---DQPENMVRVEAKKFGVS 
AS                360 HCGWNSILESVVNGVPLIAWPLYA---EQKMNAVMLTEGLKVAL 
OleD              306 HAGAGGSQEGLATATPMIAVPQAV---DQFGNADMLQGLGVARK 
GtfB              308 HGGAGTTHVAARAGAPQILLPQMA---DQPYYAGRVAELGVGVA 
UGT51’            347 HGGSGTTGASLRAGLPTVIKPFFG---DQFFYAGRVEDIGVGIA 
cGalT             358 HGGLNSIFETMYHGVPVVGIPVFG---DHYDTMTRVQAKGMGIL 
MurG              261 RSGALTVSEIAAAGLPALFVPFQHKDRQQYWNALPLEKAGAAKI 
                   :.*  .       . * :  *      ::      :   :. 
Consensus             H_G__T__E____G_P____P______DQ___A______G_G__ 
 
 
Fig. 4.7 Sequence alignments of the USS of GT-B fold family members. Dots 
represent similar residues and asterisks represent identical residues in all sequences. The 
consensus sequence is shown below. The sequences referred to are: UGT3A (human 
UDP-GlcNAc GT), AS (arbutin synthase, R. serpentina), OleD (oleandomycin GT, S. 
antibioticus), GtfB (chloroeremomycin GT, A. orientalis), UGT51’ (yeast UGTs in this 
study), cGalT (mammalian ceramide GalT) and MurG (UDP-N-
acetylglucosaminyltransferase, E. coli). 
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4.3.3.3 Analysis of UGT variants  
As mentioned earlier, point mutations within the N- and/or C-terminal domains 
led to increase in GT activity. In the case of the ScEZC24 mutant (G189E), a 
highly conserved glycine in an N-terminal helix when substituted with a 
negatively charged glutamic acid residue resulted in no significant increase in GT 
activity. However, in the ScEZC46 mutant (E61V), replacement of glutamic acid 
with a hydrophobic valine residue resulted in a two fold increase in GT activity as 
compared with the native enzyme. Interestingly, this position is occupied by 
hydrophobic alanine residues in Gtfs suggesting that hydrophobicity in this region 
may play a role in acceptor binding. The location of this residue in the 3-D model 
suggests that it is not involved directly in interaction with the acceptor and as such 
its role remains unclear. However as shown in the past, beneficial mutations 
remote from the catalytic site may influence substrate specificity, selectivity as 
well as catalytic activity of GTs (Williams and Thorson 2008; Williams et al. 
2007). 
In the case of the PaEZC62 double mutant (V316A; E433G) both mutations 
within the C-terminal domain resulted in a six fold increase in GT activity 
compared with the native enzyme. A hydrophobic Val was replaced by another 
hydrophobic residue, Ala. A Val residue at position 316 in a probable loop region 
is unique to PaUGT51’ and corresponds with an Asp or Glu residue in all other 
UGTs; for example, it corresponds to D321 of ScUGT51’ (Fig. 3.2 C). 
Interestingly, this Asp residue is also common to all Gtfs in a similar position in 
the C-terminal loop and there is no evidence of its interaction with the NDP-sugar. 
The second of these mutations, E433G (corresponding to E43λ of ScUGT51’) 
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may although play a synergistic role with the V316A, KlUGT51’ also consists of 
glycine at the corresponding position. Moreover, this residue is present in the long 
helical tail that is not involved in donor recognition or binding.  
Another double mutant, PpEZK15 displaying six-fold GT activity compared to 
the wt PpUGT51’ also consists of a replacement (N400S) in the C-terminal long 
helical region that corresponds with N407 of ScUGT51’.  The other substitution 
in this mutant, K207R in a short (3 residue long) N–terminal loop corresponding 
to N214 of ScUGT51’ may play a role in substrate positioning within the catalytic 
cleft formed between the two domains. This is because interestingly, PpUGT51’ 
consists of a Lys residue with a positively charged side chain at this position 
which was replaced by a similar residue, Arg in PpEZK15. Since PpUGT51’ 
displays the highest affinity towards cholesterol compared to all other UGTs and 
this position is occupied by a polar, uncharged Asn residue in other UGTs, this 
suggests that this residue may be involved in acceptor binding. Moreover, the 
location of this residue within the acceptor binding crevice between the N3 and 
N5 loops further suggests that it may have a possible catalytic role. 
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4.4 Discussion 
 
RM and functional analysis of UGTs 
Mutagenesis approaches have served as a powerful tool for studying GTs with 
respect to substrate specificity and providing critical structural information. 
Evolving GTs with the desired substrate specificity for the synthesis of several 
oligosaccharides and complex carbohydrates for example has facilitated the 
development of potential therapies (Aharoni et al. 2006). On the other hand, 
enhancing activity towards natural, non-natural substrates serves as the most 
popular starting point for mutagenesis studies (Dalby 2003). Family 1 GTs are 
attractive subjects for several DE studies based on the already existing knowledge 
regarding substrate specificity and catalytic activity. The crystal structures of 58 
GT-B fold members have been determined so far of which 19 have been assigned 
to GT family 1, the largest structural database for any GT family. Moreover, a 
majority of sequences within this family lack TM segments and therefore are 
amenable to cell free assays for screening large libraries of variants. Despite 
existing knowledge of this family of GTs, little is known in terms of the function 
of family 1 USGTs. The aim to evolve USGTs with higher catalytic efficiency 
apart from improving SG synthesis would allow a better understanding of USGT 
function. 
However, the success of a directed evolution experiment depends primarily on the 
sensitivity and throughput of the screen (Zhao et al. 2002). Thus it is crucial to 
optimize the screening procedure for these studies. (Palcic and Sujino 2001) have 
extensively reviewed various assays amenable to GTs. Some examples include 
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immunological assays that require specific antibodies for product identification 
and chromogenic and fluorogenic assays that require substrate or donor 
fluorescence or labelling coupled with special detection requirements not suited 
for high-throughput screening purposes. Coupled spectrophotometric assays based 
on the detection of UDP by coupling its synthesis to NADH oxidation with 
pyruvate kinase and lactate dehydrogenase have also been previously reported 
(Gosselin et al. 1994; Jackson et al. 2001). However, these assays cannot be used 
for screening crude cell extracts due to interference by NADH oxidases (Persson 
and Palcic 2008). The FACS (fluorescence-activated cell sorter) technique is 
currently emerging as a rapid and sensitive screening system using whole cells 
(Aharoni et al. 2006). Although this approach requires the fluorescence labelling 
of either substrate, it alleviates the need for time consuming cell lysis steps and 
enables sorting of a large library (106) of variants. This technique also offers the 
advantage of assessing GT activity and substrate specificity simultaneously by 
using differentially labelled substrates within the system and sorting the resulting 
cell population consisting of fluorescently labelled products (Hibbert and Dalby 
2005).  
A simple colorimetric method based on monitoring the colour change which is 
directly proportional to proton release associated with a GT catalysed reaction 
was attempted in this study. Several such studies have been reported in the past 
for nitrilases, kinases and hydrolases which require an appropriate buffer/indicator 
combination of similar pKa values (Janes et al. 1998). However in most cases, 
assay conditions such as buffer strength and substrate concentration require 
optimisation for accurate measurements that can overcome small pH changes 
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during the course of the assay. For example Banerjee et al. (2003) screened for 
nitrilase activity in crude cell suspensions using relatively high buffer (10 mM) 
and substrate amounts (12.5 mM). It was found that the relatively high buffer 
concentration reduced sensitivity but showed a more linear relationship between 
absorbance and proton concentration. Persson and Palcic (2008) also confirmed 
decrease in sensitivity of GT activity screening when acceptor amounts of less 
than 0.2 mM were used.  
pH-sensitive assays have been only recently exploited for HTS and in the case of 
GTs a few examples of previous studies are summarised in Table 4.9. Deng and 
Chen (2004) first developed such an assay for 1, 4-GalT using PR as indicator; 
however this has not been adapted to microtitre plates for HTS. An agar plate 
based colorimetric assay has also been described to monitor GT activity in whole 
cells using cresol red (Park et al. 2009a). However due to longer incubation 
periods required to detect activity, diffusion of hydrogen ions to surrounding 
colonies may lead to false positives and therefore low sensitivity ((Ben-David A 
et al. 2008). HTS for saturation mutagenesis created blood GalT variants has been 
successfully described (Persson and Palcic 2008). BB was used as the indicator as 
its pKa value of 7.1 was very similar the optimum pH of 7.0 for GT activity in this 
case.  
In order to realise the potential of colorimetric assays, further studies need to be 
undertaken with UGTs under optimised conditions to accurately translate 
increasing proton concentration to colour/absorbance change. Screening for 
improved activity leads to loss of substrate selectivity and vice versa (Ben-David 
A et al. 2008). Some reports have also argued that no obvious change in 
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absorbance associated with glycosidic bond formation and that screening still 
represents a major challenge (Aharoni et al. 2006). In this regard, a semi HTS 
system was developed in this study based on the sensitive and reliable assays 
using radio-labelled glucose (Tables 4.6 A.-C). This approach not only offered 
the advantage of isolating positive mutants, but also provided basis for screening 
UGTs displaying significant activity compared to the parental enzymes. Although 
the activities in the crude lysates were significantly lower than those determined 
for the purified enzymes, the sensitivity of the radiochemical assay was able to 
readily distinguish between active and inactive enzymes in a relatively large-scale 
screening system. However at present, due to the lack of availability of specific 
radio-labelled substrates and the huge costs associated with the synthesis and 
disposal of such compounds, this approach cannot not be fully exploited for the 
synthesis and screening of complex carbohydrates (Zea and Pohl 2004). 
 
 
Table 4.9 Examples of pH colour assays discussed in text. NI= not indicated. 
                                                                                                                                                  
GT cell 
based/CFE 
Buffer 
(mM) 
Acceptor 
(mM) 
Reference 
     
1,4-GalT 
 
 
CFE 2 10 (Deng and Chen 
2004) 
 
antibiotic  
GT 
cell based  NI 2 (Park et al. 
2009a) 
blood GalTs 
 
CFE 2.5            0.5  (Persson and 
Palcic 2008) 
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Structural homology of GT-B fold GTs 
HM is a highly valuable tool for retrieving information on topology, identifying 
important structural features such as specific residues involved in catalysis and for 
predicting the preference to alternative sugar donors (Osmani et al. 2009). It also 
represents a means to guide rational design and HM studies have been 
successfully verified in the past by biochemical analysis of wt GTs and mutants 
created based on information gathered by models (Thorsoe et al. 2005). 
ScUGT51’ was chosen as the subject for HM as SG synthesis is a well 
documented phenomenon in S. cerevisiae as well as related yeasts, such as P. 
pastoris and therefore represents a platform for DE experiments in related GTs.  
The ScUGT51’ model was produced based on Gtfs that were the best available 
candidates in the PBD database. Gtfs belong to glycopeptide (group III) 
antibiotics, the others being polyketide (group I) that includes OleD and 
aminoglycoside (group II) (Park et al. 2009b). Glycopeptide antibiotics are used 
to treat infections predominantly caused by Gram-positive bacteria such as 
Staphylococcus aureus. Sugar moieties are added to different sites on similar 
aglycone substrates during the late stages of the assembly of the peptide 
antibiotics (Hu and Walker 2002). Despite high primary sequence homology 
(~60%), Gtfs utilise different donors as well are highly regiospecific. For example 
GtfD and GtfA utilise vancosamine and epi-vancosamine sugars for vancomycin 
and choloroeremomycin biogenesis respectively whereas GtfB is specific for 
UDPG in choloroeremomycin biogenesis and all Gtfs decorate the same 
monoglycosylated vancomycin intermediate- DVV (Walsh et al. 2003). 
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Comparison of the homology generated model of ScUGT51’ and several other 
GT-B fold GTs revealed high structural similarities despite low overall sequence 
identity. The ScUGT51’ model possess a similar NDP-sugar binding motif like 
other GT-B members such as Gtfs and MurG and in general, share a higher 
similarity in their C-terminal domains as compared to the N-terminal domains, 
suggesting a probable common evolutionary origin. The high conservation of the 
α/β/α motif across GT-B members suggests that donors are held in a similar 
manner, regardless of the nature of the acceptor. This was further confirmed by 
ligand docking studies, which placed TDP in a position to adequately interact with 
the conserved residues of the conserved C-terminus loop.   
ScUGT51’ showed the closest structural similarity to a chimeric GtfA’ with a 
position specific scoring matrix E-value of 1.49x10-22.This GtfA’ was created 
using the N-terminal domain of GtfA and the C-terminus of an undisclosed ORF 
and interestingly, it was found that the C-terminal domain was highly similar to 
that of the parent GtfA despite the promiscuity in the range of substrates displayed 
by the chimera (Truman et al. 2009). However, as opposed to the vancosamine 
sugars utilised by the parent GtfA, GtfA’ showed specificity for UDPG and UDP-
GlcNAc donors instead and that may explain its higher structural similarity to 
ScUGT51’. In fact the E-value for GtfA’ was higher than that observed for GtfB, 
that has a strict UDPG preference (Mulichak et al. 2001).  
Wang et al. (2008) have recently determined the solution structure of Alg13, the 
NDP-sugar binding domain of a family 1 UDP-GlcNAc GT from S. cerevisiae. It 
was found that this shared structural topology with the donor binding domain of 
family 28, GT-B UDP-N-acetylglucosaminyltransferase (MurG) from E. coli 
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which binds N-acetyl glucosamine in a C-terminal pocket for transfer to a lipid-
linked acceptor for peptidoglycan synthesis (Hu and Walker 2002). Family 1 GTs 
are related to family 28 members in the overall CAZy system of classification, 
mainly due to the similarity in the C-terminal domains (Rosen et al. 2004). 
Interestingly however, even though GtfB shares a conserved topology with MurG 
(Mulichak et al. 2001), ScUGT51’ did not show significant structural similarity 
with MurG. This may be explained by the fact that Gtfs possess different donor 
specificities by virtue of only a few primary sequence residues whereas MurG is 
highly specific for its donor sugars. For example GtfB utilises UDPG initiating 
the choloroeremomycin pathway, whereas GtfA and GtfD utilise vancosamine 
sugars for antibiotic assembly and therefore certain sequence elements of these 
GTs may overlap with those of ScUGT51’ as well as MurG. Also, as shown in 
Fig. 4.4, instead of a conserved Asp residue in the case of other GT-B fold 
members, this position is occupied by Gln at position 288 in MurG which may 
further highlight its role in substrate specificity. Furthermore, in the case of 
MurG, the glycine-rich motif in the N-terminal domain does not make interactions 
with the NDP as opposed to Gtfs (Mulichak et al. 2004). Since the same residues 
are proposed to interact with NDP in the case of ScUGT51’, this further suggests 
the similar catalytic mechanism between Gtfs and ScUGT51’. 
Therefore, comparing enzymes with different selectivity but conserved primary 
sequence motifs could identify regions for rational engineering of GTs.  On the 
other hand, sequence comparison of divergent GTs could highlight key catalytic 
residues. 
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Substrate recognition and binding 
As discussed earlier, the hypervariable N3 and N5 loop regions are the main 
source of structural differences among Gtfs as well as between Gtfs and 
ScUGT51’. Also, since these loop regions dictate aglycone binding as shown in 
the case of GtfA and GtfD ((Mulichak et al. 2003; Mulichak et al. 2004), the 
corresponding sequence elements of ScUGT51’ may be used as templates for 
diversifying the range of acceptors. However, in the case of GtfD, it was shown 
that determinants of substrate recognition were not exclusive to a single domain 
and may need to be considered before constructing chimeras.  
All glycopeptide GTs that utilise NDP-donors belong to the GT-B fold family 
(Truman et al., 2009). Of these, TDP-hexoses are the typical NDP-sugar 
substrates for antibiotic GTs in the Streptomyces and Actinomycete group of 
microorganisms (Walsh et al. 2003). It has been suggested that the preference for 
TDP-sugars in Gtfs is as a result of a hydrophobic residue in place of the 
conserved Glu residue within the H-X7-E motif in distantly related GT-B GTs that 
interacts with the ribose of the bound UDP. However, even though the structures 
of three Gtfs have been published, the principle of donor binding remains unclear 
especially due to the range of donor sugars utilised by this group of GTs (Truman 
et al. 2009). 
Since ScUGT51’ and related USGTs in this study show significant structural 
similarities similar to glycopeptide GTs, they could act as a platform for further 
development in the synthesis of antibiotic analogs. However, structure-function 
relationships may need further elucidation. For example upon DVV docking, the 
ScUGT51’ model showed that the location of D13 was proximal to DVV to act as 
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the base catalyst with D103 located such that it may be involved assisting 
deprotonation of the acceptor. Even though ScUGT51’ shares higher sequence 
identity with GtfB as they both utilise UDPG as NDP-donor and kinetic analysis 
of the D13A GtfB mutant negated the role of D13 as the potential base, 
mutational analysis of this residue for ScUGT51’ would have to be performed to 
further confirm its exact role.   
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As described in this study, glycosylation improves bioavailability and enhances 
pharmacokinetic responses of sterol and steroidal drugs. In addition, due to the 
surge in drug-resistant pathogens, there is a growing need for the development of 
analogs of existing drugs to combat disease resistance. For example the 
development of vancomycin-resistant enterococci (VRE) has led to significant 
research in studying the function of Gtfs that are involved in the synthesis of the 
vancomycin group of antibiotics. This study reports the cloning, expression and 
functional analysis of yeast USGTs. As the mechanisms of GTs involved in 
glycan synthesis in S. cerevisiae are well characterized, putative as well as novel 
USGT sequences were identified based on the previously characterised, N-
terminally truncated ScUGT51’. Following this, gene fragments corresponding to 
USGT sequences lacking the N-terminal PH and GRAM domains were cloned 
and consequently, the earlier reported problem of low expression levels (Vogt and 
Jones 2000) of these enzymes was overcome and GT expression levels were 
found to be further enhanced by the E. coli BL21 CP (DE3) strains. N-terminally 
His6-tagged proteins were purified to appreciable yields and results from in vitro 
assays confirm that the segment of the N-terminal domain of USGTs comprising 
the PH and GRAM domains is not required for the catalytic activity of these 
enzymes, including the previously characterized non-truncated PpUGT51’. In 
addition, the promiscuity of all USGTs was assessed against a panel of sterol and 
steroidal acceptors. Following this, a putative USGT from P. angusta  and novel 
USGT from K. lactis were identified and characterized albeit with differential 
regiospecificity. This therefore supports the view that although sequence 
alignments have been commonly used in the case of GTs to propose or further 
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highlight catalytic domains within the same GT family, they do not necessarily 
predict substrate specificity. 
Furthermore, according to the CAZy classification of GTs, ScUGT51’ and 
PpUGT51B1 (PpUGT51’ in this study) are recognized as 3-β-sterol GTs 
although, to the best of our knowledge, this study for the first time reports that C-
17-OH sterols can also be included within the panel of acceptors, although with a 
significantly lower affinity compared with C-3 –OH sterols. This significant 
finding paves the way for further exploiting the existing promiscuity of this group 
of GTs. 
Interestingly, ScUGT51’ and homologs in this study showed significant similarity 
to structures of Gtfs. Homology modeling based on structures of glycopeptide 
GTs revealed the role of conserved residues of UGTs in the present study that 
may be involved in substrate binding and glycosyl transfer. In addition, 
comparison with structures of plant GTs highlighted common residues such as 
D103 in ScUGT51’ and UGT homologs in this study that are involved in catalysis 
but are not present in Gtfs suggesting an evolutionary relationship between 
members of the GT-B superfamily. Random mutagenesis followed by screening a 
relatively large library of variants via UDPG assays revealed that substitutions 
within either N- or C-terminal domains resulted in improved catalytic activity. 
Incidentally both the double mutants displaying the highest observed USGT 
activity (PaEZC62 and PpEZK15) compared to the native counterparts had 
substitutions within the long helical tail within the C-terminus and therefore 
beneficial mutations may occur away from the catalytic site.  
                                                                                Chapter 5 Conclusions 
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The scope of this study limited the use of a wide variety of NDP-sugars. As it has 
been established that the GTs discussed here are able to utilise acceptors other 
than 3-OH compounds, studies could be focussed on rational engineering (in the 
USS sugar recognising motif) of these GTs to utilise a diverse range of NDP-
sugars such as UDP-GlcNAc and TDP sugars as shown in the case of Gtfs.  
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As discussed in Chapter 4, the ScUGT51’ model suggests probable residues 
crucial for UGT activity based on previously solved GT-B structures. Mutational 
analysis of these specific residues would be required to further confirm their 
suggested roles.  
A major bottleneck for GT function elucidation has been the lack of crystal 
structures which in turn depends on the availability of pure enzymes. This study 
reports the synthesis of pure GTs which could be used for crystallisation studies 
of this class of pharmaceutically relevant enzymes. 
Also, the lack of availability of appropriate HTS systems is currently curtailing 
the DE of GTs as novel biocatalysts. Rapid and sensitive screening systems are 
therefore required that can be tailored to assess enhanced activity and/or 
promiscuity. 
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Appendix A. 
Primary amino acid sequences of truncated proteins with 
corresponding ORFs and cloning region of the YSB-LIC vector 
A.1 ORFs and amino acid sequences of truncated proteins. The N-terminal 
histidine tag is shown (in blue). A start codon methionine (M) was included as 
part of the LIC-specific sequences (in red) in cases where the truncated 
sequence did not have methionine as the first residue. 
 
>gi|577215|gb|AAB67475.1| Ylr189cp [Saccharomyces cerevisiae] 
MGSSHHHHHHMIDENPHYKTSIKPNKSYKFGLLTIGSRGDVQPYIALGKGLIKEGHQVVIITHSEF
RDFVESHGIQFEEIAGNPVELMSLMVENESMNVKMLREASSKFRGWIDALLQTSWEVCNRRKFDIL
IESPSAMVGIHITEALQIPYFRAFTMPWTRTRAYPHAFIVPDQKRGGNYNYLTHVLFENVFWKGIS
GQVNKWRVETLGLGKTNLFLLQQNNVPFLYNVSPTIFPPSIDFSEWVRVTGYWFLDDKSTFKPPAE
LQEFISEARSKGKKLVYIGFGSIVVSNAKEMTEALVEAVMEADVYCILNKGWSERLGDKAAKKTEV
DLPRNILNIGNVPHDWLFPQVDAAVHHGGSGTTGASLRAGLPTVIKPFFGDQFFYAGRVEDIGVGI
ALKKLNAQTLADALKVATTNKIMKDRAGLIKKKISKEDGIKTAISAIYNELEYARSVTLSRVKTPR
KKEENVDATKLTPAETTDEGWTMI 
ATGATTGATGAGAATCCGCACTATAAAACAAGCATAAAACCAAACAAGAGTTATAAGTTTGGATTA
TTGACGATTGGCTCAAGAGGGGATGTTCAACCATATATTGCACTTGGAAAGGGCTTGATAAAAGAA
GGTCACCAAGTGGTAATAATTACACATTCGGAATTTAGAGACTTTGTTGAAAGTCATGGAATCCAG
TTTGAAGAGATTGCTGGTAACCCAGTGGAGTTGATGTCCTTGATGGTGGAAAATGAATCAATGAAT
GTTAAAATGCTGAGAGAAGCTTCGAGCAAATTTAGGGGATGGATCGATGCTCTTTTACAGACATCT
TGGGAGGTTTGTAACAGAAGAAAATTTGATATTCTGATTGAATCACCCTCAGCTATGGTTGGTATT
CATATTACTGAAGCATTGCAAATTCCTTATTTTCGAGCATTTACCATGCCATGGACAAGAACAAGA
GCATATCCACATGCATTTATTGTACCAGATCAAAAAAGGGGCGGTAACTATAACTACCTGACACAT
GTCCTTTTCGAAAACGTTTTCTGGAAGGGAATTAGTGGGCAAGTAAACAAGTGGAGAGTTGAAACT
CTAGGTTTAGGGAAAACAAATCTTTTTCTTTTACAGCAGAATAATGTTCCTTTCTTATACAATGTT
TCTCCTACAATTTTTCCGCCATCAATTGATTTTAGCGAGTGGGTGAGAGTTACAGGATATTGGTTT
CTTGATGATAAGAGTACTTTCAAACCGCCAGCAGAATTACAAGAATTTATTTCTGAGGCAAGATCA
AAAGGAAAAAAATTGGTTTATATCGGGTTTGGTTCGATTGTAGTCTCTAATGCCAAAGAAATGACG
GAAGCTCTTGTCGAAGCAGTTATGGAAGCAGATGTATACTGCATTTTAAATAAGGGATGGTCAGAA
AGGTTGGGCGATAAGGCGGCAAAGAAGACAGAGGTAGATCTTCCAAGAAACATTTTAAATATCGGA
AACGTTCCCCATGATTGGTTGTTCCCACAAGTCGATGCTGCCGTTCACCATGGTGGTTCTGGAACT
ACTGGAGCTTCATTACGTGCTGGTTTACCTACTGTTATAAAACCTTTCTTTGGTGATCAGTTCTTT
TATGCAGGTAGAGTAGAAGACATTGGAGTTGGTATTGCTTTAAAGAAACTTAACGCTCAAACATTA
GCAGATGCTTTAAAAGTAGCTACGACGAACAAAATAATGAAGGATAGAGCTGGATTAATAAAGAAG
AAAATTTCCAAAGAAGATGGGATTAAAACTGCAATAAGTGCAATTTACAACGAACTTGAGTATGCA
AGAAGCGTTACTTTATCAAGAGTGAAAACTCCGCGCAAGAAAGAGGAAAATGTAGATGCAACCAAA
CTGACACCTGCTGAAACAACGGATGAAGGGTGGACGATGATTTAA  
(1431 bp) 
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>gi|4768597|gb|AAD29570.1|AF091397_1 UDP-glucose: sterol glucosyltransferase [Pichia 
pastoris] 
MGSSHHHHHHMNQYSTSEIRSKRRYKFVLLTIGSRGDVQPYISLAKGLLAENHKVKIVTHEEFKPW
VESYGIEFATIAGNPAELMSLMVTHKSLSVGFLKEAKEKFTGWIGELLQSSWDACQDADVLIESPS
AMAGIHIAEKLQIPYFRAFTMPWTRTRAYPHAFVVPEQKRGGSYNYLTHIIFENVFWKGISGEVNK
WREQVLMLPKTNLERLEQNKVPFLYNVSPTVFPPSMDFPHWVKVVGYWFLDEGEADSYDPPKPLLE
FMEKAKTDGKKLVYIGFGSIVVSDPKQLTEAVIDAVLSADVRCILNKGWSDRLGKQTGVEVELPEE
IYNSGNVPHDWLFGKIDASVHHGGSGTTGATLRAGIPTIIKPFFGDQFFYANRVEDIGVGIGLRKL
NSKSLSKAIKEVTTNTRIIEKAKEIGKQIQSENGVSAAIRCLYQEMEYAKKLSKSKQKYWDNQSED
ISDDSVSGSWFEV 
AACCAGTATTCTACGTCAGAAATTAGATCAAAGAGGAGGTACAAATTTGTGCTATTAACTATTGGT
TCTCGAGGAGATGTACAACCCTATATATCTTTGGCGAAAGGTTTACTTGCAGAGAATCACAAAGTC
AAGATTGTGACCCATGAAGAGTTCAAACCTTGGGTAGAAAGTTATGGTATCGAATTCGCAACAATT
GCAGGTAACCCAGCGGAGCTTATGTCATTGATGGTAACTCATAAGTCATTAAGTGTAGGGTTTTTG
AAAGAGGCTAAAGAAAAATTCACTGGCTGGATTGGAGAGTTATTGCAAAGCTCGTGGGACGCATGT
CAGGATGCTGATGTGCTTATCGAATCGCCTTCCGCAATGGCAGGTATCCATATCGCAGAGAAGTTA
CAAATTCCCTATTTCCGTGCTTTTACAATGCCATGGACACGAACTAGAGCGTATCCACATGCATTT
GTGGTCCCAGAACAGAAAAGAGGAGGTTCTTACAATTATCTCACGCATATAATATTTGAGAATGTC
TTTTGGAAAGGTATTTCAGGAGAGGTGAATAAATGGCGTGAGCAAGTCTTAATGCTTCCAAAGACC
AATTTGGAGAGATTGGAACAAAACAAGGTACCATTCCTGTACAATGTGTCTCCCACGGTTTTTCCA
CCATCTATGGACTTTCCTCATTGGGTTAAGGTAGTTGGATATTGGTTTTTGGATGAGGGGGAGGCA
GATAGTTATGATCCTCCTAAGCCATTGCTGGAGTTCATGGAGAAGGCTAAGACTGATGGTAAGAAA
TTGGTATACATTGGATTTGGATCCATTGTAGTTAGTGATCCCAAACAACTGACTGAGGCTGTAATC
GACGCGGTGCTCAGTGCTGATGTGAGGTGTATTCTAAATAAAGGCTGGTCAGATAGGTTAGGTAAG
CAGACGGGAGTGGAGGTTGAACTACCTGAAGAGATTTACAATTCAGGAAACGTTCCTCACGATTGG
TTGTTTGGCAAAATCGACGCGTCCGTTCATCATGGTGGATCTGGAACAACAGGTGCAACACTCCGC
GCTGGAATCCCCACCATCATCAAACCATTTTTTGGAGATCAATTCTTTTATGCCAACAGAGTAGAA
GATATTGGAGTGGGTATAGGGCTGAGAAAGTTAAACAGTAAGTCACTTTCCAAAGCTATCAAAGAG
GTAACTACAAACACTCGTATCATAGAAAAGGCTAAAGAAATTGGAAAGCAGATCCAGTCAGAAAAC
GGTGTCTCTGCAGCCATTCGTTGCCTCTACCAGGAGATGGAATACGCCAAGAAACTTTCCAAGAGC
AAGCAGAAATACTGGGACAACCAGAGCGAAGATATTAGCGACGACAGCGTAAGCGGATCATGGTTT
GAAGTGTAA 
(1395 bp) 
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>gi|146413689|ref|XP_001482815.1| hypothetical protein PGUG_04770 [Pichia guilliermondii 
ATCC 6260] 
MGSSHHHHHHMLEDSPLIKTEVRPSTSFKFTLLTIGSRGDVQPYLALAKGLQEEGHDVTIATHSEF
KEWIEGHNVKFREIAGNPTELMALMVRHGSMSVTFIKEASSKFRSWITELLSSSWDACQGTDILIE
SPSAMGGVHIAEALGIPYMRAFTMPWTRTRAYPHAFIVPDQKKGGSYNYLTHVMFETLFWKGISGQ
VNRWRQNELGLPRTSLLKLQQTKIPFLYNISPSIFPPSVDFPDWVKVTGYWFLNEGGSNFNPPPEL
LEFLSLAKENGKKVVYIGFGSIVVKNAKSLTKAIVEAVQEADIYCILNKGWSDRLLDSDDKAEKEK
PEIDLPPEVFNSGAVPHDWLFPRIDAAVHHGGSGTTGATLRAGLPTIIKPFFGDQFFYASRVEQMG
VGLSLKKLNSKSLTKALNTVTSDFKMIEKCRSISERINHEDGVSAALEAIYSELEYAKHLSISRRA
LGYEASGLQTPVVYEQSDESDESGYDDEDESEETETDEESTDNEDITEIENVPHLDYVQNHRKSLE
SSSEEDVAIATTTTND 
TTAGAAGATTCACCACTCATCAAGACCGAAGTCAGACCTTCTACTTCTTTTAAATTCACACTTTTG
ACGATTGGATCGAGAGGTGATGTTCAGCCGTATTTGGCTCTAGCGAAGGGTCTTCAAGAAGAAGGA
CACGATGTAACAATTGCAACTCACTCAGAATTCAAAGAATGGATTGAGGGACACAATGTGAAATTT
CGTGAAATTGCTGGTAATCCGACAGAACTTATGGCTTTAATGGTAAGACACGGTTCTATGTCTGTG
ACGTTTATCAAAGAGGCTAGTTCCAAGTTTCGCTCTTGGATAACGGAGCTTTTGTCTTCTAGTTGG
GACGCTTGTCAAGGAACCGACATCTTGATTGAAAGTCCAAGCGCTATGGGAGGAGTTCATATTGCT
GAAGCCCTTGGAATTCCATATATGAGAGCTTTCACAATGCCATGGACAAGAACGAGAGCCTATCCT
CACGCATTTATTGTTCCAGACCAAAAGAAGGGTGGCTCTTACAACTACTTGACTCACGTTATGTTC
GAAACCCTTTTTTGGAAAGGGATATCTGGTCAAGTGAACAGATGGCGCCAGAATGAGTTGGGATTA
CCACGCACAAGTTTACTCAAATTACAGCAAACCAAGATCCCGTTCCTATACAATATCTCCCCCTCG
ATATTTCCTCCATCTGTCGATTTCCCAGATTGGGTCAAAGTGACAGGATATTGGTTCTTGAATGAG
GGAGGTAGTAACTTTAATCCTCCTCCAGAGCTTCTAGAGTTTTTGAGTCTCGCCAAGGAAAACGGA
AAGAAGGTGGTGTATATTGGATTTGGATCTATTGTGGTGAAGAACGCAAAGAGTTTGACTAAGGCT
ATTGTGGAAGCGGTTCAAGAGGCTGACATCTACTGTATTTTGAACAAAGGATGGTCTGATCGACTT
CTGGATTCTGATGATAAAGCTGAAAAAGAGAAACCTGAGATTGACTTACCCCCAGAAGTATTCAAT
TCTGGAGCGGTTCCCCATGACTGGCTCTTCCCGCGTATCGATGCGGCCGTCCATCATGGAGGCTCG
GGTACCACGGGCGCAACACTTCGAGCTGGGCTTCCCACAATTATCAAGCCGTTCTTTGGAGATCAG
TTCTTCTATGCTTCTCGAGTGGAACAAATGGGAGTAGGGCTTTCCTTGAAAAAGCTCAATTCTAAA
TCACTCACAAAAGCATTGAACACAGTGACTTCTGATTTCAAAATGATCGAAAAGTGTCGAAGTATC
AGCGAAAGAATCAACCATGAAGATGGTGTATCTGCGGCCCTTGAAGCTATCTACTCCGAATTGGAG
TATGCCAAGCATCTCAGTATCTCAAGAAGAGCTCTGGGCTACGAAGCTTCGGGCCTGCAGACTCCT
GTTGTTTACGAGCAGAGTGACGAAAGTGACGAGAGTGGATATGACGATGAAGATGAAAGCGAAGAA
ACTGAGACGGATGAGGAGAGTACAGATAACGAAGATATTACTGAGATCGAAAATGTTCCACATCTT
GACTACGTGCAAAACCATAGAAAAAGTCTGGAGAGTAGTTCAGAGGAAGATGTGGCTATAGCGACA
ACGACAACTAACGACTAA 
(1602 bp) 
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>gi|156848169|ref|XP_001646967.1| hypothetical protein Kpol_2000p77 [Vanderwaltozyma 
polyspora DSM 70294; Kluyveromyces polysporus] 
MGSSHHHHHHMVEDNPYFKTKIMPTKSYNFGFLTIGSRGDVQPYIALAKGLIQEGHSVTIITHREF
KSFVECHGIDFKEIAGDPTKLMSLMVEHEAINVGMLMEASSKFRGWIHDLLVTTWEACKNLKLDIL
IESPSAMAGIHISEALQIPYFRAFTMPWTRTRAYPHAFIVPDQKRGGSFNYLTHVIFENVFWRGIC
SQVNKWRVQTLGLEKTNLAQLQQNKIPFLYNISPVIFPPAIDFDEWIKVTGYWFLDESESFEPSQE
LETFISKARKLGKKLVYIGFGSIVVNNAKEMTRAVIDSVLETDIFCILNKGWSERLGKEELRYEEE
PEYPETIFLCDSIPHDWLFPKVDAAVHHGGSGTTGATLKAGTPVVIKPFFGDQFFFASRIEDIGAG
IALKKLNVSSLSNAIKKVLTDKSIKRKAVSLKKRVAKENGVTTAINCIYSELEYARSLVVKKNHKS
SNIEFIQHPNNVNDTTKTVIPLTSMV 
GTTGAGGATAATCCATATTTTAAAACAAAAATAATGCCTACAAAGAGCTATAATTTTGGGTTTTTA
ACAATTGGGTCTCGTGGAGATGTTCAGCCATATATAGCCTTGGCAAAAGGATTGATACAAGAAGGA
CATAGTGTCACGATAATTACACATAGGGAATTTAAGTCATTTGTAGAGTGTCACGGCATCGATTTT
AAAGAAATTGCGGGTGATCCTACCAAGTTAATGTCATTAATGGTAGAGCATGAAGCAATTAATGTT
GGAATGCTTATGGAAGCTTCAAGTAAATTTCGGGGTTGGATTCATGATTTGTTAGTAACTACTTGG
GAAGCATGCAAAAATTTGAAGTTGGATATCCTGATTGAATCACCATCAGCAATGGCAGGAATACAT
ATTTCAGAAGCACTTCAGATACCCTATTTCCGAGCATTCACGATGCCATGGACTAGAACAAGGGCA
TATCCGCATGCATTTATTGTGCCTGATCAAAAGAGAGGCGGCAGTTTCAATTATCTGACACATGTT
ATATTTGAAAATGTTTTCTGGAGAGGAATCTGTAGTCAAGTTAATAAATGGAGAGTTCAGACTCTA
GGATTAGAAAAGACTAATTTAGCTCAACTTCAGCAAAATAAAATTCCTTTTCTTTACAATATATCT
CCAGTAATTTTCCCACCTGCTATAGACTTTGATGAATGGATCAAAGTTACTGGATATTGGTTTTTA
GATGAATCGGAATCATTTGAGCCTAGTCAAGAATTGGAGACATTTATCTCAAAGGCTCGAAAATTG
GGTAAAAAATTAGTTTATATTGGTTTTGGCTCAATTGTTGTCAATAATGCGAAAGAGATGACAAGG
GCAGTGATTGATTCAGTTTTAGAGACAGATATATTTTGTATACTCAATAAAGGTTGGTCAGAAAGG
CTGGGGAAAGAAGAATTAAGGTATGAAGAGGAGCCAGAATATCCTGAAACTATTTTCCTATGTGAT
TCTATTCCTCACGATTGGTTATTTCCTAAAGTTGACGCAGCAGTTCATCATGGTGGTTCTGGCACT
ACTGGCGCAACACTAAAGGCAGGGACACCTGTTGTAATTAAGCCATTTTTTGGTGACCAATTTTTC
TTTGCTTCAAGGATTGAAGATATTGGAGCAGGCATTGCATTGAAAAAGCTAAATGTCAGTAGTCTA
TCCAATGCCATCAAAAAAGTCCTAACTGATAAATCAATTAAAAGGAAAGCTGTTTCATTGAAAAAG
AGAGTTGCAAAAGAAAATGGTGTCACAACGGCTATAAATTGTATATATAGTGAGTTAGAGTATGCA
AGAAGTTTAGTTGTGAAAAAAAATCATAAATCTTCAAATATCGAATTTATACAGCACCCGAATAAT
GTCAATGATACGACTAAGACTGTGATTCCGCTCACCAGCATGGTCTGA 
(1434 bp) 
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>gi|129561955|gb|ABO31066.1| Atg26p [Pichia angusta] 
MGSSHHHHHHMIEEHPLTKTKVRPLKSYRFTLLTIGSRGDVQPYIALGKALMKEGHQVRIVTHAEF
EPWIKKHGIRFASIAGDPSELMALMVTHPTINYNFIKEAKSKFRSWIDDLLVTSWKACQDTDILIE
SPSSICGIHIAEKLQIPYFRAFTMPWTRTRAYPHAFMVPDQKLGGAYNYMTHVAFENGYWRGTAHQ
VNKWRVETLGLPKTSLAEMKQNNVPFLYNVSPTVFPPSVDFAEWVKVTGYWFLDESETYQPPEVLT
KFIEQARKDGKKVVYIGFGSIVVSKPSELTQAVVDAVLEADVRCILNKGWSDRLGTKTEIEVVLPP
EIYNAGSVPHDWLFPQIDAAVHHGGSGTTGASLRFGVPTIIKPFFGDQKFYAGRVEDLGCGVSLKD
LNYKSLARALKEVTTNTRIIEKAKLVGARIRSETGVQTAIETIYNEMEYARSLSISKVKQVSVVKS
DEEFDDDKDEEVEGSWLLV 
ATAGAAGAGCATCCATTGACCAAAACCAAAGTTAGGCCGTTGAAATCTTACAGATTCACGCTGTTG
ACGATTGGATCCAGAGGAGACGTTCAGCCTTATATTGCATTGGGAAAGGCCTTGATGAAAGAGGGC
CACCAGGTTCGCATTGTCACGCATGCCGAGTTCGAGCCTTGGATCAAGAAACATGGTATTAGGTTT
GCATCGATAGCGGGAGATCCATCTGAACTCATGGCATTGATGGTCACCCATCCAACCATAAATTAC
AACTTTATAAAGGAGGCCAAGTCAAAGTTCCGGAGCTGGATCGATGACCTGTTGGTCACATCATGG
AAAGCCTGTCAGGACACAGATATTCTGATCGAGTCTCCGTCGTCAATATGTGGTATTCACATTGCT
GAGAAGCTGCAAATTCCTTACTTCCGTGCTTTTACCATGCCGTGGACACGTACGAGAGCGTATCCT
CACGCCTTCATGGTTCCCGATCAGAAACTGGGCGGCGCATACAACTATATGACCCATGTGGCTTTC
GAAAATGGATACTGGCGAGGAACCGCTCATCAGGTGAATAAATGGCGTGTTGAAACGTTAGGGCTG
CCTAAAACGTCTCTAGCAGAGATGAAACAGAATAACGTTCCTTTCCTTTATAACGTTTCGCCAACC
GTCTTTCCTCCTTCTGTGGATTTTGCTGAGTGGGTCAAAGTTACCGGTTACTGGTTTTTGGATGAA
AGCGAGACGTACCAGCCACCCGAGGTTCTGACTAAGTTCATCGAGCAGGCGAGAAAAGACGGGAAA
AAGGTGGTTTACATTGGATTTGGGTCCATCGTCGTTTCCAAGCCTTCAGAACTCACCCAAGCGGTT
GTGGACGCTGTTCTTGAGGCCGATGTCAGGTGCATTCTGAATAAAGGGTGGTCAGATCGTCTGGGA
ACGAAGACCGAAATTGAGGTGGTGCTTCCACCTGAAATATATAATGCTGGAAGCGTGCCCCATGAT
TGGCTATTTCCTCAGATCGATGCTGCTGTTCATCACGGAGGCTCTGGAACGACAGGAGCTTCGTTG
CGGTTCGGGGTGCCGACAATCATCAAGCCGTTTTTTGGAGACCAGAAGTTTTATGCAGGAAGAGTC
GAAGACCTTGGATGTGGTGTTAGTCTGAAAGATTTGAACTATAAGAGTCTGGCGAGGGCTCTCAAG
GAGGTGACCACCAACACAAGGATTATCGAAAAGGCTAAACTTGTGGGAGCGAGAATCCGGTCCGAA
ACAGGCGTTCAAACTGCCATTGAAACAATTTACAACGAAATGGAGTACGCTCGGAGTTTATCAATC
AGCAAGGTGAAACAAGTTTCTGTTGTAAAGAGCGACGAGGAGTTTGATGACGATAAAGACGAGGAA
GTTGAAGGCTCGTGGTTACTGGTTTGA 
(1413 bp) 
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>gi|50304663|ref|XP_452287.1| unnamed protein product [Kluyveromyces lactis] 
MGSSHHHHHHMVEKNPYFTTVIKPSKSYKFGLLTIGSRGDVQPYIALAKGLQAEGHEVIILTHGEF
KDWIVSHNIGFREISGNPAELISLMVQHGSMNMGLLRDASTNFSTWISSLLDTAWEGCQGIDILIE
SPSAMAGIHIAEALRIPYFRAFTMPWTRTRAYPHAFIVPDQKRGGNYNYFTHVLFENIFWKGISGK
VNEWRETKLKLPKTNLVSMQQNRVPFLYNVSPIVFPPSVDFNEWIKVTGYWFLDEKRSYKPPAEFM
EFLNKARELKKKVVYIGFGSIVVNDPEKMTDTIIEAVRDAGVYCVLNKGWSNRFGDPLAKKIDKEL
PSYIYNSGDVPHDWLFTKIDATVHHGGSGTTGASLRAGLPTIIKPFFGDQFFYASRVEDIGAGVAL
KKLNRSSLAKALKEVTTNTRIIQKARQIGESISKEHGVATAIGAIYSELGYARSLIKTKNPVDDKE
MEAASTKLSNDAVVTAKGNEKEEYSSEGSGSNDGSWLLI 
GTTGAAAAAAACCCGTATTTCACCACTGTAATCAAACCTAGTAAAAGCTACAAATTCGGATTACTT
ACAATCGGTTCAAGAGGTGATGTACAACCATATATTGCATTGGCAAAGGGTTTGCAAGCCGAAGGT
CATGAAGTTATTATACTAACTCATGGAGAATTTAAGGATTGGATAGTTTCTCATAATATAGGATTT
AGAGAAATATCTGGTAATCCTGCAGAACTAATATCTTTGATGGTACAGCATGGATCAATGAACATG
GGTTTATTGAGGGACGCTTCTACAAACTTTTCTACTTGGATCTCATCTCTGTTGGATACAGCTTGG
GAGGGATGTCAAGGTATAGATATACTAATCGAATCTCCTAGTGCCATGGCAGGGATACATATAGCA
GAAGCTTTGAGAATACCATATTTTAGAGCGTTTACTATGCCTTGGACTAGAACTAGGGCTTATCCA
CATGCATTTATAGTACCAGATCAAAAAAGAGGTGGCAACTATAACTATTTTACACATGTTCTTTTC
GAGAACATCTTTTGGAAAGGAATCAGTGGTAAGGTTAATGAATGGAGAGAAACCAAATTAAAATTG
CCCAAGACGAATCTAGTTTCGATGCAGCAAAATCGTGTTCCATTTTTATACAATGTGTCTCCGATA
GTCTTTCCACCAAGTGTCGATTTCAATGAATGGATCAAAGTAACAGGTTACTGGTTTCTTGATGAA
AAACGGTCCTACAAACCCCCTGCAGAATTTATGGAATTTCTCAACAAGGCTAGGGAATTGAAGAAA
AAAGTGGTATATATTGGATTCGGATCGATAGTAGTTAATGACCCCGAAAAAATGACAGATACTATT
ATTGAAGCTGTACGAGATGCAGGAGTTTATTGTGTTTTGAATAAAGGCTGGTCTAATAGGTTTGGA
GATCCACTGGCAAAAAAGATCGATAAAGAGTTGCCAAGTTATATATATAATTCAGGTGATGTGCCA
CACGACTGGCTATTCACAAAAATTGATGCTACAGTTCATCATGGCGGTTCGGGAACTACAGGCGCG
TCTTTAAGAGCTGGTTTGCCTACCATTATCAAACCATTCTTTGGGGATCAATTCTTTTACGCTAGC
AGAGTTGAAGATATTGGCGCTGGTGTCGCTTTGAAAAAATTGAATAGGAGCTCGTTAGCGAAAGCG
TTGAAAGAAGTTACCACTAACACGAGGATCATCCAAAAGGCCAGGCAAATAGGTGAGAGTATTTCT
AAAGAGCATGGGGTTGCTACGGCCATAGGCGCAATTTATTCTGAATTAGGATACGCTAGAAGTTTG
ATAAAAACCAAAAATCCCGTTGATGACAAAGAGATGGAGGCTGCAAGCACAAAATTATCCAACGAT
GCTGTTGTAACCGCGAAAGGAAATGAAAAAGAAGAATATAGCAGTGAAGGCTCAGGATCAAATGAT
GGATCCTGGCTTCTGATATAA 
(1473 bp) 
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>gi|50423499|ref|XP_460332.1| hypothetical protein DEHA0E25168g [Debaryomyces hansenii 
CBS767] 
MGSSHHHHHHMLEDSPFYKTEIRPSTSFNFTLLTIGSRGDVQPYIALGKGLLNEGHNVTIATHSDF
EEWIVGHGIKFKTIAGNPVELMSLMVTHGSMSLSFLKEASSKFRGWIQELLDTSWKACQGSDILIE
SPSAMVGAHIAEALGIPYIRAFTMPWTRTRAYPHAFIVPDKKKGGSYNYITHLMFETVLWKGISSQ
VNKWRRELLGLPRTNLYRLAQYDIPFLYNISPTIFPPSVDFPDWVKVTGYWFLDEGAADDFEPLKE
LVEFMNKARADDKKVVYIGFGSIVVEDAKSLTKAIVEAVLNADVRCILNKGWSDRNSSPAKDNAEP
EVELPEEIYNSGSIPHDWLFPKIDAAVHHGGSGTTGATMRAGIPTIIKPFFGDQFFYSSRIEDIGA
GIGLKKLNARSLCTALKTATSDAKMITKAKKISERLKQENGVLNAIEAIYYELEYARSLILAKQHE
NTKHDLKSGTQTPVVNETNEYFDSDTYDADHDSDKESDHDQTYEQDNHSDYDVANDDNMTEIVEPS
LEDGNDTVRIAPDSGNDNTTVTDANK 
TTAGAAGATTCTCCATTCTATAAGACGGAAATACGGCCTTCTACTTCCTTTAATTTTACATTATTA
ACTATTGGATCACGAGGAGACGTACAACCTTACATAGCATTAGGCAAAGGGCTATTGAATGAGGGT
CATAATGTAACAATTGCCACACACTCTGACTTCGAAGAATGGATTGTAGGACATGGCATTAAATTT
AAGACAATTGCAGGAAATCCAGTTGAATTGATGTCATTGATGGTAACCCACGGGTCAATGTCTCTC
TCGTTTCTTAAAGAAGCAAGCTCCAAATTCAGAGGTTGGATTCAGGAATTATTAGACACTAGTTGG
AAGGCTTGTCAAGGGAGCGATATTTTGATTGAGAGCCCATCAGCCATGGTGGGTGCGCATATTGCA
GAAGCATTAGGTATTCCTTACATAAGGGCGTTTACAATGCCATGGACTAGGACCAGGGCATACCCA
CATGCGTTTATTGTACCCGATAAAAAGAAGGGTGGCTCGTATAATTATATTACACATTTAATGTTC
GAGACAGTTCTTTGGAAGGGAATCAGTAGTCAGGTCAATAAATGGCGTAGAGAACTGTTGGGATTA
CCAAGAACCAATTTGTACAGACTTGCACAATATGACATACCGTTTTTATACAACATCTCACCTACA
ATATTCCCACCTTCTGTTGATTTTCCAGATTGGGTCAAAGTTACTGGCTACTGGTTTCTAGACGAA
GGAGCGGCTGATGATTTTGAACCTCTGAAAGAATTGGTTGAGTTTATGAATAAGGCAAGAGCAGAC
GATAAGAAGGTTGTTTACATTGGGTTTGGTTCTATCGTGGTGGAAGATGCCAAGAGCCTTACAAAG
GCAATAGTCGAAGCTGTTCTCAATGCAGATGTTCGCTGTATCTTGAACAAAGGTTGGTCGGACAGA
AACTCTAGCCCCGCAAAGGACAATGCGGAGCCAGAAGTTGAACTACCAGAGGAAATTTACAATTCA
GGATCTATTCCACACGATTGGTTATTTCCAAAGATAGACGCGGCTGTTCATCATGGTGGATCTGGT
ACAACTGGTGCTACAATGAGAGCTGGTATTCCCACTATAATCAAACCATTTTTTGGGGATCAATTC
TTCTATTCTTCAAGGATCGAAGATATTGGCGCTGGAATTGGGTTAAAGAAGTTAAATGCTCGTTCA
TTGTGCACTGCATTGAAAACTGCAACATCGGATGCAAAAATGATTACAAAGGCAAAGAAAATTAGC
GAAAGATTGAAACAAGAGAATGGTGTTTTGAATGCAATTGAAGCCATATATTATGAACTAGAATAT
GCAAGAAGTTTAATACTTGCTAAACAACATGAAAATACCAAGCATGACCTCAAGTCCGGTACCCAA
ACACCTGTTGTTAATGAAACAAATGAATATTTCGATAGTGACACATATGACGCAGACCACGATTCA
GATAAGGAATCAGACCACGATCAGACATATGAACAGGATAATCATAGTGATTATGATGTTGCTAAT
GACGACAACATGACCGAAATTGTAGAACCTAGTCTTGAGGATGGCAATGATACTGTAAGAATCGCA
CCTGATAGTGGAAATGATAACACTACCGTTACAGATGCTAACAAATAA  
(1632 bp) 
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   A.2 Map and cloning region of the pET-YSBLIC vector 
 
Fig. A.1 Cloning region for the pET-28a derived LIC vector (Novagen, 2007). 
Target gene fragments were cloned with the inclusion of the stop codon to allow 
expression of an N-terminally his-tagged protein. 
 
 233 
 
 
 
 
 
Fig. A.2 Map of pET-28a vector 
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Appendix B. Mascot peptide analysis outputs 
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Appendix C. Protein expression using auto-induction media 
 
Starter cultures for auto-induction media 
 
 Component      Volume/ 10 ml 
Water                                                            9.55 ml 
1M MgSO4                                             20 µl 
1000 x metals                                           2 µl 
40% (w/v) glucose                                 125 µl 
25% (w/v) aspartate                               100 µl 
50 x M                                                    200 µl 
kanamycin (10 mg/ml)                                           100 µl 
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ZYM-5052 auto-induction media 
 
           Component                                            Volume (ml)/ 500 ml 
           ZY  media                                                    478.5 
           1M MgSO4                                                        1 
                       1000 x metals                                                 0.5  
                       50 x 5052 media                                                      10  
           50 x M media                                                  10  
           kanamycin (10 mg/ml)                                              5  
 
Stock solutions for auto-induction media 
 
50 x M media 
 
      Component                                                        Amount (g)/100 ml 
         Na2SO4 (anhydrous)                                                  3.6  
        NH4Cl    (anhydrous)                                              13.4  
        KH2PO4 (anhydrous)                            17.0  
      Na2HPO4 (anhydrous)                         17.7  
 
The salts were sequentially dissolved in distilled water and autoclaved prior to 
use. 
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1000 x metals solution 
 
                   Component     Volume (ml)/100 ml 
                  sterile 18.2 MΩ/cm H2O                                             36  
                  0.1 M FeCl3·6H2O                                             50  
(Dissolved in 100-fold dilution of 0.12 M HCl and filter sterilised using 0.2 µm 
filters). The following constituents were then added 
                          1 M CaCl2 (anhydrous)                                        2 
                          1 M ZnSO4·7H2O                                    1 
                          0.2 M CoCl2·6H2O                                    1 
              0.1 M CuCl2·2H2O                                    2 
                          0.2 M NiCl2·6H2O                                                1 
              0.1 M Na2MoO4·5H2O                                          2 
                          0.1 M Na2SeO3·5H2O                                            2 
                          0.1 M H3BO3 (anhydrous)                                     2 
 
All the solutions were made separately and autoclaved unless stated otherwise. 
 
20 ml of a 25% (w/v) aspartate solution was prepared and the pH was adjusted to 
7.0 by neutralisation with NaOH and autoclaved separately. 
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50 x 5052 media 
The following constituents were sequentially dissolved in distilled H2O   
 
 
        Component     Amount (g)/100 ml 
Glycerol (100%)                                        25 g 
Glucose                                               2.5 g 
α-lactose                                              10 g 
 
 
ZY media 
 
10 g Tryptone and 5 g yeast extract was sequentially dissolved in 1 L distilled 
H2O.                                              
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Appendix D. General use equipment 
 
Sterilisation 
Autoclave sterilisation was achieved at 121°C for 30 min using a bench-top 
Prestige Medical 2100 Classic autoclave or 121°C for 40 min in a  Priorclave 200 
L front loading autoclave.  Filter sterilisation was performed through a 0.2 ȝm 
Sartorius, Ministart® filter unit. 
Incubators 
For the growth of bacteria in liquid cultures an Innova 44 orbital shaker 
Brunswick Scientific (BRS) was used. Growth of bacteria on solid media was 
performed in a static GallenKamp incubator. 
pH meter  
All adjustments to the pH of solutions and media were achieved using a Jenway 
Ion Meter 3340 calibrated with buffers at pH 4.0, 7.0, and 9.2.  
Centrifugation: 
MSE Microcentaur bench-top centrifuge was used to centrifuge PCR tubes. 
Centrifugation of volumes upto 1.5ml was achieved using a small Sigma (SIG) 1-
15 bench top micro-centrifuge. Volumes above 1.5ml were centrifuged in a large 
3K18C refrigerated bench top centrifuge (SIG) using the rotors and inserts 
appropriate to the application. 
Agarose gel electrophoresis (AGE) 
Electrophoresis of DNA was performed using an electrophoresis system (BR) 
powered by a power PAC 300 apparatus (BR).  
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
gel kit 
Electrophoresis of proteins was achieved using A Mini-PROTEAN™ 3 Cell kit 
powered (BR) by a power PAC 300 apparatus (BR). 
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Gel documentation 
Visualisation of agarose gels was achieved using a Gel Doc 2000 system utilising 
Quantity One software and equipped with a UV source (BR). SDS-PAGE gels 
were visualised using a GS-800 calibrated densitometer (BR). 
Sonication 
Cell lysis was achieved using a MSE Soniprep 150 ultra-sonication machine 
(Sanyo). 
Spectrophotometer 
Spectrophotometric measurements were made using a UV-visible HeȜios α 
Spectronic Unicam spectrophotometer (TS).  
PCR 
All PCR reactions were performed using a Mastercycler® gradient thermocycler 
(Eppendorf). 
Vortexing 
Fisher Scientific (FIS) whirlmixer was used to vortex samples. 
Waterbath 
Grant (SUB series) incubator water bath used to incubate samples at digitally 
controlled temperatures. 
Pippetting 
Gilson pipettes P2-P5000 used to pipette samples and reagents from 0.01-5000 l 
accurately. 
Weighing Reagents 
Mettler AT250 analytical balance used to measure micro gram quantities of 
chemicals and reagents. 
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Protein Purification 
Akta Prime Plus™ 5.0 Series system, software version 3.0, was used for 
automated Ni2+ affinity chromatography using a High Performance Ni2+ 
Sepharose resin® (AB). 
Sample concentrator 
Techne Dri-Block® sample concentrator was used to evaporate solvents from 
samples using N2 gas supply. Speed-Vac® sample concentrator (TS) was used to 
concentrate DNA samples and drying protein gel slices. 
Plate images 
Images of agar plates and 96-well plates were captured using the Nikon Coolpix® 
995 3.34 mega pixels digital camera. 
Freeze drying 
Samples were freeze dried using an ALPHA 1-2 LD Freezer dryer (Christ) 
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Appendix E. SDS-PAGE gel images 
 
 
 
    
   
 
 
Fig E.1 SDS-PAGE analysis of membrane fractions of E. coli (DE3) (indicated above 
lanes) following expression of the Pg, Pa, Dh and Sc r-plasmids a)-d) with expected 
m.wt of 61, 54, 62, 55 KDa respectively.  L =  protein m.wt size standard ranging 
between 6.5 KDa and 66 KDa. H= protein m.wt size standard ranging between 36 KDa 
and 205 KDa. 
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Fig. E.2 SDS-PAGE analysis of membrane fractions of E. coli (DE3) (indicated 
above lanes) following expression of the Kl and Kp r-plasmids e)-f) with expected 
m.wt of 56 and 55 KDa respectively. L =  protein m.wt size standard ranging between 6.5 
KDa and 66 KDa. H= protein m.wt size standard ranging between 36 KDa and 205 KDa. 
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Fig. E.3 SDS-PAGE analysis of IMAC purified protein fractions. a) Protein 
bands of approx. 61 KDa are observed for the Pg-LIC construct transformed in CP 
(RP); b) Dh-LIC construct transformed in BL21 shows bands between 55 and 65 
KDa (predicted m.wt: 62 KDa).  
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Appendix F. DNA sequencing data for mutants 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
